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Kidney transplantation is the gold-standard treatment for end-stage renal failure but
despite many advances the incidence of graft failure remains high.
Ischemia/reperfusion injury (IRI) contributes to the occurrence of delayed graft
function and is consistently associated with poorer long-term outcome. A potential
protective strategy involves the up-regulation of heat shock, or stress proteins
(Hsps), a highly conserved group of intracellular chaperones. Heat shock protein
expression is regulated by heat shock transcription factor 1 (HSF1), which itself is
subject to a number of regulatory mechanisms. The influence of the
phosphatidylinositol 3-kinase (PI3K)/Akt pathway on HSF1 activation status was
investigated. Despite effecting significant up-regulation of the PI3K/Akt pathway
with insulin and insulin-like growth factor-1 (IGF-1), no change in the HSF1
trimerisation state, DNA-binding ability or nuclear localisation was demonstrated in
the ACHN renal adenocarcinoma cell-line. Heat shock protein 70 (Hsp70) promoter
activity, mRNA levels and protein expression were not influenced by alterations in
PI3K/Akt activity.
However, following treatment with insulin, a 5-fold increase in heme oxygenase-1
(HO-1) mRNA and a 4-fold increase in protein expression were observed in ACHN
cells; insulin-induced HO-1 expression was also demonstrated in mouse primary
tubular epithelial cells. The induction of HO-1 in the ACHN cell-line was blocked
by actinomycin D and cycloheximide and was abolished by the phosphatidylinositol
3-kinase (PI3K) inhibitor, LY294002, but not by the inactive analogue, LY303511.
The over-expression of a dominant-negative form of Akt abrogated the HO-1 -
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inducing effects of insulin, whereas cells transfected with a constitutively active Akt
construct demonstrated an increase in HO-1 promoter activity and protein
expression. The transcription factor NF-E2-related factor-2 (Nrf2) was found to
translocate to the nucleus in a PI3K-dependent manner following insulin treatment.
Pre-treatment with Nrf2 small-interfering RNA (siRNA) abolished insulin-induced
HO-1 induction. Thus, insulin induces HO-1 mRNA and protein expression in renal
cells in a PI3K/Akt and Nrf2 dependent manner.
The heat shock protein 90-binding agents (HBAs) geldanamycin and its analogues
(17-AAG and 17-DMAG) are known to up-regulate Hsps and confer cellular
protection. The ability of HBAs to protect the kidney was examined in a model
relevant to transplantation. Hsp70 gene expression was increased 30 - 40-times in
ACHN cells treated with HBAs and trimerisation and DNA-binding of HSF1 was
demonstrated. A 3-fold and 2-fold increase in Hsp70 and Hsp27 protein expression,
respectively, was found in ACHNs treated with HBAs. HBAs protected ACHN cells
from an H202-mediated oxidative stress and HSF1 siRNA abrogated HBA-mediated
Hsp induction and protection. In vivo, Hsp70 was up-regulated in the kidney, liver,
lungs and heart of HBA-treated mice. This was associated with a functional and
morphological renal protection from IRI. Therefore, HBAs mediate up-regulation of
protective Hsps in mouse kidneys and are associated with reduced renal IRI and may
be useful in reducing transplant-associated kidney injury.
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Chapter 1 - Introduction
1.1 Overview
Kidney transplantation* is the gold-standard treatment for end-stage renal failure.
Despite the great advances and clinical successes in the field, a significant rate of
graft failure still exists with dire implications for the graft recipient. The
physiological consequences of organ transplantation are complex. Many potential
targets of intervention have been identified in the quest to improve outcome. This
work seeks to discover strategies to reduce the injury sustained by the organ during
the transplantation procedure and the period immediately thereafter, with the ultimate
aim of introducing a clinical therapy that will reduce the incidence of graft loss. The
thesis focuses on a group of protective proteins called heat shockproteins (Hsps) and
how these may be harnessed to protect the transplanted organ.
In this introduction a number of arguments are presented to justify the work herein.
There is a brief description indicating that the incidence of end-stage renal failure in
the UK and other Western countries is increasing; that the best treatment, both to
reduce patient morbidity/mortality and in economic terms, is renal transplantation;
that despite being desirable, renal transplantation is often not possible due to a
shortage of organs; that renal transplantation, despite its success, still has a
significant failure rate; and that this graft failure, despite being due to a myriad of
factors, may be considerably reduced by manoeuvres prior to, and during organ
retrieval and storage. The pathophysiology of ischemia/reperfusion injury (IRI) is
*
Transplantation: transferring an organ (or part of one) from one body to another, for the purpose of
replacing the recipient's damaged or failing organ with a working one from the donor
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considered and potential strategies to reduce the effect of this process. The potential
of the Hsps in this regard are highlighted and discussed in more detail.
7.2 End-stage renal failure (ESRF)
1.2.1 Background
The kidneys are a pair of organs in the abdomen that function to excrete the waste
products of metabolism, as well as maintaining acid-base balance, blood pressure and
plasma volume. Kidney function is essential to life. Progressive and irreversible
reduction in kidney function over time is termed chronic renalfailure (CRF), or
more recently chronic kidney disease (CKD), and is characterised by the gradual loss
of nephrons, the functional unit of the kidney. While conservative management is
successful in the early stages, some patients will progress to end-stage (or
established) renalfailure (ESRF). Prior to the introduction of the first effective
replacement of renal function by Kolff and Berk in 1943, all patients with ESRF died
(1).
1.2.2 Epidemiology and aetiology
The incidence of ESRF in the UK is rapidly increasing (Figure 1.1), making its
effective diagnosis and management a priority for the healthcare profession. The
number of adults commencing renal replacement therapy (RRT)1^ in 2004 was
f Renal replacement therapy: life supporting treatments for renal failure including hemodialysis,
















Figure 1.1 Incidence of commencement of renal replacement therapy (per
million population) in the UK 1980-2004.
From UK Renal Registry Annual Report 2005 (2).
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estimated to be 103 per million population (pmp), representing a 7% rise since 2000.
The estimated prevalence of patients requiring RRT at the end of 2004 was 638 pmp.
These trends are broadly in keeping with other Western countries (Table 1.1) and
probably reflect the aging population and increasing incidence of vascular disease,
diabetes and hypertension which are all important aetiological factors in the
development of ESRF. The incidence also continues to rise in the paediatric
population, though the aetiology of the disease in this group is different. Predictive
models in both UK and US adult populations suggest that the prevalence of ESRF
will continue to rise and is unlikely to reach a steady state for at least 25 years
(Figure 1.2) (3,4). ESRF currently costs over 2% of the total NHS budget with this
figure expected to rise (5). It is essential, therefore, that current treatments for renal
failure are optimised and that research is performed to further delineate the
pathological processes contributing to this disease. Any improvement in the cost-
effective treatment of kidney disease is highly desirable.
1.2.3 Disease progression and early management
Chronic renal failure is a condition of degrees. Patients with mild disease may not
realise they have it and will often have no symptoms. While some will never need
RRT, the inexorable decline to ESRF is inescapable for many. Management initially
focuses on general health advice (smoking cessation, weight loss, aerobic exercise,
limiting sodium intake) and the avoidance of nephrotoxic drugs. Most patients will
benefit from secondary prevention of cardiovascular disease (low-dose aspirin, lipid-







United States 336 1403
Germany 184 919
Greece 163 812
Belgium (Dutch speaking) 160 855












Table 1.1 Number of patients commencing, and total patients receiving renal
replacement therapy in 2001 (5).
pmp, per million population.
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inhibitor) and all will require regular monitoring of renal function. Rigorous
glycaemic control is required in diabetics. Yet despite these measures, the renal
function of many patients will continue to decrease and symptoms may develop
(fatigue, nausea, loss of appetite, breathlessness). Fluid and electrolyte disturbances
will begin to occur and loss of renal hormonal function may result in anaemia,
hyperphosphatemia, hypocalcaemia or hyperparathyroidism.
Renal replacement therapy includes hemodialysis, peritoneal dialysis, hemofiltration
and renal transplantation. While dialysis is effective in mitigating the direct effects of
renal failure, it is not without significant negative consequences. Renal
transplantation has been shown to improve quality of life and reduce mortality, when
compared with long-term dialysis treatment (6-8). Many of these early studies,
however, did not control for the fact that transplant recipients are a highly selected
subgroup of the dialysis population - patients placed on the waiting list for
transplantation tend to be younger, in better health and of higher socioeconomic
status than those not selected (9). However, in 1999 Wolfe et al demonstrated
conclusively that in matched cohorts, long-term mortality was 48 - 82% lower in
transplant recipients as compared with patients listed for, but who did not undergo,
renal transplantation (10). Hence the current evidence clearly shows that renal









Figure 1.2 Projected number of patients requiring renal replacement therapy
from 2000 and 2030 in England.




The roots of modern solid organ transplantation lie in antiquity with the first
references occurring in 2nd-century China, where Hua-To is reported to have replaced
diseased organs with healthy ones (11). The legend of the 3rd-century Saints Cosmas
and Damian describes the painless amputation of the ulcerated leg of a Christian
verger, and its substitution with the healthy leg of a dead Moor (12).
The transition of transplantation from a spectacularly unsuccessful endeavour 60
years ago to the valuable clinical intervention of today has been dependent on two
areas of work: the achievement of reliable techniques for organ preservation and
revascularisation and the progressive understanding of the biological processes
governing rejection.
The first reported human kidney allograft1 was performed in 1936 by Yu Yu
Voronoy, a Russian surgeon, who transplanted six human cadaveric kidneys without
success (13). Further attempts in France and the US in the early 1950s were all
unsuccessful. This incredibly discouraging phase in the history of transplantation
ended in Boston on December 23 1954 when Murray, Merrill and Flarrison removed
a kidney from a healthy man, and transplanted into his uraemic identical twin
brother. Despite no efforts being made to preserve the organ, it functioned
immediately and the recipient lived for nearly 25 years (14).
* Allograft: transplantation of organs between members of the same species.
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In 1943 Medawar demonstrated that rejection of skin allografts was an
immunological phenomenon (15,16) and 10 years later, together with Billingham and
Brent, showed that tolerance to skin allografts could be achieved by injecting foetal
or newborn mice with lymphoid cells from an adult (17). These discoveries marked
the beginnings of transplantation immunology and formed the basis of the
development of immunosuppressive drugs essential to transplantation today.
Preservation of organs was initially performed by machine perfusion with
cryoprecipitated plasma (18). In spite of this, simple cold storage after a vascular
flush with a solution developed by Collins (19) was shown to yield superior results.
Various preservation solutions are now available with University of Wisconsin
solution being one of the most widely used (20).
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1.3.2 Current state of transplantation
Despite the great successes of transplantation, it is with a certain despondency that
one reviews the latest statistics compiled by UK Transplant, the regulatory body
governing all solid organ transplantation in the UK (Figure 1.3). Despite the number
of patients awaiting transplantation increasing from 5074 in 2003/04 to 5425 in
2004/05, the total number of cadaveric kidney transplants performed fell from 1388
to 1308 in the same period. During this time, 293 patients awaiting transplantation
died and a further 420 were removed from the list, which often occurs when a patient
becomes too unwell to undergo transplantation; this represents 7.8% of the total
patients waiting and receiving organs for that period (Table 1.2). The reasons behind
the scarcity of available organs are manifold but include positive factors, such as
improvements in road safety and alterations in neurosurgical practice and less
welcome factors, such as negative public attitudes towards donation.
A number of strategies have been adopted to attempt to reverse this trend. Increasing
donation rate is possible and has been demonstrated in Spain, where a comprehensive
donor management system has increased donation rates to 33 pmp, compared with
12.3 pmp (2004) in the UK (21). Living kidney donor programmes have also been
very successful: the failure rate of organs procured in this way is significantly less
compared with organs from deceased donors. The introduction of non-heart beating
donor protocols and the use of marginal, or extended-criteria organs5 has also gone
someway to trying to reduce the gap between supply and demand. As technology
§ Expanded-criteria donors: donors > 60 yrs or donors 50 - 59 yrs with two of the following
characteristics - previous cerebrovascular accident, hypertension or elevated creatinine (United
Network for Organ Sharing definition)
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progresses many exciting interventions are being developed, such as stem cell-based
therapies and xenotransplantation. However, these technologies are in their infancy
and are unlikely to yield significant clinical benefit in the near future.
Xenotransplantation*
Using animals as a source of organs for transplantation is a potential solution to
organ donors shortage (22). Xenotransplantation was first attempted in the 19th
century, however it was not until the 1960s that serious study was given to the
concept (23). Yet, despite concerted efforts over the last 50 years, results have been
very poor. Swine kidneys transplanted into primates are subject to hyperacute
rejection and acute humoral rejection (24). This is a result of antibodies directed
against a specific epitope (galactose a 1-3 galactose) on vascular endothelium.
However, Phelps et al have developed an a-l,3-galactosyltransferase gene knockout
pig that does not express the Gal epitope. When kidneys from these animals are
transplanted into baboons, hyperacute rejection is avoided. However, the grafts are
still subject to acute humoral and cellular rejection at 34 days with
immunosuppression or 83 days when a tolerance-inducing protocol is used (25). The
field, therefore, holds great potential but only if these great immunological barriers
can be overcome.
**
Xenotransplantation: (Xeno- from the Greek meaning "foreign") the transplantation of cells, tissues
or organs from one species to another
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Figure 1.3 Cadaveric kidney transplantation in the UK 1993 - 2004.
Over the last 12 years, the number of organs available for transplantation remained
static or decreased. Despite this, the number ofpatients with end-stage renal failure
being listed for transplantation has increased year on year. (Data: UK Transplant)
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1.3.3 Outcome after kidney transplantation
The success of transplantation in general and kidney transplantation specifically is
without question. Better surgical technique and superior immunosuppression have
contributed to year on year improvements in outcome (Figure 1.4A). The 3-year
survival after any type of kidney transplantation is now 86%, compared with only
70% in the late 1980s. Even better results have been seen with living-donor grafts: in
HLA-identical siblings the 3 year graft survival is 96% (Figure 1.4B), although
living-donor grafts make up only 29% of UK kidney transplants as a whole (UK
Transplant 2004/2005 data). With outcome appearing to improve so greatly, one may
question whether efforts to try and improve it further are worthwhile? There are four
good reasons why the figures quoted above do not tell the whole story:
1. Ischemia/reperfusion injury: a significant but modifiable insult that occurs at
the time of transplant often with negative long-term consequences.
2. Functional outcomes: only 47% of grafts are still functioning at 10 years.
3. Marginal or expanded-criteria donors: the shortage of organs means kidneys
that would have been discarded previously are now being used. These are
associated with poorer outcome (Figure 1.4C).
4. Immunosuppression: improvements in outcome are as much a consequence of
improved immunosuppression. However, complications are common,
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Figure 1.4 Proportion of surviving kidney grafts by year (A), donor-recipient
relationship (B) and donor age (C).
(From Collaborative Transplantation Study, www.ctstransplant,org (members
section, accessed 21 June 2006)
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The last 40 years have seen a large number of studies analysing the risk factors
contributing to negative outcomes in kidney transplantation. Patient populations are
examined in a single-centre, multi-centre or registry settings, with multivariate
analysis (linear, logistic or Cox regression) used to identify factors significantly
related to outcome (usually graft failure). These risk factors can be grouped in five
categories (adapted from (26)):
• Donor factors (tissue quality)
• Donor death circumstances (brain death/cardiovascular status)
• Preservation variables
• Donor-recipient immunological relationship
• Recipient factors
Before examining these categories further, two important points must be considered
Firstly, the majority of risk factors identified are not modifiable, i.e. it is not usually
possible to improve donor tissue quality, the circumstances of brain death and pre¬
existing recipient morbidity. The impact of these variables can be influenced by
matching donors and recipients carefully, but ultimately the effect of many of these
factors is uncontrollable. Secondly, despite many of these factors appearing to be
significant in small univariate analyses, many fail to achieve statistical significance
when entered into a multivariate model of a large heterogeneous population.
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Delayed graftfunction
An indicator of outcome that has been extensively studied (over 900 individual
studies) is the occurrence of delayed graftfunction (DGF). DGF is most commonly
defined as a requirement for dialysis within the first week post-transplantation. This
definition has been modified in different studies, for instance excluding patients who
only had one dialysis session for fluid overload or hyperkalaemia. Other studies have
used alternative criteria, such as the pattern of serum creatinine in the first week
following transplantation (27). The occurrence of DGF is consistently associated
with poor outcome. When DGF and acute rejection occur together the outcome is
even worse (28). Despite improvements in donor and recipient management, DGF
rates have remained high, possibly due to increasing use of expanded-criteria donors
(29). Most studies have found a direct correlation between DGF and long-term graft
function and survival (Table 1.3). DGF represents the immediate impact of the sum
of the five factors listed above, with some factors predicting in the incidence of DGF
better than others. The risk factors for DGF commonly found to be significant are:
1. Cold ischemic time (CIT)t1\
2. Donor age.
3. High panel reactive antibody (PRA)**.
4. Recipient ethnicity.
5. Donor sex.
Again, it should be noted that other than CIT, none of the other risk factors are
modifiable. CIT represents a combination of injury to the organ occurring during
^ Cold ischemic time: time between retrieval of kidney from the donor and transplant into recipient.
** Panel reactive antibody: a measure of pre-formed anti-human antibodies in recipient's blood.
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cold storage and IRI. A number of strategies have been implemented to decrease cold
ischemic time. These typically stipulate time limitations by which the organ has to be
transplanted into the recipient (usually 24 h following retrieval). However, the
detrimental effects occurring at a cellular level during cold storage and particularly
as a result of IRI represent an attractive target for intervention. If these damaging
effects could be lessened then it is possible that the incidence of DGF (with its
intrinsic worsening of outcome) could be decreased. Additionally, it is possible that





















































































































Donorage Gendermismatch Non-traumaticde th
100%vs84 at3yrs
(39)4)
Table1.3Non-comprehensive/repres ntativeli fstudi sa aly ingti cidenceodelay dgr ffunctio(DGF)c d v r c kidneyallograftrecipients.
1.4 Ischemia/reperfusion injury
1.4.1 Overview
The process of organ transplantation, by its very nature, requires the disconnection of
the blood supply of an organ followed by the restitution of that supply during the
recipient procedure. The physiological consequence of this is termed
ischemia/reperfusion injury (IRI). The ischemic injury to an organ is the sum of the
periods of warm ischemia (prior to cooling and flushing with preservation fluid) and
cold ischemia (the period during which the organ is stored on ice prior to
revascularisation). Reperfusion injury begins at the point in the recipient procedure
when the clamps are released and the blood supply to the organ is restored. The
importance of IRI in transplantation cannot be over-emphasised. In the previous
section, the contribution of cold ischemia to the occurrence of DGF and ultimately
graft failure was demonstrated. CIT is a surrogate for the magnitude of IRI to the
organ. Despite the great number of experiments that have been performed looking at
IRI, it remains one of the least well described phenomena in transplantation. In
recent years, the 'classical' understanding of IRI has gradually evolved to emphasise
the specific roles of the inflammatory and immune responses (40,41). The classical
division of the pathological consequences of'ischemia' and 'reperfusion' is
becoming irrelevant, but still serves the purpose of illustrating the different processes
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Figure 1.5 A classical representation of the mechanisms contributing to tissue
injury following IRI.
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1.4.2 Physiological renal hypoxia
Although the kidney receives 25% of the cardiac output of a resting adult, it is very
susceptible to ischemic injury. Why does this contradiction exist? A major function
of the kidney in land mammals is the conservation of water. The concentration of
urine is dependent on a gradient of osmolality between the renal cortex and medulla
established by the well described countercurrent mechanism. The increased
medullary tonicity resulting from this process is inversely proportional to medullary
blood flow - put simply, greater blood flow would 'wash away' solute thus
abolishing the osmotic gradient essential for urinary concentration. To compound
this, re-absorption along the medullary thick ascending limb of Henle is an active
process requiring oxygen. The majority of renal blood-flow is directed to the cortex
which has a partial pressure of oxygen around 50 mm Hg, compared with 10-20
mm Hg in the medulla. Medullary hypoxia, therefore, is the inevitable consequence
of efficient urinary concentration, but leaves the kidney susceptible to ischemic
injury should any alteration in blood-flow or oxygen delivery occur (42).
1.4.3 IRI - the classical understanding
The primary effect of diminished blood supply to an organ is hypoxia (Figure 1.5).
Depletion of energy-rich phosphates (ATP) results in a failure to maintain ion
balances across cell membranes resulting in intracellular accumulation of water. This
cell swelling, together with microthrombosis, contributes to decreased capillary
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perfusion and has been implicated in the 'no reflow' phenomenon*, exacerbating the
already present hypoxia. Endothelial activation is a poorly defined term for the
response to injury of the vascular endothelium, which includes increased
thrombogenicity and a rapid up-regulation and surface expression of various
adhesion molecules including intracellular adhesion molecule-1 (ICAM-1), vascular
cell adhesion molecule (VCAM) and the selectins. These molecules facilitate the
recruitment of leukocytes allowing binding to the vascular endothelium, further
compromising microvascular blood flow. Leukocyte-endothelial interaction occur
predominantly in the outer medulla, leading to the vascular congestion in this area
evident after 1R1 (40). The adherent leukocytes release reactive oxygen species
(ROS), a variety of cytokines and contribute to the activation of complement (44),
further exacerbating the inflammatory reaction and tissue injury.
1.4.4 Role of ROS
Reactive oxygen species (ROS) are generated when molecular oxygen is reduced to
water and are central to the pathogenesis of IRI. ROS are produced by endothelial
cells and leukocytes during IRI (45). Small quantities occur in mitochondria during
normal respiration while an ischemic episode is associated with significant changes
in mitochondrial function. Impairment of oxidative metabolism at the level of the
electron transfer chain results in 'electron leak' leading to the formation of
superoxide radicals (02*")- Hydroxyl radicals (OH*) can also be formed via the
Fenton reaction. The efficacy of antioxidant mechanisms, including mitochondrial
No-reflow phenomenon: the inability to achieve myocardial reperfusion after removal of a coronary
artery occlusion (43). Possible mechanisms include capillary vasospasm, oxygen free radical mediated
injury, neutrophil and erythrocyte plugging and endothelial cell oedema secondary to IRI.
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superoxide dismutase, is decreased and depletion of important substrates like
glutathione occurs. Xanthine oxidase is also a significant source of ROS. Anaerobic
respiration results in accumulation of hypoxanthine which cannot be converted to
xanthine without oxygen. On reperfusion, the reaction proceeds with formation of
ROS. Lipidperoxidation describes the oxidative degradation of lipids whereby free
radicals "steal" electrons from lipids within cell membranes resulting in damage.
Under physiological conditions, a number of anti-oxidant mechanisms act to negate
the effects of ROS (46), including heme oxygenase-1 (HO-1; see section 1.6.3, page
53 and chapter 5, page 110) and mitochondrial superoxide dismutase. However,
during IRI these mechanisms are typically overwhelmed.
Targeting ROS as a strategy for reducing IRI in transplantation is attractive and has
been popular. A number of agents have been used experimentally but few have been
examined in the clinical setting (see section 1.5, page 41). Although high
concentrations of ROS result in cell damage, low concentrations may have a role as
stress signalling molecules (47). Thus, even if complete elimination of ROS was
possible, it may be undesirable as it would inhibit protective responses.
1.4.5 Role of adhesion molecules and inflammatory cells
Endothelial activation results in the up-regulation and surface expression of the
selectins and the intracellular adhesion molecules (ICAMs) (48). The former act to
slow and tether the rolling leukocyte, while the latter provide firm adhesion leading
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to diapedesis1) Anti-E- and anti-P-selectin antibodies protect rat kidneys from IRI
(49) and p-selectin glycoprotein ligand-1 is also protective in this model (50,51).
Fuller et al demonstrated that the mode of protection following selectin-inhibition
was an improvement in renal mircorperfusion, rather than the prevention of
leukocyte extravasation which was similar in control and treated groups (50).
Singbartl et al went on to demonstrate that platelet p-selectin inhibition, and not
endothelial p-selectin, was important in reducing injury (52).
ICAM-1 blockade is protective in mice (53) and rats (54). In human trials, the use of
anti-ICAM-1 was shown initially to reduce DGF (55), but was later found in a
randomised multi-centre trial to be of no benefit (56). It should be noted that in both
these trials, the drug was given to the recipient after organ implantation and not the
donor prior to IRI.
Leukocytes are activated by cytokines and ROS, resulting in up-regulation of surface
adhesion molecules on the leukocytes, which interact with endothelial adhesion
molecules (40). The relative role of different leukocyte populations in mediating
kidney injury following ischemia is the subject of great debate. Neutrophils have
been studied most widely, yet their role remains the most controversial. Neutrophils
are readily identifiable following ischemic injury in animal models, yet few are seen
in biopsies from human kidneys subject to acute renal failure (48). Myeloperoxidase
(MPO) activity following ischemic injury has been attributed by a number of authors
as evidence of neutrophil infiltration (57), yet histological evidence remains scant
f Diapedesis: One step of extravasion, diapedesis refers specifically to the penetration of the vessel
wall. Other steps incude the adhesion to the wall and the migration once through the wall.
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(58) and MPO activity is also associated with monocytes/macrophages (59).
However, if neutrophil infiltration is blocked, kidney injury is significantly reduced
(49,52,60), although the specificity of effect in such experiments has been questioned
(40). In balance, it is likely that the neutrophil plays a modest role as an effector cell
in early IRI, also contributing to poor microvascular blood flow.
The increasing appreciation of the role of the T-cell in IRI has led some to pronounce
that IRI is a "T-cell disease" (61). CD4/CD8 knockout and T-cell deficient (nu/nu)*
mice are protected from renal IRI, in the latter the injury being restored by adoptive
transfer of T-cells (62,63). The mechanisms by which T-cells mediate IRI remain
unclear, although it has been suggested that endothelial cells may act as antigen-
presenting cells providing co-stimulatory signals to circulating T-cells (61).
1.4.6 Other mechanisms
A number of other important mechanisms exist in the pathogenesis of IRI, but are not
examined directly in this work.
Complement. The activation of the complement cascade occurs in IRI and is
associated with apoptosis. Inhibition of both C5 (64) and C3 (65) have been shown to
reduce IRI in the mouse.
* nu/nu mice: mice homozygous for the nu/nu spontaneous mutation exhibit abnormal hair growth and
defective development of the thymic epithelium and are , therefore, athymic due to a developmental
failure of the thymus.
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Vasospasm. Alteration in the vascular perfusion of an organ is a common feature of
IRI and contributes to disease progression. Severe injury to the proximal tubule
results in altered eicosanoid expression. Excess thromboxane and decreased
prostacyclin result in vasoconstriction and poorer tissue perfusion (66). Endothelin
has also been proposed to have an important role: blockade of the endothelin receptor
is protective in rat renal IRI (67) and patients with DGF have high serum levels of
endothelin-1 (68).
Cytokines/chemokines. Endothelial cells, leukocytes and proximal tubular epithelial
cells all express pro-inflammatory cytokines in response to IRI. Pro-inflammatory
cytokines include tissue necrosis factor-a (TNF-a), interleukin-6 (IL-6), interleukin-
1(3 (IL-ip) and transforming growth factor-P (TGF-P) act to enhance the
inflammatory response taking place. Chemotactic cytokines (chemokines) including
monocyte chemoattractant protein-1 (MCP-1), IL-8 and regulated upon activation
normal T-cell expressed and secreted (RANTES) are expressed contributing to the
inflammatory cell response to IRI (40).
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1.5 Strategies to reduce IRI
1.5.1 Overview
As has been shown, IRI is a multifactorial condition and a number of targets are
available as potential targets for intervention, some ofwhich have already been
mentioned. As was discussed in section 1.3.3 (page 27), the incidence of DGF is
closely associated with the degree of IRI. Of the five factors that contribute to DGF,
in the context of IRI only three are modifiable:




The management of the donor after the diagnosis of brainstem death, and particularly
maintaining haemodynamic stability, has been neglected at times in the past. There
are a number of reasons for this including: a lack of active management after
brainstem death diagnosis; referring physicians unaware of optimal donor
management; a lack of reliable data on optimal donor management; delay in referral
resulting in cardiovascular instability; and ethical concerns in treating the deceased
donor. Maintaining cardiovascular stability in the donor patient is paramount and a
loss of cardiac output prior to preservation is associated with poorer outcome in some
series (69). Accurate fluid management and the judicious use of inotropes is
beneficial (70). Brain stem death is associated with a loss of the pituitary-
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hypothalamic axis leading to diabetes insipidus in 70 - 80% of brain-dead patients
(71). Treatment with fluid replacement and desmopressin helps to maintain serum
electrolyte levels. Replacement of insulin, triiodothyronine (T3) and Cortisol helps to
maintain normal organ function. A large, retrospective study demonstrated a
significant increase in the number of organs transplanted in donors treated with
methylprednisolone, vasopressin and T3/thyroxine (72).
Preservation factors
This study focuses on strategies to treat the donor prior to commencement of the
multi-organ retrieval procedure. This is dealt with in detail in the next section. Other
preservation variables are of the organ itself. A great deal of work has been done in
the development of the preservation solutions used to flush and store organs in prior
to implantation. These are balanced to maintain cellular homeostasis, provide energy
and reduce the effect of ROS. University of Wisconsin solution has emerged as the
standard (20). The method of preservation has also been examined by comparing
cold storage with pulsatile machine perfusion. With improvements in technology the
perfusion technique may be shown to be of benefit, but in a recent large registry
study no benefit was demonstrated over cold storage (73).
Recipient management
The most important modifiable factor that has been shown to be of benefit in the
recipient is adequate hydration. The administration of human albumin solution to




The concept of treating an organ in order to protect it, prior to a known impending
injury is termed preconditioning. It was first described by Murry el al in 1986 in the
heart and has since been shown to apply in numerous circumstances (75). Many
different strategies have been explored, which can be classified as physical or
pharmacological.
Physical
Physical manoeuvres that can confer protection include hyperthermia, ischemia and
oxidative stress. Whole-body or organ hyperthermia has been shown to be of benefit
in a number of models relevant to transplantation (76-83) but is unlikely to be
practical in the clinical setting. Hyperthermia is associated with induction of Hsps,
which are believed to confer cellular protection. This thesis explores the up-
regulation of Hsps and the potential cellular protection conferred in detail; Hsps are
discussed further in section 1.6 (page 51).
Ischemic preconditioning (IP) is the most widely studied form of preconditioning. It
can be used in different forms of surgery where an organ is to be subjected to a
period of prolonged ischemia. Figure 1.6 illustrates examples of the different forms
of IP that have been described. Organ transplantation is particularly suited to IP
given that it is logistically relatively straight forward to render an organ ischemic for




Figure 1.6 Ischemic preconditioning strategies in surgery.
Continuous ischemia (A), ischemic preconditioning (B), intermittent ischemia (C)
and ischemic preconditioning as applied to solid organ transplantation (D). Ischemia,
black; reperfusion, white. (Re-produced from Selzner et al (84))
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In the kidney, results following IP have been inconsistent and appear to depend on
the exact timing of the insult and the species. Initial studies focussed on whether
renal artery occlusion prior to a second ischemic insult resulted in a poorer outcome.
The investigators were surprised to find that it did not, and indeed 'a modicum of
protection appeared to exist' (85,86) (Table 1.4). Islam et al found no benefit from
20 or 40 min renal artery obstruction in the rat, followed by a further ischemic insult
30 min later (87). A follow-up study from the same group identified a benefit when
the second insult was performed only 5 min after the initial ischemic insult (88). It
should be noted that any benefits or otherwise found in these studies cannot be
attributed to processes requiring protein translation, given the short time periods
examined. The most significant findings in the subject are from Park et al, who
demonstrated protection from 30 min bilateral ischemia 8 and 15 days after a 30 min
initial ischemic insult (89). In a follow-up study, the protection afforded by a 30 min
ischemia insult persisted for 12 weeks, with improved post-ischemic renal function,
less leukocyte infiltration and reduced post-ischemic disruption of the actin
cytoskeleton noted (90). IP in larger animals has been less successful and has not
been shown to be of benefit in dogs (91) and pigs (92), although the numbers in these
studies were possibly too small to show a statistically significant effect.
Ischemic preconditioning has been performed in humans with success (Table 1.5).
Clavien et al demonstrated the protective effects of IP in liver resection with inflow
obstruction, finding serum levels of aspartate transferase and alanine transferase were
reduced by more than twofold in the IP group versus controls, together with a
reduction in the levels of apoptosis, although there was no significant change in the
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Author Year Species Preconditioning Subsequent
insult
Ref
Zager 1984 Rat BO IR (85)
Zager 1985 Rat BO IR (86)
Yoshioka 1990 Rat BO IR (93)
Zager 1994 Rat UO/BO IR (94)
Islam* 1997 Rat UO IR (87)
Cochrane 1999 Rat BO IR (95)
Riera 1999 Rat Unknown IR (96)
Toosy 1999 Rat UO IR (88)
Behrends 2000 Pig UO IR (92)
Park 2001 Mouse BO IR (89)
Torras 2002 Rat BO Isograft (97)
Kosieradzki1" 2003 Dog UO IR/Allograft (91)
Park 2003 Mouse BO IR (90)
Fuller 2005 Rat UO Isograft (98)
J 00 2006 Mouse BO IR (99)
Table 1.4 Ischemic preconditioning in the kidney.
BO, bilateral occlusion. * no benefit shown in this study, but the following report by
Toosy et al from the same group showed a benefit, f no benefit shown. UO,
unilateral occlusion; BO, bilateral occlusion; IR, ischemic reperfusion.
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Author Year Organ Setting Study
design
Ref
Jenkins 1997 Heart CABG RCT (100)
Chen 1999 Lung Lung resection RCT (101)
Clavien 2000 Liver Liver resection RCT (102)
Nuzzo 2002 Liver Liver resection RCT (103)
Yang 2002 Lung Lung resection RCT (104)
Clavien 2003 Liver Liver resection Large RCT (105)
Azoulay 2005 Liver Liver transplantation RCT (106)
Koneru 2005 Liver Liver transplantation RCT (107)
Jassem 2005 Liver Liver transplantation RCT (108)
Cescon 2006 Liver Liver transplantation RCT (109)
Amador 2007 Liver Liver transplantation RCT (110)
Koneru 2007 Liver Liver transplantation RCT (111)
Table 1.5 Ischemic preconditioning in humans.
RCT, randomised controlled trial; CABG, coronary artery bypass grafting
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caspase 3 and 8 activity (105). The same group went on to show benefit in 100
consecutive liver resection patients randomised to IP or control (102). A prospective
randomised clinical trial of the safety and efficacy of IP in deceased donor liver
transplantation found that the procedure did contribute to a negative outcome, but did
not demonstrate any benefit with the conservative protocol used (112).
An interesting continuation of IP is the remarkable observation that ischemia at a site
remote to the organ in question has also been shown to be protective. For instance,
subjecting the liver to a short ischemic episode has been shown to protect the kidney
(113). Even effecting limb ischemia using a tourniquet has been shown to protect
distant organs. This was shown in a pig model of myocardial infarction with four 5
min cycles of lower limb ischemia; the same study demonstrated a reduction in
endothelial dysfunction in a human forearm IR model (114). Most excitingly for the
field of transplantation, four cycles of 10 min IR of the hind limb of rats was shown
to reduce the serum transaminase rise resulting from partial hepatic ischemia of the
left lobes for 45 min followed by 240 min of reperfusion. This protection was
associated with an induction of the small heat shock protein heme oxygenase-1 (HO-
1), and was abolished with the HO-1 inhibitor zinc-protoporphyrin IX (ZnPP). In
humans, an initial study found four 5 min cycles of lower limb IR to be protective in
children undergoing cardiac surgery (115).
Pharmacological
Although ischemic preconditioning has shown to be efficacious in many situations, it
may not always be practical to carry out and may carry unknown negative effects.
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The quest for a pharmacological means of inducing similar protective effects
promises much. Many different agents have been tried, although not as many in the
kidney model as in that of the liver (Table 1.6) (84). As discussed in section 1.4.4
(page 36), reactive oxidant species are thought to have a fundamental role in the
pathogenesis of IRI. A number of different antioxidants have been shown to be of
benefit in models of IRI, yet none have entered clinical practice, with the exception
of some constituents of preservation solutions (116-132). Anti-inflammatory agents
have also been used at every level of the inflammatory response: adhesion molecule
inhibition (49-51), inhibition of neutrophil infiltration (133), cytokine inhibition
(134) and leukocyte activation (135). Apoptotic pathways have been targeted with
caspase inhibitors (136). Of significant interest is the up-regulation of heat shock
proteins, which will be discussed in the next section. This is associated with heating
the organ (80-82) and with a number of pharmacological mediators of protection
(137-141).
Ethics
Preconditioning presents ethical dilemmas which require to be fully considered and
discussed within wider society. A paper exploring these ideas has recently been
published (142) and is included in appendix V (page 288).
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Mechanism Drug Species Insult Effector system Ref
Anti-oxidant Allopurinol Rat IRI Anti-oxidant (116,117)
CoPP Rat Isograft HO-1 (118-120)
SnPP Rat IRI HO-1 (121)
























Ascorbic acid Dog Autograft Anti-oxidant (128)
a-tocophheroi Rat IRI Anti-oxidant (129-131)














Bimosiamose Rat Isograft Selectin inhibition (144)
P-selectin glycoprotein
ligand-1
Rat IRI Selectin inhibition (50,51)















Erythropoeitin Rat IRI Hsp70 (140)
1,25-dihydroxyvitamin D3 Rat IRI Hsp70 (141)
Apoptosis Caspase-1 inhibitor Rat IRI Caspase-1 (136)
Unknown* Insulin Rat IRI - (145)
Table 1.6 Pharmacological agents reported to confer protection against IRI in
kidneys.
* see chapter 5. CO-RM, carbon monoxide-releasing molecule; HO-1, heme
oxygenase-1; CO, carbon monoxide; SNP, sodium nitroprusside; SnPP, tin-
protoporphyrin IX; CoPP, cobalt protoporphyrin; IRI, ischemia/reperfusion injury
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1.6 The heat shock protein response
1.6.1 Overview
Heat shock, or stress proteins (Hsps) are a highly conserved group of intracellular
chaperones that are expressed when a cell is exposed to one of an array of metabolic
insults including heat (146), oxidative stress (147), hypoxia (148), ischemia (149),
osmotic stress (150) and heavy metals (151). Increased Hsp expression following
stress is associated with a tolerance to a subsequent injury that would otherwise be
lethal (152). Hsp up-regulation has been associated with cytoprotection in many
models of cellular stress and has great potential for future clinical intervention (153).
One area of promise is solid organ transplantation (Table 1.7). Heat-induced
expression of stress proteins has been associated with protection in rat models of
kidney (80,81), liver (76,154) and lung (79) transplantation. Increased Hsp70
expression by gene transfer has improved outcome in rat lung isografts (155) and
reduced IRI injury following rat heart transplantation (156). Much interest has been
shown lately in the small heat shock protein, HO-1 (also known as Hsp32) (157),
which has been associated with an improvement in outcome in heat-treated rats
subjected to liver (76,158) and kidney transplantation (119). HO-1 gene transfer has
been associated with improved outcome in kidney transplantation (159) and chemical
up-regulation of HO-1 protects livers from IRI (160).
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Author Year Species Stimulus Organ Model Protein Ref
Perdrizent 1993 Swine Heat Kidney Allograft Hsp72 (78)
Hiratsuka 1998 Rat Heat Lung Isograft Hsp70 (79)
Hiratsuka 1999 Rat Gene
transfer
Lung Isograft Hsp72 (155)





Matsumoto 2001 Rat Heat Liver Isograft Hsp72 (154)
Lin 2001 Rat Heat Liver IR Hsp72 (77)
Fudaba 2001 Rat GGA* Liver Isograft Hsp72/90 (161)
Redaelli 2001 Rat Heat Kidney Isograft Hsp72/HO-1 (80)
Redaelli 2002 Rat Heat Kidney Isograft Hsp72/HO-1 (81)
Redaelli 2002 Rat Heat Liver Isograft HO-1 (158)
Wagner 2003 Rat Heat Kidney Isograft HO-1 (82)
Yamagami 2003 Rat Heat Liver IR Hsp72/HO-1 (83)
Mokuno 2004 Rat Heat Liver Isograft Hsp72/90/HO-1 (76)
Patel 2004 Human Ischemia Liver IR HO-1 (162)
Suzuki 2005 Rat GGA* Kidney IR Hsp70 (137)
Jo 2006 Rat Heat Kidney IR Hsp70 (163)




1.6.2 Heat shock proteins
The first description of a response associated with stress was in 1962 when Ritossa
reported the occurrence of 'chromosomal puffs' in drosophila busckii subjected to
mild heating, sodium salicylate or dinitrophenol (164). This heat shock response
occurred very quickly and was associated with RNA synthesis (165,166). With the
advancement of laboratory techniques, a group of proteins were identified that were
up-regulated in association with the stress (167). These were termed heat shock
proteins (168). Hsps of different molecular weights exist with Hsp27, Hsp40, Hsp60,
Hsp70 and Hsp90 being the most widely studied. A group of related proteins, termed
the glucose-regulated proteins (Grps), are homologues found in the endoplasmic
reticulum of cells. These were discovered to be induced when cells were starved of
glucose, but are also induced following heat and other stresses.
Initial work in the mid-70s was carried out exclusively in drosophila. When
researchers began investigating the Hsp response in other organisms it was apparent
that it was highly conserved across species (169). Another interesting feature,
identified in 1975 by Gerner and Schneider, was that HeLa cells subjected to a non-
lethal heat shock were protected against a subsequent heat stress (152).
1.6.3 Heat shock protein function
It is an important observation that Hsps are well conserved across virtually all
organisms and suggests that that Hsp function is essential to cell survival. It has long
been appreciated that protein folding is determined by protein structure, i.e. amino
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acid sequence (170). However, in order for protein folding to occur accurately other
proteins, termed chaperones, are required to assist proper conformational
arrangement (171,172). Hsps have been identified in fulfilling this chaperone
function (173). Hsps are present in physiological conditions, but a number are only
expressed during stress. The function of Hsps in general has been found to be more
wide-ranging than just assisting in protein folding (Table 1.8) and specific heat shock
proteins have been identified in having particular roles. HO-1 has been shown to
have antioxidant and anti-inflammatory functions (see Chapter 5) (174); Hsp25/27
inhibits actin polymerisation (175,176); Hsp60 is important in mitochondrial protein
folding and assembly (177); the Hsp70 family may have a role in protein trafficking
(178) and degradation (179); and Hsp90 takes part in multi-chaperone complexes
(see chapters 6, 7 and 9). In models of cellular protection involving Hsps, it is often
unclear which Hsp function is acting to reduce the injury, but it is highly likely to be
a combination of a number of effects.
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State Function




Stress Repair damaged protein
Prevent aggregation damaged protein




Table 1.8 Functions of heat shock proteins in physiological and stress conditions.
Adapted from Kelly K. Heat Shock (Stress Response) Proteins and Renal
Ischemia/Reperfusion Injury (180).
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1.6.4 Heat shock protein regulation
The heat shock protein response is regulated by heat shock transcription factor-1
(HSF1). In order to achieve transcriptional activation, HSF1 must form a
homotrimer, move to the nucleus and become hyperphosphorylated (181). The
mechanisms that control this transactivation continue to be delineated but important
components appear to include the repressive phosphorylation by a number of kinase
cascades (explored further in chapter 4) and the formation of a repressive multi-
chaperone complex (discussed in chapters 6).
Heat shock proteins, therefore, are strongly associated with cellular protection and
up-regulation in the clinical setting promises significant benefits. Transplantation
necessitates inflicting an injury on an organ, but the planned nature of this insult
presents opportunity to act to reduce the magnitude of this injury. This thesis will
examine potential mechanisms by which Hsps can be induced and any associated
protective effect in the kidney.
56
Chapter 2 - Aims
The principal aim of this study:
To identify new strategies ofprotection utilising the heat shock/stress protein
response that can be applied to ischemia/reperfusion injury in the kidney.
Within this overall aim:
1. To increase the understanding of the repressive phosphorylation of heat shock
transcription factor-1 (HSF1) and how this might be reversed to stimulate the
stress protein response.
2. To increase the understanding of the repressive multi-chaperone complex and
how this might be manipulated to stimulate the stress protein response.
3. To increase the understanding of heme oxygenase-1 (HO-1) regulation and
how it may contribute to protection from ischemia/reperfusion injury.
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Chapter 3 - Materials and Methods
3.1.1 Materials
All reagents were obtained from Sigma-Aldrich Co. Ltd. (Poole, Dorset, UK) unless
otherwise stated. GSK3, Nrf2 and lamin A/C antibodies were obtained from Santa
Cruz (Wembley, UK); Hsp90, Hsp70, Hsp27, Hsp25 and HO-1 from Stressgen
(Victoria, BC, Canada); P-actin antibody from BD Biosciences (San Diego, CA,
USA); phospho-GSK3p (ser9) (pGSK3P), phospho-ERKl/ERK2 MAPK
(Thr202/Tyr204) (E10) monoclonal (p-ERKl/2), ERK1/ERK2 MAPK (total-
ERK1/2), phospho-p38 MAPK (Thrl80/Tyrl82) (28B10) monoclonal (p-p38), p38
MAP kinase (5F11) monoclonal (total-p38) antibodies from New England Biolabs
(Hitchin, Hertfordshire, UK).
3.1.2 Cell culture
Renal adenocarcinoma cells (ACHN) (European Collection of Cell Cultures, Porton
Down, UK) were maintained in Dulbecco's modified Eagle's medium (Gibco,
Paisley, UK) supplemented with 10% fetal bovine serum, penicillin (50 U/ml),
streptomycin (50 pg/ml) and non-essential amino acids (5%). Cultures were
maintained at 37°C in a humidified atmosphere of 5% CO2, 95% air. Cells were
passaged regularly and all experiments were performed with sub-confluent cultures.
Stocks of cells were stored in liquid nitrogen following suspension in 10% DMSO in
FCS. Following 10-12 passages, working cell cultures were discarded and new ones
established from stock cells.
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3.1.3 Plasmid DNA amplification
The various plasmids used were grown up in the following manner.
Mini-broth preparation
5 pg of plasmid DNA was added to 50 pi transformation competent E. coli. After 30
min on ice, tubes were heat shocked at 42 °C for 45 seconds and returned
immediately to ice for 2 min. 450 pi of SOC medium was added and reactions
incubated at 37 °C with vigorous shaking for 1 h. Reactions were diluted 1/10 with
SOC medium and 100 pi plated onto LB agar plates which were incubated overnight
at 37 °C. White colonies were 'picked' from the plates, transferred to 3 ml LB broth
containing 50 pg/ml ampicillin and incubated overnight at 37 °C with shaking.
Mini-prep
1.5 ml mini-broth was centrifuged at 13 000 g for 2 min. The pellet was resuspended
in 100 pi TE buffer (pH 8.0). To this was added 200 pi 0.2N NaOH/1% sodium
dodecyl sulphate (SDS), followed immediately by 150 pi 3M potassium
acetate/11.5% acetic acid, followed immediately by 400 pi phenol/chloroform (1:1).
This was centrifuged at 13 000 g for 5 min at 4 °C and the upper phase transferred to
a new tube. 200 pi isopropanol was added and following further centrifugation at
13 000 g for 10 min at 4 °C, the supernatant was removed and discarded. The pellet
was washed in 100 pi cold 70% ethanol, recovered by centrifugation, air-dried and
resuspended in TE buffer with RNAse (100 pg/ml), which was incubated 37 °C for 5
min. An digestion with appropriate restriction enzymes was then performed to
confirm presence of plasmid DNA.
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Maxi-broth preparation
The remaining 1.5 ml of mini-broth was added to 250 ml LB medium and incubated
overnight at 37 °C with vigorous shaking. Bacterial cells were harvested by
centrifugation at 6000 g for 15 min.
Maxi-prep
Plasmid DNA was extracted bacteria using the Endofree plasmid maxi kit (Qiagen,
Crawley, UK) as per the manufacturer's instructions. The yield was determined by
spectrophotometry.
3.1.4 Western blot
Whole cells extracts were produced by scraping cells in ice-cold RIPA buffer
(typically 150 pi for a 6-well plate) with protease inhibitors (Sigmafast protease
inhibitor tablets). Extracts were centrifuged at 10 OOOg for 10 min and the
supernatent kept. Total protein concentration was determined by the Lowrie method
(BioRad, Hemel Elempstead, UK). Cytoplasmic/nuclear lysates were prepared using
Gobert's method (182). Proteins were separated by SDS-PAGE: typically, a 10%
Tris/HCl gels was made with 3.96 ml dELO, 2.5 ml 1.5M Tris-HCl (pH 8.8), 100 pi
10% SDS, 3.33 ml Acrylamide/Bis 30% stock (BioRad), 100 pi 10% ammonium
persulphate and 10 pi TEMED. A stacking gel was placed on top of this (see
Appendix 1, page Appendix I - Buffers278). 20 pg of protein was used per minigel
well. Gels were run for 40 min at 200V. Transfer was to nitrocellulose membranes
(BioRad) was performed with electroblotting (1 h at 80 mA). The membranes were
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soaked in blocking buffer (TBS, 0.05% Tween 20, 5% non-fat milk) followed by
blocking buffer containing primary antibody. After washing, the membranes were
exposed to a horseradish peroxidase-conjugated secondary anti-mouse (Upstate,
Milton Keynes, UK) or anti-rabbit (Santa Cruz) antibody and were used at a
concentration of 1:5000. Enhanced chemiluminescence reagent (Amersham,
Chalfont St Giles, UK) was used followed by development using autoradiography.
Membranes were stripped by washing in Restore Western Blot Stripping Buffer
(Pierce, Rockford, IL, US) for 15 min at room temperature and equality of loading
confirmed by probing for P-actin for whole-cell extracts, and lamin A/C for nuclear
extracts.
3.1.5 DNA mobility shift assay
[y32P]ATP method
Forward and reverse oligonucleotides specific for the sequence being analysed (as
detailed in the relevant chapters) were obtained (TAGN, Newcastle, UK). Heat shock
elements (HSE) forward 5' ATCTCGGCTGGAATATTCCCGACCTGGCAGCCGA
and reverse 5' GATCTCGGCTGCCAGGTCGGGAATATTCCAGCCGA. These
were annealed in 0.5M NaCl by heating at 95°C for 3 min, followed by 2 h at room
temperature. To radiolabel, 50 ng double-stranded probe was added to 1 pi T4
polynucleotide kinase (T4 PNK) (Promega), 1 pi 10X PNK buffer, 3 pi water and 3
pi [y32P]ATP; the reaction mixture was incubated at 37 °C for 1 h. Excess unlabelled
[y P]ATP was removed using the QIAquick nucleotide removal kit (Qiagen) as per
the manufacturers instructions. The binding reaction was performed in 20 mM
HEPES (pH 7.5), 50 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol (DTT), 0.05%
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NP40, 10% glycerol (all final concentrations). 10 pg protein, around 0.25 ng (1 pi)
labelled probe and 100 pg poly [d(I-C)] were added and incubated for 20 min at
room temperature. Control reactions using 20X molar excess of unlabelled consensus
sequence, unlabelled mutant probe or with the inclusion of a shift antibody specific
to the protein being analysed were also performed as appropriate. Reactions were run
on 5% TBE polyacrylamide gels (Biorad) at 200V, the length of time being dictated
by the size of product sought. Gels were dried and exposed to x-ray film.
Digoxigenin method
Digoxigenin-labelled forward and reverse oligonucleotides were obtained (TAGN)
and annealed as above. The binding reaction was performed in 20 mM HEPES (pH
7.6), 1 mM EDTA, 10 mM ammonium sulphate, 1 mM DTT, Tween 20 0.2% (w/v),
30 mM KC1 (all final concentrations). 20 pg protein, around 0.04 ng digoxigenin-
labelled probe, 50 pg poly [d(I-C)] and 5 pg poly L-lysine were added and incubated
for 20 min at room temperature. Loading buffer with bromophenol blue (0.05X TBE
buffer, 12% glycerol final concentrations) was added and samples run as above. Gels
were transferred to positively charged PVDF membranes, oligonucleotides cross-
linked by exposure to around 120 mJ UV light, blocked, probed with anti-
digoxygenin antibody (Fab fragments conjugated with alkaline phosphatase), treated
with chemiluminescent substrate (CSPD) and exposed to x-ray film.
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3.1.6 RNA isolation and fluorescence detection real-time
polymerase chain reaction
RNA extraction and purification was performed using a TRIzol (Invitrogen, Paisley,
UK). RNA samples were treated with DNAse and then run as a template for a
standard PCR reaction using (3-actin primers to exclude the presence of
contaminating DNA. RNA was then reverse transcribed to cDNA using avian
myeloblastosis virus reverse transcriptase (Promega, Southampton, UK) and random
decamers (Ambion, Huntingdon, UK). Fluorescence-detected real time PCR was
then performed using specific primers and TAMRA labelled FAM-probe. The
following primer and probes were designed: Human Hsp70: Forward, 5'
CAGAGTGCTGCCAAAAACTC; reverse 5' CCTAAGGCTTTCCTCTTGCAAA;
Probe: 6-FAM-CTGGAGGCCCATGTCTTCCATGTGA-TAMRA. Mouse Hsp70:
Forward, 5'-GGTGGTGCAGTCCGACATG; reverse, 5'-TTGGGCTTGTCGCCGT;
Probe: 6-FAM-CACTGGCCCTTCCAGGTGGTGAA-TAMRA. A standard reaction
contained Taqman universal master mix 12.5pl (Applied Biosystems, Warrington,
UK), primer probe/mix 7pl (primers 25 pM, Probe 5pM), 18S primer/probe mix
1.25pl, and water 1.75jal) and cDNA template 2.5pl. Samples were run on an ABI
Prism 7700 Sequence Detection System and analysed using Sequence Detector 7.1
(Applied Biosystems).
3.1.7 Transfections
Akt expression constructs (Upstate) are based on the pUSEamp vector. The activated
form (Akt-myr) contains an N-terminal myristoylation sequence targeting Akt to the
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plasma membrane. The dominant-negative form (Akt-K179M) contains a methionine
for lysine substitution at residue 179 abolishing Akt kinase activity. Wild-type form
(Akt-WT) contains the unaltered Akt sequence and an empty vector (pUSEamp) was
used as a control. The HO-1 luciferase reporter construct (pHOGL3/l 1.6) was a kind
gift of Dr A Agarwal (University of Alabama, USA). The heat shock protein 70-P-
galactosidase (Hsp70-P-gal) reporter construct was a kind gift from WJ Welch
(UCSF, USA). The HIF1 reporter construct (pHRE-luc) was a kind gift of Professor
Esumi (National Cancer Center Research Institute East, Japan). Transfection
efficiency was controlled by co-transfecting with a p-galactosidase (pSV-P-gal) or a
luciferase (pGL3-luc) expressing control vector (Promega). Transient transfections
were performed using Fugene (Roche, Lewes, East Sussex, UK) at a 6:1 ratio reagent
to DNA. Experiments on transfected cells were performed 24 - 48 h later.
3.1.8 Luciferase/p-galactosidase assay
Cells were co-transfected with the appropriate reporter vector and control vector and
treated as per experimental protocol the following day. Cells were lysed with reporter
lysis buffer (Promega) after which 20 pg lysate was combined with 50 pg luciferase
assay reagent and the resulting light emission measured on a luminometer
(Fluoroskan Ascent Fl, Thermo Electron, Basingstoke, UK). The remaining lysate
(80 pg) was combined with P-galactosidase assay 2X buffer and following
incubation at 37°C for 4 h was read at 420 nm on a spectrophotometer (Ultraspec
2000, Pharmacia Biotech).
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3.1.9 Cell viability assays
MTT assay
Cells were treated as per experimental protocol in 96-well plates and recovered in
100 pi medium per well. 20 pi of 3-(4,5-dimethylthiazole-2-yl)-2,5-
dipenyltetrazolium bromide (MTT) (5 mg/ml) was added for 2 h. Wells were then
carefully emptied and resulting tetrazolium crystals were dissolved in 10 % SDS
(pH3.0). Samples were analysed on a plate reader (test: 570nm; reference: 630nm),
decreasing optical density reflecting a decreasing number of viable cells. Hydrogen
peroxide was typically used as a stressor at a concentration that resulted in 50%
cellular death (Figure 3.1).
Figure 3.1 Relative survival of ACHN cells following H2O2 treatment.
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Cells were exposed to increasing concentrations of H2O2 for 16 h. MTT was added
for 2 h and the resulting tetrazolium crystals dissolved in SDS. Samples were
analysed on a plate reader.
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3.1.10 Immunohistochemistry
Tissue was fixed in methacarn (70% methanol, 20% chloroform, 10% glacial acetic
acid) for 24 h before being mounted in paraffin. Sections were cut and mounted on
SuperFrost slides (Fisher Scientific, Pittsburgh, PA, US). Sections were de-waxed in
xylene for 10 min and rehydrated through decreasing concentrations of alcohol into
distilled water. Endogenous peroxidase was blocked with 3% H2O2 for 10 min
followed by washing in distilled water. Antigen retrieval was performed by
microwaving sections in 10 mM citrate buffer (pH 6.0) for 15 min. Slides were
cooled and transferred to TBS. Sections were blocked in 10% normal serum of the
species the secondary antibody was raised in for 20 min. Primary antibody in 10%
normal serum was then applied for 1 h at room temperature or overnight at 4 °C.
After washing in TBS the sections were exposed to peroxidase-conjugated secondary
antibody for 30 min. After washing in TBS for 5 min, sections were exposed to
peroxidase substrate solution (3,3-diaminobenzidine tetrahydrochloride, DAB)
(DAKO, Glostrup, Denmark). Following counterstaining with haematoxylin, sections
were dehydrated through increasing concentrations of alcohol to xylene, before a
cover-slip was mounted. Sections were then examined with light-microscopy.
Appropriate primary antibody-only and secondary antibody-only controls were
always performed to ensure no non-specific staining was taking place.
3.1.11 Immunofluorescence
Cells were cultured in chambered slides and treated as per experimental protocol.
They were subsequently fixed with methanol and blocked in 10% normal serum of
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the species the secondary antibody was raised in for 20 min. Primary antibody in
10% normal serum was then applied for 1 h at room temperature or overnight at 4
°C. After washing in TBS the sections were exposed to FITC-conjugated secondary
antibody for 30 min, and typically counterstained with Hoechst prior to mounting.
Fields were visualised with a Leica DM IRB microscope fitted with a Hamamatsu
camera. Images were stored using the Leica Improvision software. Primary antibody
only and secondary antibody only groups were always included as controls.
3.1.12 RNA interference
Cells were seeded in 6-well plates and transfected the following day with the
appropriate siRNA (Santa Cruz) or control siRNA as per manufacturer's protocol. 48
h later transfected cells were treated and lysed. Adequacy of effect was ascertained
with Western blot analysis with anti-Nrf2 antibody.
3.1.13 Statistical analyses
Data are presented as means and standard error of the mean (S.E.M.). Statistical
comparisons for parametric continuous data were made using Student's t-test, one¬
way analysis of variance (ANOVA) and two-way ANOVA without interaction
(using the Tukey post hoc correction for multiple comparisons). Non-parametric data
was compared using the Mann-Whitney U test. All comparisons were performed on
SPSS vl4.0 (SPSS, Chicago IL, USA).
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3.2 Firefly luciferase terminally degraded by mild heat
exposure: an underappreciated phenomenon with
implications for transfection efficiency control
3.2.1 Introduction
The use of reporter vectors is a rapid and highly sensitive method of investigating
factors regulating gene expression (183). The promoter region of the gene of interest
is cloned upstream of a sequence encoding the reporter enzyme; the resulting protein
expression is proportional to gene activity and can be easily and reliably determined.
In order to control for potential variation in transfection efficiency, it is common
practice to co-transfect the reporter vector with a control vector, constitutively
expressing a second distinct reporter enzyme under a viral promoter. For this second
vector to function as an accurate control, enzyme expression must be independent of
the experimental treatment and depend only on the number of cells that took up the
plasmid DNA (184).
Heat shock proteins are highly conserved intracellular chaperones and are expressed
when a cell is exposed to a stress (173). While investigating the induction of heat
shock protein 70 (Hsp70) following heat exposure in renal adenocarcinoma cells
(ACHN), an Hsp70B p-galactosidase reporter vector (Stressgen Biotechnologies
Corp) was used. It was necessary to control for transfection efficiency so cells were
co-transfected with the pGL3 luciferase control vector (Promega), which contains the
luc+ gene and expresses firefly luciferase under the control of the simian virus 40
(SV40) promoter. It was observed that luciferase activity in groups transfected with
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the pGL3 vector and subjected to a mild heat exposure was much lower than
expected.
In order to investigate whether this observation was an effect of heat on transcription
we co-transfected the pGL3 vector with the pSV p-galactosidase control vector
(Promega), also under the control of the SV40 promoter. The following day, groups
were exposed to a mild heat induced stress (43 °C) for increasing lengths of time up
to 45 min, after which all remaining groups were returned to 37 °C and recovered for
further increasing time intervals. Additional examination involved exposing
recombinant firefly luciferase (Sigma, Poole, UK) to a series of mild heat exposures
for increasing lengths of time. All experiments were independently repeated 3 times.
3.2.2 Results and discussion
Cells transfected with both the pGL3 luciferase vector and the pSV p-galactosidase
control and subjected to mild heat exposure demonstrated a marked reduction in
luciferase activity compared with P-galactosidase activity, which remained
unchanged (Figure 3.2). This occurred despite both enzymes being under the control
of the same SV40 promoter, suggesting the effect was independent of transcription.
The reduction was related to the length of heat exposure and a statistically significant
difference between the pGL3 luciferase group and the pSV p -galactosidase control
was observed following 30 min of heat exposure (Mann-Whitney U p<0.05).
Luciferase activity increased during recovery and the difference between the groups
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ceased to be statistically significant at 2 h, and remained so until the end of the
experiment at 24 h (Figure 3.2B).
On exposing recombinant firefly luciferase to varying temperatures (Figure 3.3) a
time and temperature dependent response was observed with luciferase activity
decreasing markedly over time and with increasing temperature.
Firefly luciferase is the most commonly used bioluminescent reporter (185). Despite
the sensitivity and convenience of the enzyme assay inherent problems exist,
particularly relating to thermostability, both in vivo and in vitro (186). Improved heat
tolerance of luciferase has been demonstrated using mutagenesis to achieve a single
amino acid substitution in both the Japanese Firefly (Luciola cruciata and Luciola
lateralis) (187) and the North American Firefly (Photinus pyralis) (188).
Modifications of the luciferase gene have improved performance in other areas,
including elimination of peroxisomal translocation (185); however, thermostability is
not a feature of current commercial versions. Nguyen and colleagues have previously
demonstrated the sensitivity of luciferase to heat. Inconsistent with our findings, his
data demonstrates a significant decrease in p -galactosidase activity in mouse-
derived cells exposed to heat, although no loss of activity was seen in in vitro studies.
However, our model used a human cell-line, protein translation was not abolished
with cycloheximide and cells were heated to 43 °C, not 45 °C. These factors may
explain the difference in findings.
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In conclusion, when a luciferase reporter vector is used to determine gene expression
in cells exposed to mild heat, the activity of the gene in question may be
underestimated. When, however, a luciferase control vector is used in cells exposed
to heat, transfection efficiency may be under estimated, and so gene expression
overestimated between groups.
These data demonstrate the propensity of firefly luciferase to become inactive
following mild heat exposure. The pGL3 control vector should be used with caution
in protocols that involve exposure to a mild heat insult. These findings have been
published and the paper is included in Appendix V (page 288).
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Figure 3.2 Luciferase and p-galactosidase activity following mild heat exposure.
(A) The pGL3 luciferase and pSV p-galactosidase control vectors were co-
transfected into a renal adenocarcinoma cell-line (ACHN) using the Fugene
transfection reagent (Roche), as per the manufacturers protocol. The following day,
groups were heated to 43 °C for varying lengths of time. Whole cell extracts were
prepared with reporter lysis buffer (RLB). A protein assay was performed (Lowrie
method; BioRad) and luciferase activity determined using the luciferase assay system
(Promega). P-galactosidase activity was determined using the colorimetric P-
galactosidase assay system (Promega). NT, non-transfected control; T, transfected
control; * Mann-Whitney U p<0.05. (B) Cells were transfected as above and heated
to 43 °C for 45 min 24 h later. Cells were lysed in RLB and luciferase and P-








Figure 3.3 Activity of recombinant firefly luciferase (Sigma) following mild heat
exposure.
1 pg of firefly luciferase was dissolved in distilled water (1 pg/p.1) and made up to
20 pi with PBS. Samples were placed in a thermocycler (Techne PHC3) and heated
for the times specified. Luciferase activity was determined using the luciferase assay
system (Promega).
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Chapter 4 - Heat shock transcription factor-1
regulation through the PI3K/Akt axis
4.1 Introduction
4.1.1 Background
As discussed in section 1.6, the induction of Hsps in both in vivo and in vitro models
of cell stress has been shown to confer cytoprotective benefit. In particular, in animal
models of transplantation Hsps have been shown to improve survival, both in the
transplanted organ and the animal itself (Table 1.7). A clear understanding of the
molecular mechanisms underlying this response is fundamental to the success of
potential clinical interventions. This chapter focuses on the regulation of Hsps by
heat shock transcription factor-1 (HSF1) and examines a potential mechanism of
activation. In this introduction evidence will be presented that forms the basis of a
hypothetical mechanism by which HSF1 is activated. It will be contended that the
inducible stress protein response is mediated exclusively by HSF1; that repression of
HSF1 occurs following phosphorylation of certain serine residues; that glycogen
synthase kinase 3p (GSK3P) mediates the most important component of this
repression; that GSK3P can be inactivated through activation of the
phosphatidylinositol 3-kinase (PI3K)/Akt cascade; and that PI3K/Akt is activated by
insulin-like growth factor-1 (IGF-1) and insulin. This description can be followed
with the aid of Figures 4.1 and 4.3.
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4.1.2 Heat shock transcription factor-1
Heat shock protein expression is regulated by members of the heat shock
transcription factor (HSF) family5. Following the isolation of a single hsfgene in
Saccharomyces cerevisiae (189,190) four members of the HSF family have been
identified in vertebrates (191-194). Of these, HSF1 and HSF-3 (exclusively avian)
are activated in response to classical stress stimuli; HSF-2 is not and appears to have
a role in developmental regulation (195-198); HSF-4 is most recently described and
awaits full characterisation (194).
In mammalian cells, the stress protein response is mediated exclusively by HSF1
The importance of HSF 1 in the induction of Hsps in response to stress became clear
from studies performed in the mid-90s. As Voellmy observes in a recent review
(199), the inducible stress protein response (as distinct from constitutive Hsp
expression) appears to be mediated by HSF1 alone in vertebrate cells**. In support of
this view is the observation that although cultured embryonic cells derived from
HSF mice do express constitutive Hsps, the Hsp response to stress is completely
abolished (200). Likewise, Zhang et al reported elimination of stress-inducible
Hsp70 and Hsp25 in mouse fibroblasts derived from HSFl"7" mice (201). In mice at
least then, the expression of stress-induced Hsps can only occur following HSF1
activation. There have been no studies providing direct evidence of HSF 1 exclusivity
in mediating the stress protein response in human cells; however, convincing data
§ Hsp32/HO-l is termed a heat shock protein but does not take part of the classical heat shock
response. It is not regulated by the HSFs in humans, although does come under their control in other
mammalian systems, including murine. It is regulated by a number of transcription factors including
AP-1, AP-2, NFkB and Nrf2. This is dealt with in more detail in chapter 5.
excluding avian cells where HSF1 and HSF3 both contribute to stress resistance
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exists suggesting HSF-2 does not respond to heat shock in humans (or any other
eukaryote) (202), that HSF-3 is exclusively avian (193) and that human HSF-4
appears transcriptionally inactive (194). It is reasonable to assume, therefore, that in
human models of stress, Hsp gene induction is HSF1-dependent.
Analysing HSF1 structure as a means ofelucidatingfunction
The activation of HSF1 in response to stress is multi-faceted but there is compelling
evidence that it occurs in a predominately post-translational setting (203). A number





4. Loss of transcriptional repression
These four events can be seen to occur prior to specific Hsp gene activation
following exposure of a cell to the appropriate stimulus. Through systematic
mutagenesis experiments, the functional contribution of different HSF1 protein
domains has been determined (Figure 4.2). Two hydrophobic repeat sequences have
been identified that are likely to contribute to the repression of trimerisation (HR-
B/C). A further hydrophobic repeat sequence is necessary for trimerisation to occur
(HR-A).
+t Homotrimerisaton: the formation of a reaction product containing three identical molecules (in this











Figure 4.1 Activation of heat shock
transcription factor-1 (HSF1).
Following exposure to a number of
different stressors FISF1 undergoes
trimerisation, nuclear localisation and
loss of transcriptional repression. These
processes are governed by
phosphorylation/dephosphorylation
events at key residues (chapter 4) and
protein-protein interactions (chapters 6 -
8). Despite significant study, the kinetics
of phosphorylation/dephosphorylation
events and implications thereof remain
relatively poorly defined.















1 A B 1 C
Helix-turn-helix
Nuclear localisation signal
Hydrophobic repeat (leucine zippers)
C-terminal repeat
Phosphorylatable serines (- transcription)
Phosphorylatable serine (+ transcription)
Repression of
trimerisation
Figure 4.2 Structure of human HSF1 with functional corollaries.
(after Voellmy 2004 (199)).
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The nuclear localisation signal exists in the region of amino acids (aa) 117 and 208.
An amino-terminal DNA-binding helix- loop-helix interacts with so called heat
shock elements (HSE) upstream of the specific Hsp gene. The region from aa 203 to
around 330 functions as a repressor of transcription, while aa 409 to 529 facilitates
transcription activation.
Although the four requirements for transcriptional activation are distinct and
correspond to specific regions of the HSF1 structure, it is unlikely that
homotrimerisation can be uncoupled from DNA-binding, and by implication nuclear
localisation (204). Consequently, any event that effects trimerisation is likely to
result in HSF1 DNA-binding. Nonetheless, DNA-binding does not imply
transcriptional activation, the latter requiring further steps in order to occur. This is
most apparent in cells treated with salicylate, where HSF1 trimerisation and DNA-
binding occurs, but Hsp gene activation does not (205).
Attempts to rationalise the events required for homotrimerisation/DNA-binding and
transcriptional activation have fallen short. As yet, a cohesive description of HSF1
activation does not exist and while great progress has been made much remains
unclear. During the four step activation process (in which monomeric HSF1 becomes
trimerised and transcriptionally active), three global alterations in the HSF1 state
have been observed:
1. Loss of a repressive multi-chaperone complex.
2. Dephosphorylation of 'repressive' residues.
3. Hyperphosphorylation of'facilitative' residues.
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Repression of trimerisation through interactions between HSF1 and one or more
other proteins has become increasingly evident over recent years: the multi-
chaperone complex theory. Additionally, a number of
phosphorylation/dephosphorylation events alter both HSF1 DNA-binding ability and
transcriptional activity. Crucially, the relationship between these alterations in FISF1
state and each step in the four step activation process remain obscure.
The importance of the multi-chaperone complex in HSF 1 regulation is now
recognised and will be discussed and investigated in detail in chapters 6-9. This
chapter will focus on the role of phosphorylation/dephosphorylation events in
mediating HSF1 regulation. Specifically, I will examine one putative mechanism by
which transcriptional repression of HSF 1 is maintained.
Phosphorylation at certain serine residues represses HSF1 activation
Phosphorylation of HSF1 alters its transcriptional activity (203): phosphorylation of
certain residues represses transcription while phosphorylation at other sites increases
transcriptional competence. One of the most important factors in altering HSF1
activity by phosphorylation is GSK3p.
Numerous factors have been reported to alter the activation state of HSF 1, but
contradictions exist (Table 4.1). Some studies describe transactivation of HSF1,
while others report repression following up-regulation of the same factor e.g. PKC,
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Kinase Function Reference
GSK-3 (-) transactivation (206-211)
ERK (-) transactivation (206,209,210,212-215)
JNK (-) transactivation (216)
p38 MAPK (-) transactivation (214)
PKC (-) transactivation (210)
CaMKII (+) transactivation (217)
JNK (+) transactivation (218,219)
PKA (+) transactivation (220-222)
PKC (+) transactivation (220,221,223-227)
Rac1 (+) transactivation (228-230)
Table 4.1 Kinases reported to alter HSF1 activity.
A myriad of kinases have been implicated in the regulation of HSF1. This table
presents those reported to alter the transactivation state of HSF1 to date.
Methodological problems exist in many of the reports and the picture remains
confusing. Note that PKC and JNK have been described in some reports as being
required for transactivation, but in others as being negative regulators of HSF1.
GSK-3, glycogen synthase kinase-3; ERK, extra-cellular regulated kinase; JNK, c-
JUN N-terminal kinase; p38 MAPK, p38 mitogen activated protein kinase; PKC,
protein kinase C; CaMKII, calcium/calmodulin-dependent kinase II; PKA, protein
kinase A.
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JNK. While the possibility exists that the same kinase exerts different effects at
different stages of HSF1 activation, it is more likely that these observations are
mutually incompatible and methodological explanations will be found. Many reports
describe alterations in HSF1 activity following up or down regulation of a given
kinase, but most of this data is associative, with few demonstrating any causal link.
Even fewer have examined the phosphorylation/dephosphorylation of specific
residues in HSF1, arguably a more robust line of enquiry (Table 4.2).
One such study by Chu et al (209) identified the importance of two kinases in
repressing HSF1 transcriptional activity. The extracellular signal-regulated kinases
(ERK1/2) and GSK3p were shown to phosphorylate Ser-307 and Ser-303
respectively, both in vitro and in vivo, resulting in repression of transcriptional
activity. Through a number of elegant mutagenesis experiments the authors
concluded that in phosphorylating Ser-307, ERK1 primed subsequent
phosphorylation at Ser-303 by GSK3P, a so called canonical mechanism. When Ser-
303 was substituted for glycine (thus eliminating repressive phosphorylation at this
site), the ability of this mutated HSF1 to activate a Eisp70 promoter reporter
construct increased significantly. The same mutation at Ser-307 resulted in a less
prominent increase in activity. Mutations at both Ser-303 and Ser-307 caused an
increase in activity no greater than that seen with the Ser-303 mutation alone. So
while over-expression of both kinases resulted in repression of HSF1, it seemed
likely that ERK1 repression was GSK3P mediated. The importance of
phosphorylation at Ser-303 and Ser-307 in the negative regulation of FISF1 was
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Phosphorylation site Kinase Function Reference
Ser-230 CaMKII (+) transactivation (217)
Ser-303 GSK3 (-) transactivation (209-211)
Ser-307 ERK (-) transactivation (209,211,215)
Ser-363 PKC/JNK (-) transactivation (210,216)
Table 4.2 Serine residues in HSF1 identified to be phosphorylated by specific
kinases.
There have been few reports examining phosphorylation/dephosphorylation at
specific residues in HSF1. Four serine residues have been identified as targets for
phosphorylation. CaMKII, calcium/calmodulin-dependent kinase II; GSK-3,
glycogen synthase kinase-3; ERK, extra-cellular regulated kinase; PKC, protein
kinase C; JNK, c-Jun N-terminal kinase.
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substantiated by Kline and Morimoto (211) (who did not address the mechanisms by
which this occurred) and by Knauf et al (215).
Moving to earlier events in HSF1 activation, further studies examined the ability of
GSK3p to alter the DNA-binding ability of HSF1. In heat shock conditions, GSK3P
inhibition by LiCl (a chemical inhibitor of GSK3P) or GSK-binding protein were
found to increase HSF1 DNA-binding, as well as transcriptional activity in Xenopus
oocytes (208). Conversely, when the cells were microinjected with GSK3P mRNA or
active GSK3P, a significant reduction in DNA-binding (and transcriptional activity)
was observed , suggesting a role for GSK3P beyond that of mere transcriptional
repression. Additionally, Fie et al confirmed that ERK primes GSK3p
phosphorylation and that over-expression of GSK3P facilitates the inactivation of
activated HSF1 (206).
A contradictory report from Xia et al described the mapping of tryptic
phosphopeptides of HSF1 from HeLa cells. This suggested that phosphorylation at
Ser-307 was of greater significance in the negative regulation of HSF1 than
phosphorylation at Ser-303 (231). This report was never substantiated and the
inconsistency remains unresolved.
In a follow-up study by Chu et al, reference was made to Akt, an upstream inhibitor
of GSK3P:
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"[The fact that] overexpression of GSK3a or GSK3|3 directly represses HSF1
suggests a sub-population of HSF1 molecules may be constitutively phosphorylated
at Ser-307 and that FISF1 may be directly regulated by the GSK3 pathway as well as
indirectly through the [ERK1] pathway ... [Akt] is activated by heat shock and could
potentially activate HSF1 through GSK inhibition (210)."
4.1.3 PI3K/Akt
GSK3 was originally discovered during the fraught race to describe the intracellular
consequences of insulin receptor activation. GSK3 was found to phosphorylate and
inactivate glycogen synthase, the enzyme catalysing the rate limiting step of
glycogen synthesis (232). Insulin was later found to inactivate GSK3 (233,234), but
the link between the insulin receptor and GSK3 remained elusive.
Akt was described simultaneously as the cellular homolog to the v-Akt oncogene of
the AKT8 retrovirus (235), a serine/threonine kinase related to A- and C- protein
kinase(s) (RAC-PK) (236), and as protein kinase B (PKB) (237). It was identified as
the kinase responsible for GSK3 phosphorylation and inactivation - the missing link
between extracellular insulin action and glycogen metabolism. It has since been
found to have a diverse set of roles and is a 'key mediator of cell proliferation and
survival' (238). Akt up-regulation has been implicated in cell survival in a number of
different models of cell stress (239-242). Much of the initial interest in Akt derived
from the fact it was activated by insulin and other growth factors in a manner
dependent on phosphatidylinositol 3-kinase (PI3K) (243) (Figure 4.3). PI3K is
activated by receptor tyrosine kinases following ligand binding and acts to
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phosphorylate the membrane phospholipid, PI(4,5)P2 to PI(3,4,5)P3. This product
regulates Akt in a complex manner which has taken a number of years to elucidate.
Akt has a pleckstrin homogeny (PH) domain which allows it to bind directly to
PI(3,4,5)P3 with two distinct results: firstly, Akt is recruited to the plasma membrane
allowing it to co-localise and interact with other proteins; secondly, it undergoes a
conformational change revealing two sites which require to be phosphorylated for
activation. The exact mechanism of this dual phosphorylation is still the subject of
debate and is out with the scope of this discussion. Suffice to say that following PI3K
activation, Akt is recruited to the cell membrane and activated.
GSK3JS is phosphorylated and inactivated by Akt
GSK3J3 is an unusual signalling kinase in that it is fully active in unstimulated cells.
It is inactivated by phosphorylation at the serine 9 residue. Ample evidence now
exists that this is mediated by Akt (244). Many studies since the late 1990s have




Fig. 4.3. Putative pathway: de¬
repression of HSF1 following
activation of the PI3K/Akt pathway.
Following ligand binding and receptor
tyrosine kinase activation, PI3K is
recruited to the cell membrane and
activated. PI3K phosphorylates PI(4,5)P2
to PI(3,4,5)p3 facilitating co-localisation
and activation of Akt at the cell
membrane. GSK3P is phosphorylated and








GSK3[i is the best targetfor modification ofHSF1 activity by phosphorylation
In summary, significant evidence exists that GSK3(3 acts to repress HSF1
transcriptional activation in unstimulated cells, represses DNA-binding in cells
exposed to heat shocked and accelerates the deactivation of HSF1. This is based on
robust data from independent laboratories examining phosphorylation at specific
HSF1 residues. Evidence of a significant role for ERK also exists, but it appears to
act in a GSK3P dependent manner; thus, altering ERK and GSK3[1 activity would not
be additive. Some data on specific phosphorylation by PKC and JNK is promising,
but in contradiction to a significant number of other reports in the literature. Thus,
GSK3P represented the best target for manipulation of HSF1 transactivation by
phosphorylation. Inhibition of GSK3P through stimulation of the PI3K/Akt pathway
was a potential mechanism by which HSF1 could be activated, stimulating the stress
protein response without the requirement of classical stressors, with their inherent
potential for toxicity. As the ultimate aim of this work was a clinical intervention, the
investigation commenced using IGF-1 as an upstream activator of PI3K/Akt as it had
been previously used in humans and had low side-effect profile (249).
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4.2 Hypotheses
1. Activation of the PI3K/Akt pathway phosphorylates and inactivates GSK3P
in ACHN cells.
2. De-repression of HSF1 at Ser-303 results in trimerisation and DNA-binding
of HSF1.
3. Inactivation of GSK3P results in transactivation of HSF1 and induction of
heat shock proteins.




IGF-l does not induce Hsp70 in ACHN cells
Cells were exposed to various concentrations of IGF-l for 6 h (Figure 4.4A) and
IGF-l at a concentration of 100 pg/ml for various periods of time (Figure 4.4B/C).
Western blots were performed on whole-cell lysates using antibody to inducible
Hsp70. No induction of Hsp70 was observed following IGF-l treatment. Western
blots were performed for the stress proteins Hsp90, Grp94 and Hsp27 (Figure 4.4C).
Similarly, no induction of these proteins was seen following IGF-l treatment.
GSK3J3 phosphorylated at serine 9 in untreated cells
In order to determine whether IGF-l treatment activated the PI3K/Akt axis, the
phosphorylation state of GSK3P was determined. Cells were treated with IGF-l (100
pg/ml) for various periods of time. Whole cell lysates were prepared and a Western
blot performed using the phospho-specific antibody (Ser-9) for GSK3P (Figure
4.5A). It was found that GSK3P was phosphorylated in control cells, and the amount
of pGSK3p present did not increase following IGF-l treatment.
Culturing cells in serum free conditions for 16 h dephosphorylates GSK3/3 at Ser- 9;
IGF-l does not phosphorylate GSK3J3 at Ser- 9 in ACHN cells
Cells were plated out at a confluency of around 50% on day 1 in normal culture
medium containing 10% fetal calf serum (FCS). The evening of day 2, the medium
was changed to normal culture medium containing no FCS.
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Figure 4.4 Stress protein expression in ACHN cells following IGF-1 treatment.
ACHN cells were exposed to increasing doses of IGF-1 for 6 h (A) and IGF-1
(100 pg/ml) for various periods of time (B, C). Whole-cell lysates were prepared and
analysed by Western blotting using antibody to Hsp70 (A, B) and antibody to Hsp90,
Grp94 and Hsp27 (C). p-actin was used as a loading control.
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Figure 4.5 Phosphorylation of GSK3P at Ser-9 following IGF-1 treatment in
ACHN cells cultured in 10% FCS (A) and 0% FCS (B).
Cells were exposed to IGF-1 (100 pg/ml) for increasing periods of time (A). Whole-
cell lysates were prepared and analysed with Western blotting using antibody to
pGSK3p with total GSK3(3 being used as a loading control. (B) Cells were plated out
at a confluency of around 50% on day 1 in normal culture medium containing 10%
fetal calf serum (FCS). The evening of day 2, the medium was changed to normal
culture medium containing no FCS. Cells were treated with treated with IGF-1 (100
pg/ml) for increasing periods of time. Whole-cell lysates were prepared and analysed
by Western blotting using antibody to pGSK3p with total GSK3(3 being used as a
loading control.
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Cells were treated with treated with IGF-1 (100 pg/ml) for various periods of time as
before (Figure 4.5B). Phosphorylation at GSK3P Ser-9 was greatly reduced in cells
cultured in 0% FCS. Flowever, GSK3P was not phosphorylated at Ser-9 in response
to IGF-1 treatment.
IGF-1 receptor expression low in ACHN cells, but insulin receptor expression
significantly greater
To determine whether the absence of GSK3P phosphorylation in response to IGF-1
treatment was due to low expression of the IGF-1 receptor, immunofluorescence
with an antibody to IGF-IRa was performed on ACHN cells with HUH-7 cells (liver
adenocarcinoma cell-line) used as a positive control (Figure 4.6). IGF-IRa
expression was found to be very low compared to expression in HUH-7 cells. As
insulin is an alternative stimulator of the PI3K/Akt axis, the expression of the insulin
receptor was also determined in ACHN cells. Immunofluorescence experiments were
performed using an antibody to the insulin Rp receptor protein with ACHN and
HUH-7 cells. The expression of insulin Rp was found to be high in both cells lines
(Figure 4.7). Therefore, IGF-IRa is poorly expressed on ACHN cells, while insulin
RP expression in ACHN cells is comparable with the expression in HUH-7 cells.
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Figure 4.6 IGF-IRa expression in ACHN and HUH-7 cells lines.
ACHN (A) and HUH-7 (B) cells were fixed with methanol, blocked with normal
goat serum and exposed to the IGF-IRa monoclonal antibody. After washing, cells
were exposed to a secondary goat-anti-mouse FITC-conjugated antibody. Cells were
counterstained with Hoechst. Fields were visualised with a Leica DM IRB
microscope and images were stored using the Leica Improvision software. Primary
antibody only and secondary antibody only groups were included as controls and on
microscopy were found to have no staining.
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Figure 4.7 Insulin Rp expression in ACHN and HUH-7 cells lines.
ACHN (A) and HUH-7 (B) cells were fixed with methanol, blocked with normal
goat serum and exposed to the insulin Rp rabbit polyclonal antibody. After washing,
cells were exposed to a secondary goat-anti-rabbit FITC-conjugated antibody. Cells
were counterstained with Hoechst. Fields were visualised with a Leica DM IRB
microscope and images were stored using the Leica Improvision software. Primary
antibody only and secondary antibody only groups were included as controls and on
microscopy were found to have no staining.
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Insulin phosphorylates GSK3J3 at Ser-9
ACHN cells were cultured as before in serum free conditions and treated with insulin
(200 nM) for various periods of time. Phosphorylation of GSK3P at Ser-9 was found
to increase very quickly in response to insulin treatment with maximal levels being
attained within 15 min (Figure 4.8).
Serum deprivation in ACHN cells does not induce heat shockproteins
In order to ensure that serum-free cell culture did not itself induce the stress protein
response, cells were cultured in serum-free conditions for 16 h after which whole-cell
lysates were produced and Western blots performed using antibody to Grp94, Hsp90,
Hsp70 and Hsp27 (Figure 4.9). No induction of these proteins was seen in cells
incubated in 1%, 0.1%, 0% FCS for 16 h.
Insulin does not induce Hsp70 in ACHN cells
As in the IGF-1 experiments, cells were exposed to various concentrations of insulin
for 6 h (Figure 4.1 OA) and insulin at a concentration of 200 nM for increasing
periods of time (Figure 4.10B). Western blots were performed on whole-cell lysates
with antibody to inducible Hsp70. No induction of FIsp70 was observed following
insulin treatment.
Insulin does not cause nuclear localisation ofHSF1, increase the DNA-binding
ability ofHSFl, nor induce trimerisation ofHSFl in serum-deprived ACHN cells
In order to determine whether insulin altered the oligomeric state or DNA-binding
ability ofHSFl, cells were treated with insulin (200 nM) for 2 h and nuclear
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Figure 4.8 Phosphorylation of GSK3P at serine 9 following insulin treatment in
serum-free ACHN cells.
Cells were plated out at a confluency of around 50% on day 1 in normal culture
medium containing 10% fetal calf serum (FCS). The evening of day 2, the medium
was changed to normal culture medium containing no FCS. Cells were treated with
treated with insulin (200 nM) for increasing periods of time. Whole-cell lysates were
prepared and analysed by Western blotting using antibody to pGSK3|3 with total
GSK3P being used as a loading control.
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Figure 4.9 Expression of stress proteins following serum deprivation in ACHN
cells.
Cells were cultured in medium containing varying concentrations of FCS for 16 h.
Whole-cell lysates were prepared and analysed by Western blotting using antibody to
Grp94, Hsp90, Hsp70 and Hsp27.
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Figure 4.10 Hsp70 protein expression following insulin treatment in serum
deprived cells.
ACFIN cells were cultured in medium containing no FCS for 16 h, then exposed to
insulin (200 nM) for various periods of time. Whole-cell lysates were prepared and
analysed by Western blotting using antibody to FIsp70. P-actin was used as a loading
control.
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lysates prepared. A DNA-mobility shift assay was performed with [y32P]ATP-
labelled HSE oligonucleotides (Figure 4.11). No alteration in the oligomeric state or
DNA-binding ability was seen following insulin treatment, when compared to
controls subjected to heat treatment at 43 °C for 45 min. To determine whether
insulin resulted in HSF1 nuclear localisation, the intracellular compartmentalisation
of HSF1 was established. Cells were treated with insulin for 2 h, after which
cytoplasmic and nuclear cell lysates were prepared and Western blot with antibody to
FISF1 was performed (Figure 4.12). No change in the intracellular
compartmentalisation was observed following insulin treatment.
Insulin does not increase Hsp70 induction following exposure to heat
Finally, to ascertain whether treatment with insulin alters the threshold of stress-
induced Flsp70 induction, cells were treated with insulin (200 nM) for 30 min and
incubated at 43°C for 45 min, followed by 4 h recovery (Figure 4.13). No alteration
in Hsp70 expression was identified between those cells submitted to heat shock alone
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Figure 4.11 HSF1 DNA-binding ability and oligomeric status following insulin
treatment.
Cells were cultured in serum-deprived conditions and treated with insulin (I) (200
nM) or vehicle (V) for 1.5 h; a further group was subjected to heating at 43 °C for 45
min. A DNA mobility shift assay was performed with [y32P]ATP-labelled heat
shock element consensus oligonucleotides. Excess unlabelled mutant (Mut) and
consensus (CP) sequences were included as controls.
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Figure 4.12 HSF1 intracellular compartmentalisation following insulin
treatment.
Cells were cultured in serum-deprived conditions for 16 h and treated with insulin for
1.5 h. Nuclear and cytoplasmic lysates were prepared and analysed by Western
blotting using antibody to HSF1, with loading control with P-actin for cytoplasmic
extracts and lamin A/C for nuclear extracts. Band densitometry was ascertained
using Quantity One software and nuclear:cytoplasmic ratios calculated. These are
expressed graphically (B) with error bars representing S.E.M. over 3 independent
experiments.
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Figure 4.13 Insulin does not alter Hsp70 expression following heat exposure.
Cells were treated with insulin (200 nM) for 30 min, incubated at 43°C for 45 min
and recovered for 4 h. Whole-cell lysates were prepared and Western blotting
performed with antibody to Hsp70. (3-actin was included as a loading control.
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4.4 Discussion
It was reported in 1985 that insulin induces Hsp70 in Hep3B/T2 cells, although the
mechanism was not determined (250). Following the publication of data suggesting a
regulatory role for GSK3P in HSF1 activation, it was hypothesised that insulin-
induced Hsp70 induction may occur through the PI3K/Akt axis. With the ultimate
goal of identifying a clinical strategy for inducing the protective stress protein
response in kidneys IGF-1 was used. The rationale for this was that the alternative,
insulin, has a plethora of physiological actions rendering its candidacy as an inducer
of the stress protein response with no other side-effects impossible. IGF-1, on the
other hand, is known to activate the PI3K/Akt axis in a similar manner to insulin, but
has a lower side-effect profile (249). However, following treatment with IGF-1 no
induction of the stress protein response was observed, bringing this hypothesis into
question (Figure 4.4). There were a number of possibilities why the anticipated
response did not occur and further investigation was warranted. First, it had to be
demonstrated that GSK3(3 was phosphorylated at Ser-9 by IGF-1 as predicted.
Western blots of IGF-1-treated cells revealed that unstimulated cells were maximally
phosphorylated at Ser-9 on GSK3fl (Figure 4.5A) and that IGF-1 treatment had no
additional effect. Fetal calf serum contains a number of hormones and growth factors
and it was hypothesised that one or more of these components was effecting
constitutive phosphorylation of GSK3p. Indeed, depriving cells of FCS for 16 h
resulted in dephosphorylation at the Ser-9 residue on GSK3P (Figure 4.5B) with no
alteration in stress protein expression (Figure 4.10). Yet, treatment of cells with IGF-
1 in serum-deprived conditions did not cause phosphorylation of GSK3P (Figure
4.5B). It had been shown by Ouban et al, when looking at the expression of the IGF-
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1 receptor in various human cancers, that kidney adenocarcinoma expressed
relatively little IGF-1 receptor (251). Indeed, no significant expression of IGF-IRa
was demonstrated in ACHN cells, confirming the findings of Ouban (Figure 4.6);
however, high-levels of the insulin receptor (insulin RP) were demonstrated (Figure
4.7). In order to continue the investigation, insulin was used as an upstream activator
of Akt. Despite demonstrating that insulin phosphorylated GSK3P, insulin treatment
did not result in Hsp70 induction (Figure 4.10). This contradicts the findings of Ting
(250) who demonstrated increased Hsp70 gene expression in response to insulin in a
human hepatoma cell-line (Hep3B/T2). With the knowledge that HSF1 activation is
a multi-step process and subject to a number of different layers of regulation, it was
decided to pursue the hypothesis further. However, neither HSF1 nuclear localisation
nor trimerisation were observed following insulin treatment (Figure 4.11 and 4.12).
Altering GSK3P activity, therefore, did not alter the activation state of HSF1 in
unstressed cells. To determine whether GSK3P repression lowered the threshold of
HSF1 activation, cells were pre-treated cells with insulin and subjected to mild heat
treatment. No difference in Hsp70 protein expression was seen in insulin-pre-treated
cells subjected to heat compared to cells exposed to heat alone (Figure 4.13).
A number of issues are raised in analysing why in this part of the investigation the
null-hypothesis was proven correct. Previous data from Ting et al showed Hsp70
induction following insulin treatment (250), but a number of methodological
differences exist between this study and that presented here. The most obvious
variation is the cell-line used: Hep3B/T2 cells, a human hepatoma cell-line. The
concentration of insulin used by Ting et al was similar, but no details are provided of
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the type of insulin (e.g. bovine, porcine, human recombinant) or if it was
reconstituted in a particular manner (e.g. acidic conditions). Additionally, cells were
serum starved for 6 days while in the present study cells were only deprived of serum
over night. This time period was established following measurement of the
phosphorylation status of GSK3p and showing that 16 h was sufficient for
dephosphorylation. But if the mechanism of Hsp70 induction was different (i.e.
GSK3(3-independent) then 16 h may be insufficient to bring basal Hsp70
concentration down to a level where changes could be observed. Furthermore, insulin
has been shown to induce reactive oxygen species in cells (252); while we did not
find this in our cell model (see chapter 5), it is possible that this effect was occurring
in Ting's model and was sufficient to induce a stress protein response. Ting et al did
not provide any mechanistic data so further analysis is limited.
Data of excellent quality on the contribution of GSK3P and ERK1 to HSF1
repression is presented in two papers by Chu et al (209,210), however, a major flaw
exists when taken in the context of this work. The data generated in these studies is
based on the over-expression of recombinant HSF1 in cells, be that in wild-type or
mutated forms. Intracellular HSF1 concentrations, therefore, are much greater in
these models than would occur in physiological circumstances. Taken with the
present understanding of HSF1 regulation, this would result in inhibitors of FISF1 (be
those of a phosphorylation/dephosphorylation nature, or a multi-chaperone complex)
being titrated out. Thus, over-expression of HSF1 is sufficient to activate HSF1 with
no other stimulation (demonstrated aptly by the activation of an Hsp70 reporter
following transfection of a wild-type HSF1 expressing construct alone (209)). In the
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'physiological' model of the present study, therefore, the ratio of HSF1 to repressive
systems is much lower than in the model used by Chu, presumably making HSF1
activation much more difficult. This observation is also true for the papers by Kline
and Knauf (211,215).
Insulin has many physiological effects that could have acted to confound the present
study. In particular, insulin is known to up-regulate ERK1 which has been implicated
in the repression of HSF1 activity (206,209,210). The possibility exists, therefore,
that ERK1 is activated by insulin and acts to repress HSF1. In the present study, it
had been conjectured that as ERK1 action is GSK3p-dependent, turning off GSK3P
would render ERK1 action redundant. Nevertheless, if GSK3P inactivation was
incomplete, this could have contributed to the lack of response.
Although GSK3P represses HSF1 activation, this does not necessarily mean that
removal of that repression will activate HSF1. Xavier et al demonstrated that GSK3P
inhibition increased DNA-binding and transcriptional activation in heat shock
conditions (208). But in cells pre-treated with insulin and heated (Figure 4.13), no
increase in Hsp70 was observed. It is possible that the GSK3P inhibitors (lithium
chloride and GSK-binding protein) used by Xavier et al were more effective than
PI3K/Akt-mediated inhibition of GSK3P, or that they were having off-target effects.
Also, it is not clear what the influence of cell choice (Xenopus oocytes) is on HSF1
activation. Lastly, the sensitivity of Hsp70 detection by Western blot was possibly
not high enough to discern differences between insulin treated and control groups.
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Whatever the reasons behind the failure to elicit Hsp induction via PI3K/Akt
activation, it was clear that this was not a viable strategy for the induction of Hsps in
models of transplantation. However, during the course of our investigation we
noticed an interesting and unexpected effect: the small heat shock protein, heme
oxygenase-1 (HO-1), was up-regulated following insulin treatment. HO-1 does not
take part in the classical stress protein response and is controlled independently of
HSF1 in humans (although not mice) (174). HO-1 is known to confer significant
cellular protection, but up-regulation following insulin had not been previously
described. The investigation of this response is the subject of the next chapter.
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Chapter 5 - Heme oxygenase-1 induction through the
PI3K/Akt pathway and the Nrf2 transcription factor
5.11ntroduction
5.1.1 Background
During the investigation described in chapter 4 of the possible effects of insulin on
HSF1 activity, it was observed that heme oxygenase-1 (HO-1) protein was induced
in response to insulin. HO-1, also known as Hsp32, is a heat shock protein but does
not take part in the classical heat shock response in humans, i.e. it is not under the
control of HSF1. Thus, a role for HO-1 was not predicted in the original hypothesis
of heat shock protein induction in response to insulin/IGF-1. Insulin-mediated HO-1
induction has not been previously described and warranted further investigation.
5.1.2 Heme oxygenase-1
HO-1 catalyses the rate-limiting step in the degradation of heme to carbon monoxide
(CO), free iron and biliverdin, which is immediately converted to bilirubin by
bilverdin reductase (253) (Figure 5.1). At least two isoenzymes are known to exist:
HO-1, which is strongly induced by its substrate heme and a number of stress stimuli
including UV radiation and heavy metals; and constitutive HO-2 (254-256). The
exact role of HO-1 in oxidative stress is not clear but it has been shown to be
protective in a number of cell-types and animal models, by virtue of the products of
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Figure 5.1 Heme oxygenase-1 catalyses the rate limiting step of heme
degradation.
HO-1 acts to catalyse the breakdown of heme to the protective biliverdin (which is
almost immediately converted to bilirubin), carbon monoxide and free iron.
Although free iron can result in oxidative stress its release induces ferritin, an iron-
sequestering protein which is also protective.
Ill
the reaction it catalyses (for recent review see (257)). Bilirubin is known to be a
powerful antioxidant (258,259) and HO-derived bilirubin has been shown to provide
protection in neuronal cells (260). CO was first demonstrated to be protective in a
model of acute lung injury (261), subsequently in rodent cardiac (262,263) and renal
transplantation models (122). Two important mechanisms of CO protection
involving p38 mitogen-activated protein kinase (MAPK) and guanylyl cyclase have
been identified, but these appear to be cell-type specific (257). Although HO-1
releases the pro-oxidant Fe2+, this is associated with the rapid expression of the iron-
sequestering protein ferritin, which is also known to be protective (264). It is
generally accepted, therefore, that induction of heme degradation represents an
adaptive response to oxidative insult.
Insulin is a polypeptide hormone that regulates glucose, lipid and protein metabolism
and promotes cell growth and differentiation. On ligand binding, the insulin receptor
tyrosine kinase initiates multiple signalling cascades including the activation of the
phosphatidylinositol 3-kinase (PI3K) pathway and its downstream effectors (265).
This pathway is a key signal transducer of many growth factors and cytokines and
has been implicated in the regulation of cell growth, cell migration and cell survival
(266). The protein kinase B/Akt family of serine/threonine kinases has been
identified as an important target of PI3K in cell survival (239-242). Moreover, recent
work has shown a direct link between the PI3K/Akt pathway and HO-1 regulation in
PC12 cells (267,268). This may be through nuclear factor E2-related factor-2 (Nrf2),
a member of the cap'n'collar family of basic leucine transcription factors and a well
established regulator of HO-1 (269).
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Table 5.1 Studies describing protective effects of HO-1 and products in
transplantation.
The beneficial effects of HO-1, CO and biliverdin/bilirubin have been studied
extensively in many organ systems, including models of transplantation. Studies
examining chronic allograft nephropathy have been excluded. CVF, cobra venom
factor; CoPP, cobalt protoporphyrin; Ad-HO-1, adenoviral HO-1; CO, carbon
monoxide; IR, ischemia/reperfusion.
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In view of the beneficial effects of up-regulation of HO-1 in models of organ
transplantation, it is important to identify signalling pathways involved in regulation
of HO-1 gene expression. In this chapter, data is presented demonstrating a PI3K/Akt
dependent induction of HO-1 following the administration of insulin to renal
adenocarcinoma cells (ACHN). PI3K activity was necessary and sufficient for HO-1
induction and Nrf2 blockade was found to abolish the response. Supporting data




1. Insulin induces de novo HO-1 production.
2. HO-1 induction is dependent on a specific intracellular signalling pathway(s).
3. HO-1 induction is dependent on a specific transcription factor(s).
4. HO-1 induction facilitates renal protection in a murine model of ischemia
reperfusion injury.
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5.3 Methods and materials
Mouse primary tubular epithelial cell culture
The kidneys of 6 week old male BALB/c mice were removed in sterile conditions
and placed in ice-cold HBSS containing penicillin (100 U/ml), streptomycin (100
pg/ml) and IX antibody/antimycotic solution (Gibco). After decapsulation and
bisection the medulla was removed and the cortices reduced with repeated incisions
to 1 mm pieces. Kidney pieces were incubated at 37 °C with HBSS containing
collagenase type IV (0.5 mg/ml) and DNa.se (10 pg/ml) freshly prepared. Following
confirmation of the presence of tubules, they were resuspended in DMEM-F12 with
glutamax, penicillin (100 U/ml), streptomycin 100 pg/ml) (all Gibco), lx
insulin/transferrin/selenium, dexamethasone (35.7 ng/ml) and epidermal growth
factor (25 ng/ml). Tubules were cultured in 6-well plates for 5 days or until 70%
confluent. Culture conditions were then changed to DMEM-F 12 with glutamax,
penicillin, streptomycin and dexamethasone for 40 h, after which experiments were




Insulin increases HO-1 expression in ACHN cells
Treatment of serum-deprived ACHN cells with increasing concentrations of human
insulin resulted in a 4-fold induction of HO-1 after 6 h (Figure 5.2A). Maximal
induction of HO-1 protein was achieved at concentrations of 200 nM insulin. A time
course using insulin (200 nM) demonstrated accumulation of HO-1 after 2 h
treatment (Figure 5.2B). HO-1 mRNA was found to increase over the same
concentration range of insulin (Figure 5.2C) and achieved maximum induction after
2 h treatment with insulin (200 nM) (Figure 5.2D). HO-1 mRNA returned to resting
levels after 16 h of treatment. To ensure HO-1 induction was not related to serum-
deprivation, cells were cultured in medium containing different concentrations of
fetal calf serum for 16 h (Figure 5.2E); no alteration in HO-1 protein expression was
detected. To confirm that HO-1 accumulation was dependent on gene transcription,
ACHN cells were pre-treated with actinomycin D (AD) followed by insulin (Figure
5.3A and C). Basal levels of HO-1 protein were reduced following AD and the HO-1
protein and mRNA response to insulin was abolished. Similarly, cycloheximide
(CHX) was administered to establish the role of protein synthesis in insulin-induced
HO-1 expression (Figure 5.3B and C). CHX abrogated HO-1 protein induction
following insulin treatment but, in keeping with other studies, also eliminated HO-1
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Figure 5.2 Insulin stimulates HO-1 protein and mRNA accumulation in ACHN
cells.
Cells were serum-deprived for 16 h and treated with increasing concentrations of
insulin for 6 h (A), 4 h (C) or insulin (200 nM) for various times (B, D). ACHN cells
were cultured in medium supplemented with different concentrations of fetal calf
serum (FCS) (E). Whole-cell lysates were prepared and analysed by Western blotting
(A, B, E) using antibody to HO-1, with |3-actin being indicated as loading control.
mRNA extracts were prepared (C, D) using TRIzol and reverse transcribed to cDNA.
Fluorescence-detected real time PCR was performed using HO-1 primers and probe
with an 18s primer/probe control; results are expressed as mean relative expression ±
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Figure 5.3 Insulin stimulated HO-1 accumulation is transcription and
translation dependent.
Cells were serum-deprived for 16 h and pre-treated with actinomycin D (AD) (5
pg/ml) (A, C) or cycloheximide (CHX) (10 pg/ml) (B, C) for 30 min, followed by
insulin (I) (200 nM) for 6 h (A, B) or 2 h (C). Whole-cell lysates were prepared and
analysed by Western blotting (A, B) using antibody to HO-1, with p-actin being
indicated as loading control. mRNA extracts were prepared (C) using TRIzol and
reverse transcribed to cDNA. Fluorescence-detected real time PCR was performed
using HO-1 primers and probe with an 18s primer/probe control; results are
expressed as mean relative expression ± S.E.M. of 3 independent experiments.
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Insulin increases HO-1 expression in mouse primary renal tubular epithelial cells
In order to ensure insulin-induced HO-1 expression was not a characteristic of
transformed cells alone, mouse primary renal tubular epithelial cell cultures were
prepared. These were treated in a similar manner with insulin (200 nM) for
increasing periods of time (Figure 5.4). A robust induction of HO-1 protein was
observed.
Insulin-mediated induction ofHO-1 is PI3K dependent
In this model, phosphorylation GSK3P at Ser-9 was used as an indicator of PI3K/Akt
axis activity. GSK3P phosphorylation was observed after 30 min of insulin at a
concentration of 200 nM (Figure 5.5A). Following 30 min pre-treatment with the
PI3K inhibitor LY294002 (Figure 5.5B), or its inactive analogue LY30351 1 (Figure
5.5C), ACHN cells were treated with insulin (200 nM) for 6 h to determine HO-1
protein accumulation and for 30 min to confirm GSK3P phosphorylation status. HO-
1 was induced as expected following insulin, but this effect was abolished with
increasing concentrations of LY294002. Following treatment with LY303511, HO-1
induction was not altered. LY294002-mediated reduction in GSK3P phosphorylation
correlated with inhibition of insulin-induced HO-1 accumulation.
Akt activity is necessary and sufficientfor HO-1 induction
48 h after transfection of ACHN cells with the pHOGL3/l 1.6 reporter construct and
a constitutively-active Akt expressing construct (Akt-myr), an increase in luciferase
activity was observed, representing a 6-fold increase in HO-1 promoter activity
(p<0.05 ANOVA) (Figure 5.6A). Accumulation of HO-1 protein was also found
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Figure 5.4 Insulin stimulates HO-1 in mouse primary epithelial cells.
Mouse primary renal tubular epithelial cells were prepared and treated with
increasing concentrations of insulin. Whole-cell lysates were prepared and analysed


































Figure 5.5 Insulin stimulates HO-1 accumulation through a PI3K-dependent
pathway.
ACHN cells were serum-deprived for 16 h and treated with increasing concentrations
of insulin (200 nM) for 30 min (A). Other groups were pre-treated with the PI3K
inhibitor LY294002 (B), or its inactive analogue LY303511 (C) for 30 min, followed
by insulin (200 nM) for 30 min to determine GSK3P phosphorylation status, and 6 h
to determine HO-1 accumulation. Whole-cell lysates were prepared and analysed by
Western blotting using phospho-specific antibody to GSK3a/p (ser 21/9)
(pGSK3a/p) and antibody to total GSK3 as a loading control. As previously,
antibody to HO-1 was used, with P-actin being indicated as loading control.
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following transfection with either the Akt-myr or wild-type (Akt-WT) construct, in
association with an expected increase in GSK3J3 phosphorylation (Figure 5.6B).
Treating cells transfected with Akt-myr with insulin did not increase the HO-1
promoter activity (Figure 5.6A) over cells transfected alone, demonstrating that the
effects of insulin and Akt over-expression on HO-1 accumulation are not additive. In
cells transfected with a dominant-negative Akt expressing construct (Akt-K179M),
and treated 48 h later with insulin, HO-1 promoter activity was found to increase
slightly but this was not statistically significant (Figure 5.6A).
Insulin-mediated HO-1 accumulation is neither p38-MAPK nor ERK dependent
Insulin was found to phosphorylate p38-MAPK (Figure 5.7A) and ERK (Figure
5.7B) in a time-dependent manner. ACHN cells were then pre-treated with the p38-
MAPK inhibitor, SB202190, or the MEK1 inhibitor, PD98059, and treated with
insulin. Adequate inhibition of p38-MAPK was demonstrated by probing for
phosphorylated Hsp27, a known downstream target of p38-MAPK (282) (Figure
5.7C). MEK1 inhibition was confirmed with blots for phosphorylated ERK1/2
(Figure 5.7D). In cells pre-treated with SB202190 or PD98059 and exposed to
insulin, no decrease in the expected HO-1 accumulation was observed (Figure 5.7C
and D), suggesting neither p38-MAPK nor ERK activity is required for insulin-
induced HO-1 accumulation.
Insulin treatmentfails to activate HIF1.
HO-1 is known to be regulated by hypoxia-inducible factor 1 (HIF1). To test whether
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Figure 5.6 Over-expressing active Akt causes HO-1 reporter activation.
(A) ACHN cells were triple-transfected with the pHOGL3/l 1.6 reporter construct,
the pSV-fl-galactosidase control construct and vectors expressing membrane-targeted
active Akt (Akt-myr), dominant-negative Akt (Akt-K179M) or empty vector control
(pUSE-amp). 48 h later cells were treated with insulin (200 nM) for 6 h and then
lysed and luciferase and P-galactosidase assays performed. Results are expressed as
luciferase activity per unit P-galactosidase activity ± S.E.M. of 4 independent
experiments. * p<0.05 ANOVA. (B) ACHN cells were transfected with constructs
expressing wild-type Akt (Akt-WT), membrane-targeted active Akt (Akt-myr),
dominant-negative Akt (Akt-K179M) or empty vector control (pUSE-amp). 48 h
later whole-cell lysates were produced and analysed by Western blotting using
antibody to HO-1, phospho-specific antibody to GSK3P (ser-9) (pGSK3P) and




































Figure 5.7 p38-MAPK and ERK inhibition has no effect on insulin-induced HO-
1 accumulation.
(A, B) Cells were serum-deprived for 16 h and treated with insulin (200 nM) for
various times. Whole-cell lysates were prepared and analysed by Western blotting
using antibody to the phosphorylated form of p38 MAPK (Thrl80/Tyrl82) (p-p38)
(A) and phosphorylated ERK 1/2 MAPK (Thr202/Tyr204) (p-ERKl/2) (B). Total-
p38 (A) and total-ERKl/2 (B) are indicated as loading controls. (C, D) Cells were
serum-deprived for 16 h and pre-treated with the p38-MAPK inhibitor, SB202190
(C), or the MEK1 inhibitor, PD98059 (D) for 30 min, after which insulin (200 nM)
was added for 6 h. Whole-cell lysates were prepared and analysed by Western
blotting using antibody to HO-1 and P-actin to control for protein loading. Adequacy
of p38-MAPK inhibition was established with blots for phosphorylated Hsp27 (C).
MEK1 inhibition was confirmed with blots for phosphorylated ERK1/2 (D).
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construct (Figure 5.8). 48 h later cells were treated with increasing concentrations of
insulin for 4 h, or treated with cobalt chloride (100 pM) for 4 h. No activation of
pHRE-luc reporter was demonstrated.
Nrf2 translocates to the nucleus following insulin treatment
In ACHN cells treated with increasing concentrations of insulin for 1.5 h the nuclear
fraction ofNrf2 was found to increase as the cytosolic component decreased (Figure
5.9A). Immunofluroescent labelling ofNrf2 revealed increased nuclear staining
following insulin treatment (Figure 5.9B). Pre-treatment with LY294002 abolished
nuclear accumulation of Nrf2 in response to insulin at doses previously shown to
inhibit PI3K activity (Figure 5.9C); the inactive analogue, LY303511, had no effect
on insulin-mediated Nrf2 nuclear accumulation (Figure 5.9D).
Insulin mediated HO-1 induction abolished by Nrf2 siRNA
ACHN cells were transfected with Nrf2 siRNA as per the manufacturer's
instructions. 48 h later they were treated with insulin or the proteosome inhibitor
MG132 (used as a positive control for Nrf2 accumulation) for 6 h. Cobalt chloride
(CoCl2) is a hypoxia-mimetic that activates the HO-1 promoter and was also used as
a control. Groups treated with the Nrf2 siRNA demonstrated greatly reduced Nrf2
and HO-1 protein expression when compared with control siRNA treated groups
(Figure 5.10). InNrf2 siRNA groups treated with insulin, no HO-1 induction was
observed; however, in Nrf2 siRNA groups treated with C0CI2, HO-1 induction did
occur, demonstrating Nrf2 activity is not a prerequisite for promoter activation.
While nuclear localisation ofNrf2 following insulin was apparent, it was not clear
whether insulin treatment resulted in increased total Nrf2. There was a suggestion on
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Western blotting of whole-cell lysates that total cellular Nrf2 was increased
following insulin, but on quantification of 3 independent blots no difference was
demonstrated.
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Figure 5.8 Insulin treatment fails to activate HIF1.
ACHN cells were transfected with a pHRE-luc reporter construct and the pSV-p-gal
control vector. 48 h later cells were treated with increasing concentrations of insulin
for 4 h, or treated with cobalt chloride (100 pM) for 4 h. Cells were then lysed and
luciferase and P-galactosidase assays performed. Results are expressed as luciferase
activity per unit P-galactosidase activity ± S.E.M. of 3 independent experiments.
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Figure 5.9 Insulin treatment causes PI3K-sensitive nuclear migration of Nrf2.
(A) Cells were serum-deprived for 16 h and treated with increasing concentrations of
insulin for 1.5 h. Nuclear and cytosolic lysates were prepared and analysed by
Western blotting using antibody to Nrf2, with loading control with p-actin for
cytosolic extracts and lamin A/C for nuclear extracts. (B) Cells were treated similarly
with insulin (200 nM) for 1.5 h, prepared for immunofluorescence and treated with
antibody to Nrf2, followed by Floechst counterstaining. (C, D) Cells were serum-
deprived for 16 h and pre-treated with the PI3K inhibitor LY294002 (C), or its
inactive analogue LY303511 (D) for 30 min. Insulin (200 nM) was added for 1.5 h
after which nuclear lysates were prepared and analysed by Western blotting using
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Figure 5.10 Nrf2 silencing with siRNA prevents insulin-induced HO-1
accumulation.
Cells were transfected with Nrf2 siRNA and 48 h later treated with insulin (200 nM),
the proteosome inhibitor MG132 (20 pM) or cobalt chloride (C0CI2) (1 mM) for 6 h.
Whole-cell lysates were prepared for Western blotting using antibody to HO-1 and
Nrf2 with (3-actin used as a loading control. Optical densities of bands were
quantified (Quantity One, Biorad). Bars represent the mean of 3 independent
experiments with error bars representing S.E.M.
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5.5 Discussion
In this chapter, direct evidence has been provided for a link between insulin
activation of the PI3K/Akt cascade, Nrf2 transactivation and HO-1 induction.
Insulin-induced HO-1 protein expression was sensitive to PI3K/Akt inhibition and
Nrf2 gene silencing. The fold-increase in both HO-1 protein and mRNA in response
to insulin was consistent, as well as being time and concentration dependent. The
HO-1 response to insulin was also shown in mouse primary renal tubular epithelial
cultures, demonstrating that the response is not limited to transformed cells alone.
The role of the PI3K/Akt pathway in the regulation of HO-1 has been the source of
much interest lately. Data has been shown here demonstrating that insulin-induced
HO-1 accumulation is sensitive to PI3K inhibition with LY294002. This is in
keeping with results from other work demonstrating the importance of PI3K/Akt
activation in HO-1 regulation following cell stimulation with nerve growth factor
(NGF) (267), carnosol (268), hemin (283) and cadmium (284). Over-expression of
active Akt alone was sufficient to mimic the effects of insulin on HO-1 expression in
the model used here, adding weight to the suggestion that the effect of insulin on
HO-1 is mediated predominantly or possibly exclusively, by the PI3K/Akt axis.
Over-expressing membrane-targeted active Akt stimulated the HO-1 promoter, but
significantly, adding insulin did not increase this activation. In contrast, Salinas et al
report that although the basal level of HO-1 mRNA, measured by semi-quantitative
reverse-transcriptase PCR, was higher in cells transfected with a membrane-targeted
active Akt expressing construct, administration ofNGF further increased this
expression. This may indicate that NGF exhibits its effect through additional
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mechanisms in comparison with insulin, though differences may be due to cell-type
or transfection technique.
The exact role of the MAPK cascades in HO-1 regulation remains controversial.
Inhibition of p38-MAPK reduces HO-1 expression following carnosol (268), diallyl
sulfide (285) and cadmium (284), although an earlier report found that p38 inhibition
had no effect on HO-1 mRNA expression following cadmium, arsenate or hemin
(286). Data provided, however, shows that despite concentrations of insulin being
sufficient to phosphorylate p38, inhibition of p38 did not alter insulin-induced HO-1
protein expression. Similarly, ERK inhibition did not impact on HO-1 expression
following carnosol (268) or arsenite (287); however, ERK activity was required for
HO-1 induction in HepG2 cells treated with diallyl sulfide (285) and LMH cells
exposed to arsenite (288). It remains unclear why these disparities exist but it appears
that p38 and ERK play a significant role in HO-1 regulation in some models, but not
in others.
During this investigation, a number of different transcription factors were studied
that may be involved in mediating the effect of insulin on HO-1 expression including
hypoxia-inducible factor-1 (HIF1) and NF-E2-related factor 2 (Nrf2). The basic
helix-loop-helix transcription factor HIF1 mediates essential homeostatic responses
to reduced oxygen (289,290). HIF1 has been shown to mediate transcriptional
activation of HO-1 in a rat model of hypoxia (291), rat renal medullary cells (292)
and Chinese hamster ovary cells (293). In addition, an associative increase in HIF1
DNA-binding and HO-1 induction in a rat model of liver IRI (162). The relationship
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between HIF1 and HO-1 induction in humans is less clear. Hypoxia has been shown
to repress HO-1 mRNA expression in primary cultures of human umbilical vein
endothelial cells, despite HIF1 transactivation. This reflects our observation that
ACHN cells subjected to hypoxia demonstrate a decrease in HO-1 protein expression
(data not shown). Controversial evidence exists linking PI3K activity with regulation
of HIF1, both in hypoxic (294,295) and normoxic (296-300) conditions, although
this appears to be cell-type specific (301,302). Insulin has been shown to up-regulate
HIF1 directly through the PI3K/Akt pathway (300). However, despite all this, in our
model HIF1 transactivation not seen following insulin treatment, as determined by a
HIF1 luciferase reporter construct.
Nrf2 has been shown to regulate HO-1 (269) and is known to be under the influence
of PI3K (268,283,303-306). Consistent with results presented here, insulin has
previously been shown to cause nuclear localisation of Nrf2, although PI3K
dependency was not investigated in that study (305). However, hemin has been
shown to induce Nrf2 nuclear localisation in a PI3K sensitive manner (283). Using
Nrf2 small-interfering RNA, dependence of basal HO-1 expression onNrf2 activity
has been shown: Nrf2 gene silencing practically abolished HO-1 expression. No HO-
1 response was seen following insulin in Nrf2 siRNA treated cells, suggesting
insulin-induced HO-1 expression has an absolute dependence on NrfZ activity.
In this chapter, the ability of insulin to induce HO-1 in a PI3K/Akt and Nrf2
dependent manner has been demonstrated. Establishing mechanisms of HO-1
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induction which can be implemented clinically is important for future organ
protection strategies in transplantation.
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Chapter 6 - Hsp90 inhibition as a means of
stimulating the stress protein response in renal cells
6.1 Introduction
6.1.1 Background
In chapter 4, the regulation of HSF1 by GSK3(3-mediated phosphorylation was
examined. No influence on the activation state of HSF1 could be demonstrated by
this mechanism in this cell model. One explanation for this could be the dominance
of other regulatory systems and in particular the influence of the multi-chaperone
complex in the repression of HSF1. In chapters 6-8, the role of this complex in
HSF1 regulation will be examined, focusing on the contribution of heat shock protein
90 (Hsp90). In this introduction, the current evidence for regulation of HSF1 by the
multi-chaperone complex is presented and Hsp90 is shown to be a component of
intermediate and mature HSF1-protein complexes. The hypothesis presented
contends that Hsp90 is the most important component of the HSF1 repressing multi-
chaperone complex and that inhibition of Hsp90 results in HSF1 activation and
stimulation of the stress protein response.
135
6.1.2 The multi-chaperone complex
Our current understanding of HSF1 regulation by the multi-chaperone complex
stems from two distinct lines of enquiry:
1. Investigations based on the premise that classical stressors almost always
give rise to increased quantities of unfolded proteins.
2. Work on steroid receptor regulation.
Unfoldedproteins
As discussed in section 1.6 the diverse array of insults that stimulate the stress
protein response share a common property: they adversely affect the proper
conformation of proteins. A reasonable suggestion for the regulation of the stress
protein response , therefore, is that unfolded proteins act as a collective proximal
stimulus initiating the response; this had been proposed as far back as 1980 (307).
The ability of unfolded proteins to stimulate the stress response was proven in an
experiment where Xenopus oocytes were injected with an hsp70 reporter construct
and either denatured or native proteins - only the denatured proteins activated the
hsp70 promoter (308). Thus, while it was clear that unfolded proteins could stimulate
the stress protein response, the mechanism by which cells 'sensed' the presence of
these proteins remained unclear.
It had long been appreciated that a major function of stress proteins themselves,
particularly Hsp70 and Hsp90, was to facilitate the correct folding of other proteins
(see chapter 1 and review (151)). It was hypothesised that regulation of the stress
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response may involve the interaction of a stress protein with HSF1 and unfolded
proteins (Figure 6.1). If the stress protein acted to repress the activation state of
HSF1 and was competitively bound by unfolded proteins, a regulatory mechanism
would exist whereby HSF1 activation was sensitive to the cellular levels of unfolded
proteins. Thus, stress protein expression would reflect the quantity of unfolded
proteins present and, by inference, the magnitude of stress inflicted on the cell.
Progress in the study of this hypothesis, however, was greatly hampered by the






Figure 6.1 Negative regulation of HSF1 by a stress protein: hypothesis circa
The generation of unfolded proteins following metabolic insult was thought
sufficient to stimulate the stress protein response. An attractive hypothesis for the
regulation of such a response placed HSF1 in association with a repressive stress
protein. Unfolded proteins would compete with HSF1 for stress protein binding, thus
de-repressing HSF1 with resulting transactivation. An important component was the
negative feedback loop: HSF1-mediated induction of the stress protein would only
continue until sufficient stress protein had been synthesised or unfolded protein




The steroid hormone receptors (SHR) are a family of proteins that reside in the
cytoplasm or nucleus of a cell and act as signal transducers for steroid hormone.
Ligand binding of steroid hormone to the SHR results in dimerisation, nuclear
translocation and transactivation of steroid-dependent genes (309). In the mid-80s,
unstimulated SHR was found to take part in large multi-protein complexes that acted
to repress transactivation and were later shown to be a prerequisite for ligand binding
(310). Immunoprecipitation studies identified a number of component proteins
including Hsp90 (311,312). Multi-chaperone complexes based on Hsp90 have now
been shown to be essential for the correct function of a number of different proteins
and signalling cascades (313). In 1993, while studying its ATPase activity, Nadeau et
al demonstrated that Hsp90 could bind HSF in vitro.
The importance ofHsp90 in the HSF1 multi-chaperone complex
The year before Nadeau made the link between HSF and Hsp90, similar work had
been published suggesting Hsp70 could associate with HSF (314). A number of
studies pointed to Hsp70 as the hypothetical protein most likely to bind and repress
HSF1, yet the evidence remained unconvincing (315-318). Although a further study
demonstrated in vitro binding of HSF 1 with Hsp90* (319), it was a number of years
before Hsp90-HSF1 binding was finally demonstrated in vivo (320) (Table 6.1). Ali
et al showed that Hsp90-HSF1 heterocomplexes existed in both unshocked and heat-
shocked Xenopus oocyte nuclei and furthermore, that Hsp90 antibodies activated
HSF1 DNA-binding (in the absence of heat shock) and that this effect was reversed
*
Nair et al also demonstrated the ability of HSF to bind in vitro with a number of other proteins
including Hsp70, p60, Fkbp51, Fkbp52, CyP40 and p23 (319)
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by the subsequent injection of recombinant Hsp90 protein. For the first time in the 20
years since the hypothesis had been proposed, convincing evidence existed that
HSF1 was regulated by a stress protein, Hsp90.
It was established from the work on steroid hormone receptors that other proteins
were required in the formation of the complex as well as Flsp90. p23 stabilised the
interaction between the mature Hsp90 complex and its substrate. Members of the
immunophilin1 family were also identified to form a necessary part of the complex,
although the specifics of this remain unclear. Other proteins were also required in the
formation of intermediate complexes including Hsp70 and the Hsp70/90 binding
protein, Hop. At around the same time as Ali et al published the in vivo work on
Hsp90-HSF1 interaction (320), Zou et al successfully demonstrated the importance
of Hsp90 in repressing HSF1 activation in a novel in vitro model based on HeLa cell
lystate (321). While immunodepletion of Hsp90 activated HSF1, immunodepletion
of other proteins suspected of being involved (Hsp70, Hop, Hip, p23, Cyp40 or
Hsp40) had no effect. In follow-up to the Ali et al paper, Bharadwaj et al (from the
same group) showed that Hsp90 was not alone in associating with HSF1. In the
Xenopus oocyte model they demonstrated, in a similar manner to SHR complexes,
that p23 was also present in the HSF1-Hsp90 complex in stimulated and
unstimulated cells (322). The immunophilin, Fkbp52, was also shown to be
associated with Hsp90 only in stimulated cells. Accelerated recovery following heat
shock was also seen following injection of purified Hsp90/70 and Hip/Hop. A
+
Immunophilins: receptors for immunosuppressive drugs including cyclosporin A, FK506, and
rapamycin. Cyclosporin A receptors are referred to as cyclophilins (CyP). FK506- and rapamycin-
binding proteins are abbreviated to Fkbp.
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Nadeau 1993 In vitro - - (323)
Nair 1996 In vitro - p23, Hsp70,
various IPs*
(319)
Zou 1998 In vitro/vivo (-) transactivation - (321)
Ali 1998 In vivo (-) DNA-binding - (320)
Bharadwaj 1999 In vivo (-) transactivation p23, (Fkbp52)f (322)
Guo 2001 In vivo (-) transactivation p23, (Fkbp52)f (324)
Table 6.1 Papers reporting HSF1-Hsp90 complex formation, functional
implications and associated proteins.
In 1993 the first description of HSF-Hsp90 interaction in vitro was published. It was
not until 1998 that this observation was confirmed in vivo. A number of other
proteins have been implicated in the multi-chaperone complex. * IPs,
immunophilins: receptors for immunosuppressive drugs including cyclosporin A,
FK506, and rapamycin. Cyclosporin A receptors are referred to as cyclophilins (CyP)
and FK506- and rapamycin-binding proteins are abbreviated to Fkbp. Fkbp51,
Fkbp52 and Cyp40 were all shown to interact with HSF1 in vitro. * Fkbp52 was
shown by Bharadwaj and Guo to bind to HSF1 but only after heat shock. This
association was not demonstrated in unstimulated cells.
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delay in the recovery of HSF1 from heat shock was shown when antibodies to
Hip/Hop and Fkbp51 (as well as Hsp90, p23 and Fkbp52) were injected, despite the
fact neither Hip/Hop nor Fkbp51 could be co-immunoprecipitated with HSF1.
Lastly, Guo et al (from the same group as Zou et at) showed that Hsp90 binds HSF1
in unstimulated cells, but this was vastly reduced following heat shock. Fkbp52 and
p23 were shown to bind HSF1 in stimulated, but not unshocked cells.
What conclusions can be drawn from this body of work? The finding of Zou showing
that p23 did not associate with Hsp90-HSF1 is likely to be erroneous and explained
by differences in the model (and the artificial nature of the in vitro activation model).
Work from the same group (Guo et at) confirmed associations between Hsp90-FISF1
and p23 and this is likely to be the case. It is clear that p23 and Hsp90 associate with
HSF1 in both unstimulated and stimulated cells. Yet, the hypothesis relies on the fact
that the repressive Flsp90 complex dissociates from HSF1 on stimulation of the cell
resulting in activation of HSF 1. The concept emerging is that complex inhibition is
likely to exist at the level of the monomer and the trimer. This assertion is based on
evidence that Hsp90-p23 interaction with HSF1 in the trimeric form has been
identified. Also the immunophilin, Fkbp52, has been shown to be associated with the
Hsp90-HSF1 heterocomplex only in stimulated (e.g. heat-shocked) cells, but not in
unstimulated cells. It is likely, therefore, that this other complex acts to repress the
trimeric form of HSF1 independently of monomeric repression. Figures 6.2 and 6.3
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Formation ofHSF1 multi-chaperone complex: hypothesis
The mechanism of formation of the HSF1 multi-chaperone complex is still
hypothetical and much is based on the current understanding of steroid receptor
biology. Hsp70, Hsp40 and Hop form an early complex, Hop facilitating the binding
of first Hsp70, then Hsp90 to form an intermediate complex. Hsp70, Hsp40 and Hop
are substituted for p23 and (presumably) an immunophilin (313). Exposure to stress
increases the molar-ratio of unfolded proteins to chaperones with the unfolded
proteins associating with Hsp90. With fewer chaperones available for HSF1 binding,
HSF1 trimerises and is transactivated resulting in transcription of heat shock
proteins. With an increase in the availability of Hsps, HSF1 becomes complexed
again, a negative feedback loop thereby being formed1.
* HSF multi-chaperone complex: there is evidence that a multi-chaperone complex involving Hsp90,
Fkbp52 and p23 acts to repress trimerised HSF 1, i.e. two levels of regulation exist, one at the level of
the monomer, the other at the trimer (322,324). For the purposes of this study, it does not matter
whether Hsp90 is exerting greater influence on repression of monomeric or trimeric HSF1, the
outcome is the same.
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6.1.3 Hsp90-binding agents (HBAs)
The identification of geldanamycin (GA) marked the first description of a group of
drugs termed the benzoquinone ansamycins. It was isolated from streptomyces
hygroscopicus in the early 1970s and was noted for its antiprotozoal activity
(325,326). Herbimycin A was subsequently identified and found to have herbicidal
properties (327,328).
Anti-neoplastic properties
The anti-tumour potential of the benzoquinone ansamycins was suggested in the late
1970s (329-332), but it was not until the mid-1980s that first herbimycin (333) and
then GA (334) were shown to inhibit the malignant transformation of fibroblasts by
the v-Src oncogene. Src kinase belongs to a family of non-receptor tyrosine kinases
and the benzoquinone ansamycin effect was believed to be due to tyrosine kinase
inhibition. It was, however, shown that Src formed a stable complex with Hsp90 and
the benzoquinone ansamycins were specific Hsp90 inhibitors (335). Hsp90 inhibition
prevented complex formation resulting in Src degradation by the ubiquitin-
proteosome pathway. The benozoquinone ansamycins work by binding to the ATP-
binding site of Hsp90, thus preventing its intrinsic ATPase activity (336) and have
been shown to be very specific (335,337). Src is only one of a number of oncogenic
proteins that require functioning Hsp90 to exert their effects. Hsp90 inhibition,
therefore, is now the subject of trials assessing anti-neoplastic potential.
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Cytoprotective properties
A number of studies have demonstrated cellular protection associated with HBA
treatment, but none of these have been in a model relevant to transplantation (Table
6.2). Two studies have shown protection against IRI following HBA treatment
(338,339). Lu et al also showed a GA-mediated reduction in co-immunoprecipitation
of HSF1 with Hsp90 in brain tissue homogenates, an increase in HSE-binding of
HSF in brain nuclear extracts and an increase in luciferase reporter gene transcription
for the Hsp70 promoter in PC 12 cells.
Given the beneficial effects of HBA-treatment in these models, it was hypothesised
that HBAs could reduce the effects of IRI in renal transplantation. To investigate this
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6.2 Hypotheses
1. Geldanamycin-mediated Hsp90 inhibition induces HSF1 trimerisation and
DNA-binding.
2. Geldanamycin-mediated Hsp90 inhibition induces the stress protein response
in renal cells.
3. Hsp90 inhibition protects renal cells from oxidative stress.
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6.3 Methods and materials
6.3.1 HSF1-GFP vector transfection
ACHN cells were prepared in 6-well plates and a transient transfection was
performed 24 h later. A vector expressing green fluorescent protein under the control
of an HSF-dependent promoter (HSF-GFP) was a kind gift of Mr Richard Morimoto
(Northwestern University, IL, US) (350). The transfection agent fugene (Roche,
Lewes, East Sussex, UK) was used at a 6:1 ratio of reagent to DNA. 24 h later
transfected cells were treated with GA (2 pM) for 1.5 h. Cells were fixed with
methanol, counterstained with Hoechst 33258 (0.2 mM) and visualised with a Leica




Geldanamycin induces Hsp70 in ACHN cells
ACHN cells were treated with GA (2 pM) for various times (Figure 6.4A). A 2.6 fold
increase in Hsp70 was seen at 4 h and a 5 fold increase at 6 h. Hsp70 induction
persisted for at least 8 h. No induction of Hsp70 was seen with vehicle (DMSO)
alone. A dose response of GA showed a 5 fold induction of Hsp70 with 0.2 pM GA
at 8 h (Figure 6.4B).
Geldanamycin-induced Hsp70 expression is transcription and translation dependent
To confirm that Hsp70 accumulation was dependent on gene transcription, ACHN
cells were pre-treated with actinomycin D (AD) for 30 min, prior to 6 h treatment
with GA (Figure 6.5). Basal levels of Hsp70 were slightly reduced following AD and
the response to geldanamycin was abolished. Similarly, cycloheximide (CHX) was
administered to establish the role of protein synthesis in Hsp70 expression following
exposure GA for 6h. CHX completely abrogated Hsp70 induction following GA
treatment.
Geldanamycin is not toxic to cells at concentrations that induce Hsp70
After 24 h of GA treatment cell viability was determined by MTT assay (Figure 6.6).
No significant difference was seen between groups treated with increasing
concentrations of GA and control groups.
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Figure 6.4 Hsp70 expression in ACHN cells following geldanamycin treatment.
ACHN cells were exposed geldanamycin (GA) (2 pM) or vehicle (Veh) (DMSO) for
various times (A) or to various concentrations of GA for 6 h (B). Whole-cell lysates
were prepared and analysed by Western blotting using antibody to Hsp70. P-actin
was used as a loading control.
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Figure 6.5 Geldanamycin stimulated Hsp70 accumulation is transcription and
translation dependent.
ACHN cells were pre-treated with actinomycin D (5 pg/ml) (AD) or cycloheximide
(10 pg/ml) (CHX) for 30 min, followed by GA (2 pM) for 6 h. Whole-cell lysates
were prepared and analysed by Western blotting using antibody to Hsp70, with P-
actin being indicated as loading control.
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Figure 6.6 Cell viability following geldanamycin treatment.
ACHN cells were treated with various concentrations of GA for 24 h. MTT was
added for 2 h and the resulting tetrazolium crystals dissolved in SDS. Samples were
analysed on a plate reader and results are mean of 3 independent experiments
expressed as a proportion of the control; error bars S.E.M.
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Geldanamycin induces HSF1 trimerisation and DNA-binding
An increase in trimerised HSF1 was seen in cells treated with GA for 1.5 h which
was similar to that observed in heat-treated cells (Figure 6.7). Specificity was
confirmed with a band-shift seen when the binding reaction was run in the presence
of anti-HSFl antibody. The HSF1 bands disappeared when the reaction was run in
the presence of a 20x molar-excess of unlabelled probe.
Geldanamycin induces HSF1 stress-granule formation
Nuclear localisation of HSF1 following GA treatment was confirmed in cells that
had been transfected with an HSF1-GFP expressing construct (Figure 6.8). Nuclear
stress-granule formation was seen in cells treated with GA, compared with diffuse
cytoplasmic expression of HSF1 in control cells.
Geldanamycin activates an Hsp70 reporter construct
A reporter construct containing the luciferase gene under the control of five repeats
of the heat shock elements (HSE; FISF1 binding site) portion of the Hsp70 promoter
was co-transfected with the pSV-|3-gal control vector into ACHN cells using the
fugene transfection reagent (Figure 6.9). 24 h later cells were treated with GA (2 pM)
for various times. A 2 fold increase was seen in promoter activity following GA was
found after 4 h but did not achieve statistical significance after 3 independent repeats.
Geldanamycin stimulates Hsp70 mRNA accumulation in ACFIN cells
ACHN cells were treated with geldanamycin (2 pM) for various times (Figure 6.10).
Fluorescence detected real-time PCR was performed using an 18s primer/probe
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control on whole-cell extracts. A 30 fold increase in Hsp70 gene expression was seen
in cells treated with GA for 4 h.
Geldanamycin protects ACHN cells from oxidative damage
ACHN cells pre-treated with GA for 6 h were found to be protected from H2O2 (2
pM) when compared to untreated cells (Figure 6.11). In fact, there was a trend in GA
treated groups to have a greater cell viability following H2O2 treatment than cells that
had not received H2O2.
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Figure 6.7 HSF1 DNA-binding ability and oligomeric status following
geldanamycin treatment.
ACHN cells were treated with geldanamycin (GA) (2 pM) or vehicle (V) (DMSO)
for 1.5 h; a further group was subjected to heating at 43 °C for 45 min and recovered
for 45 min. Nuclear lysates were prepared and a DNA mobility shift assay performed
using i2P-labelled heat shock element consensus oligonucleotides. As controls, lysate
from the GA group was run with either anti-HSFl antibody (Shift) or excess
unlabelled consensus oligonucleotides (CP).
157
B
Figure 6.8 Geldanamycin induces nuclear HSF1 stress-granules formation.
ACHN cells were transfected with the HSF1-GFP construct and 24 h later treated
with GA (2 pM) for 1.5 h. Cells were fixed with methanol and counterstained with
Hoechst. Fields were visualised with a Leica DM IRB microscope and images were
stored using the Leica Improvision software.
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Figure 6.9 Geldanamycin activates a reporter construct containing the Hsp70
promoter.
ACHN cells were transfected with an Hsp70-luciferase reporter construct and the
pSV-[3-gal control vector. 24 h later cells were treated with GA (2 pM) for various
periods of time. Cells were lysed and luciferase and P-galactosidase assays
performed. Results are expressed as mean luciferase activity per unit P-galactosidase













Figure 6.10 Geldanamycin stimulates Hsp70 mRNA accumulation in ACHN
cells.
ACHN cells were treated with increasing concentrations of geldanamycin (GA) for 4
h. mRNA extracts were prepared using TRIzol and reverse transcribed to cDNA.
Fluorescence-detected real time PCR was performed using Hsp70 primers and probe
with a 18s primer/probe control; results are expressed as mean relative expression ±
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Figure 6.11 Geldanamycin protects cells from F^C^-induced oxidative stress.
ACHN cells were treated with increasing concentrations of GA for 6 h after the
medium was changed and included H2O2 (2 pM) for 16 h. MTT was added for 2 h
and the resulting tetrazolium crystals dissolved in SDS. Samples were analysed on a
plate reader (spectrophotometer) and results are the mean of 3 independent
experiments expressed as the relative proportion of cells protected from H2O2; error
bars S.E.M; * p<0.05 Mann-Whitney U test.
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6.5 Discussion
In this chapter, it has been shown that treating a renal adenocarcinoma cell-line with
the Hsp90-binding agent, geldanamycin, up-regulates Hsp70 mRNA and protein in a
transcription- and translation-dependent manner. GA treatment was associated with
HSF1 trimer formation, DNA-binding and stress-granule formation. GA was also
shown to protect cells from H202-induced oxidative stress. These results confirm
observations in other cell-types that treatment with HBAs is associated with Hsp
induction and cellular protection. Hegde et al demonstrated Hsp28/72/73 and Grp94
induction following treatment with the HBA, herbimycin A, and that this was
associated with cellular protection similar to that conferred by heat treatment (340).
Morris et al also demonstrated Hsp70 induction following herbimycin A in
cardiomyocytes, and although Hsp25/60/90 induction was not demonstrated, cells
were protected in a model of simulated ischemia* (341). Javadpour et al showed
decreased lung injury following infrarenal aortic clamping associated with Hsp70
induction following herbimycin A treatment (338). Dinh et al found herbimycin A
protected human retinal epithelial cells from heat and was associated with increased
Hsp70/90 mRNA expression on cDNA array (although no attempt was made to
confirm this with real-time PCR) and Hsp70 protein induction (342).
Sachidhanandam et al demonstrated Hsp70 expression following herbimycin A
treatment associated with lower levels of heat-induced hepatocyte apoptosis (343).
Interestingly, the core body temperature (as measured by an implanted temperature
sensor) of animals pre-treated with herbimycin A reached a lower maximum than
*
Simulated ischemia (Morris): buffer simulates the extracellular milieu of myocardial ischemia, with
concentrations of potassium, hydrogen, and lactate ions approximating in vivo conditions.
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control animals, despite both groups of animals being placed in a Perspex container
with tight temperature and humidity control.
A number of investigators have examined the ability of GA to protect cells and
organs. Conde et al subjected cardiomyocytes to simulated ischemia^ and
demonstrated protection in GA treated groups associated with heat shock protein
induction (344). Xiao demonstrated decreased apoptosis in GA pre-treated
hippocampal cells subjected to oxidative stress (345). Pittet et al used a
haemorrhagic model of lung injury to examine the benefits of GA pre-treatment or
heat. Alveolar liquid clearance was significantly better in GA and heat-treated
animals when compared with control groups (346). Lu et al infused GA directly into
the middle cerebral artery, after which animals were subjected to 2 h of ischemia and
22 h of reperfusion (339). Decreased infarct volumes, fewer TUNEL-positive cells,
reduced brain oedema and improved behavioural outcomes were shown in the GA
treated groups. GA treatment was associated with HSF1 activation and Hsp70 and
Hsp25 induction. Xu et al demonstrated protection of mature astrocytes from
necrotic cell death and young astrocytes from apoptotic death with 8 h pre-treatment
with GA (347). This was associated with increased Hsp70 protein expression. Kiang
et al found GA inhibited hemorrhage-induced ATP loss in the jejunum, lung, heart,
kidney, and brain of mice. Hsp70 gene transfer into intestinal epithelial cells
promoted pyruvate dehydrogenase and ATP levels, whereas Hsp70 short-interfering
RNA reduced them.
f Simulated ischemia (Conde): Hypotonic HBSS without glucose or serum, and made hypoxic for 4 -
6 h at 37 °C.
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Fewer studies have been performed using the HBA, radicicol. Griffin et al
demonstrated protection in rat cardiomyocytes subjected to simulated ischemia*
(349). This was also associated with Hsp induction.
While these studies are important and show strong a strong association between
HBA treatment, Hsp induction and cellular/organ protection, little in the way of
causal data has been reported. This is also true of the data presented in this chapter
and is due in part to the lack of a specific chemical inhibitor of HSF1. A
bioflavonoid, quercetin, has been widely used as an inhibitor of the heat shock
response and may work by down-regulation of HSF1 (351). However, it is a very
promiscuous inhibitor and has significant effects on a large number of kinases
involved in different molecular mechanisms (Table 6.3). For this reason, published
data based on its use must be treated with some scepticism. The development of
short-interfering RNA (siRNA) has greatly aided study in this field and will be
explored in the next chapter.
A criticism of this part of the study could be the choice of cell-line. The use of a
renal adenocarcinoma cell-line may not provide a model that accurately reflects the
physiological conditions encountered in a human kidney during renal transplantation.
While the criticism is valid, the experiments act as a proof of principle prior to using
the drugs in a mouse model of renal IRI.
* Simulated ischemia (Griffin): buffer lacking glucose and Na2HP04 bubbled for 30 min with argon
and maintained at 0.03% 02 for 16 h.
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While these experiments were successful I was aware of the limitations of GA as a
potential therapeutic intervention. In pre-clinical studies, significant hepatotoxicity
had been found in dogs limiting its clinical application (352). However, analogues of
the drug had been developed and became available during the period of this study.
Similar Hsp90 inhibition had been demonstrated with these analogues, but lower
degrees of toxicity and better bioavailability than GA. The ability of these agents to
protect cells has not previously been studied. The next chapter examines these drugs
and tests their ability to induce the stress protein response in cell culture, comparing
their ability against that of GA.
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Table 6.3 Inhibition of protein kinases by quercetin.
The effects of quercetin (20 pM) on a core panel of common kinases. From (353).
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Chapter 7 - Analogues of geldanamycin (17-AAG and
17-DMAG) stimulate the stress response and protect
renal cells from oxidative stress
7.1 Introduction
7.1.1 Background
In chapter 6, the efficacy of geldanamycin (GA) in stimulating the stress protein
response through HSF1 inhibition was demonstrated. This is important proof-of-
principle evidence, but the clinical use of GA is limited by toxicity. Having
successfully demonstrated protection of renal cells with Hsp90 inhibition, the clinical
potential of newly developed related drugs was examined. Modifications to GA have
been attempted aiming to improve the bioavailability, reduce the side-effect profile,
while maintaining potent Hsp90 inhibition.
7.1.2 Geldanamycin analogues
Two such drugs which fulfil these criteria have been developed by the US National
Cancer Institute: 17-allylamino-17-demethoxygeldanamycin (17-AAG) and 17-NN-
dimethyl ethylene diamine-geldanamycin (17-DMAG).
17-AAG
When GA is treated with alkylamines bearing one displaceable hydrogen, it reacts to
lose its 17-methoxy group to form 17-amino-17-demethoxy derivatives (354). The
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anti-neoplastic properties of 17-AAG have been studied in pre-clinical, phase I (355-
360) and phase II trials (361) (a further nine phase I and eight phase II trials are
registered with the National Library for Medicine; www.clincialtrials.gov, accessed
16th March 2007). Few studies have specifically examined Hsp expression following
17-AAG treatment (Table 7.1). 17-AAG induces Hsp70 in colorectal cancer cells
(362), primary glial cultures (363) and motor neurons (364,365), and a phase I
clinical trial in patients with advanced solid tumours found Hsp70 induction in
peripheral blood mononuclear cells (358).
17-DMAG
17-DMAG is another analogue of GA which is water soluble affording it excellent
bioavailability and wide tissue distribution compared with 17AAG (366). X-ray
crystallography suggests it has a much greater affinity for Hsp90 than 17-AAG (367)
and pre-clinical trials suggest similar anti-neoplastic activity as 17-AAG (368). Six
phase I clinical trials are registered for the treatment of advanced-stage solid tumours
(www.clincialtrials.gov, accessed 16th March 2007) (369). As with 17-AAG, no
reports exist at present looking at cellular protection associated with 17-DMAG
treatment. Hsp70 induction in liver and kidney has been demonstrated in severe
combined immunodeficiency (SCID) mice bearing breast cancer tumours treated
with 17-DMAG (75 mg/kg IV) (370).
17-AAG and 17-DMAG both effect excellent Hsp90 inhibition in vitro and in vivo
and cause significantly lower side-effects than GA in phase I (371) and pre-clinical
trials (372), respectively. Unlike GA, the ability of 17-AAG or 17-DMAG to protect
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cells has not been reported in the literature, either in vitro or in vivo. These drugs
represent a potentially safe and efficacious way to stimulate the stress protein
response conferring cellular protection that could be applied clinically. In this
chapter, the ability of the analogues to do this in vitro was examined prior to moving
into an animal model described in Chapters 8 and 9.
Drug Author Year Species Cell/organ Protein Ref
17-AAG Clarke 2000 Human Colorectal Hsp70 (362)
cancer cells
Dello 2006 Mouse Glial cells Hsp70 (363)
Waza 2005 Mouse Motor Hsp40/70 (365)
neurons
Batulan 2006 Mouse Motor Hsp40/70 (364)
neurons
Nowakowski 2006 Human PBM cells Hsp70 (358)
17-DMAG Eiseman 2005 Mouse Kidney/liver Hsp70/90 (370)
Table 7.1 Reports of heat shock protein induction following 17-AAG/17-DMAG
treatment.
PMB, peripheral blood mononuclear.
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7.2 Hypotheses
1. 17-AAG and 17-DMAG cause Hsp90 inhibition and induce HSF1
trimerisation and DNA-binding.
2. 17-AAG- and 17-DMAG-mediated Hsp90 inhibition induces the stress
protein response in renal cells.
3. HSF1 gene silencing abrogates the effects of 17-AAG and 17-DMAG.
4. Hsp90 inhibition protects renal cells from oxidative stress.
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7.3 Methods and materials
7.3.1 Estimation of ROS production
ACHN cells were grown to 90% confluence in a 96-well plate. Cells were then
treated with GA, 17-AAG, 17-DMAG (all 2 pM) or glucose oxidase (0.1 unit/ml) for
1 h after which 5-(and-6)-chloromethy1-2',7'-dichlorodihydrofluorescein diacetate
(DCFDA) (Molecular Probes, Invitrogen, Paisley, UK) (5 pM) was added. The plate
was placed on a thermostatically controlled plate reader and read at 15 min intervals
for 2 h (excitation 485 nm, emission 535 nni).
7.3.2 Annexin V/propidium iodide flow cytometry
ACHN cells were treated with GA, 17-AAG and 17-DMAG (all 2 pM) for 8 h. After
incubation, detached cells were collected and pooled with trypsinized adherent cells.
Cells were centrifuged at 200 g for 5 min at 4 °C, and the supernatant removed. Cells
were washed three times with ice-cold PBS buffer and re-suspended in 100 pi of
binding buffer (10 mM Hepes, [pH 7.4], 150 mM NaCl, 5 mM KC1, 1 mM MgCf,
1.8 mM CaCh). 5 pi of FITC-conjugated annexin V and 10 pi of propidium iodide
were added and the cell suspension gently mixed and incubated in the dark on ice for
10 min. Samples were assayed for viable, apoptotic, and necrotic cells by FACS
analysis (Coulter Epics XL-MCL, Beckman Coulter High Wycombe,
Buckinghamshire, UK). Necrotic cells were defined as cells demonstrating positive
staining for both FITC-conjugated annexin V and propidium iodide. Viable cells
were not positive for either FITC-conjugated annexin V or propidium iodide.
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Apoptotic cells were defined as cells exhibiting positive staining for FITC-
conjugated annexin V and negative staining for propidium iodide. Fluorescence was
measured on a double-parameter histogram, using logarithmic scales. For each tube,
5000 events were analyzed. No significant FITC staining was seen in control or HBA
treated cells. Necrotic control cells stained positively for both PI and FITC.
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Figure 7.1 Structural differences between geldanamycin analogues.
Two analogues of GA have been synthesised with side-chain alterations at the 17-
position (shown in red). Both analogues have better bioavailability and are less toxic
in vivo than GA. 17-DMAG has the added advantage of being water-soluble. 17-




HBAs induce Hsps in ACHN cells
The effects of different HBAs in vitro were examined in a human renal
adenocarcinoma cell line (ACHN). A time course using GA, 17-AAG and 17-
DMAG (all 2 pM) demonstrated a 3.5 fold increase in Hsp70 expression after 6 h
(Figure 7.2A). Hsp90 was 3.4 fold greater 4 h after treatment with GA and 2.5 fold
greater 4 h after 17-AAG or 17-DMAG. Maximal dose response of Hsp70 and
Hsp90 was seen with HBAs at a concentration of 0.2 pM (Figure 7.2B). The small
heat shock protein Hsp27 was not found to be up-regulated at these early time points,
however, in 17-DMAG (2 pM) treated cells there was a 2 fold increase at 12 h, with
the same increase at 16 h in cells treated with GA or 17-AAG (both 2 pM) (Figure
7.3). Hsp27 induction was demonstrated 12 h following 17-DMAG treatment and 16
h following GA and 17-AAG. HO-1 (Hsp32) expression was increased at 4 h by GA
alone. HO-1 expression was not altered by 17-AAG or 17-DMAG. Cells treated for 1
h with HBAs demonstrated trimerisation of HSF1 on a DNA mobility shift assay
(Figure 7.4). Hsp70 gene expression was increased 30, 35 and 42 fold, following 2 h
treatment with GA, 17-AAG and 17-DMAG respectively (all 2 pM) (Figure 7.5).
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Figure 7.2 Induction of Hsp90 and Hsp70 by geldanamycin, 17-AAG and 17-
DMAG.
ACFTN cells were exposed to 2 pM GA, 17-AAG or 17-DMAG for various periods
of time (A) and various doses of GA, 17-AAG or 17-DMAG for 8 h (B). Whole-cell
lysates were prepared and analysed by Western blotting using antibody to Hsp90 and
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Figure 7.3 - Induction of small Hsps by geldanamycin and analogues.
ACHN cells were exposed to increasing doses of geldanamycin (GA), 17-AAG or
17-DMAG for periods up to 16 h. Whole-cell lysates were prepared and analysed by
Western blotting using antibody to HO-1 (Hsp32) and Hsp27. P-actin was used as a
loading control.
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Figure 7.4 HSF1 DNA-binding ability and oligomeric status HBA treatment.
ACHN cells were treated with geldanamycin (GA), 17-AAG, 17-DMAG (all 2 pM)
or vehicle (V) (DMSO) for 1.5 h; a further group was subjected to heating at 43 °C
for 45 min and recovered for 45 min (HS). Nuclear lysates were prepared and a DNA
mobility shift assay performed using i2P-labelled heat shock element consensus
oligonucleotides. As controls, lysate from the HS group was run with anti-HSFl
antibody (Shift) or excess unlabelled consensus oligonucleotides (CP).
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Figure 7.5 Geldanamycin, 17-AAG and 17-DMAG stimulate Hsp70 mRNA
accumulation in ACHN cells.
Cells were treated with various concentrations of GA, 17-AAG or 17-DMAG for 4 h.
mRNA extracts were prepared using TRJzol and reverse transcribed to cDNA.
Fluorescence-detected real time PCR was performed using Hsp70 primers and probe
with a 18s primer/probe control; results are expressed as mean relative expression ±
S.E.M. of 3 independent experiments; NS, non-significant (ANOYA with Bonferroni
correction).
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Toxicity ofHBAs on ACHN cells
To determine whether HBAs reduce cell viability, ACHN cells were treated with
increasing concentrations of the drugs for 16 h (Figure 7.6). A trend was observed
where GA reduced the cell viability; however, no statistical difference was
demonstrated between GA and any other group (ANOVA).
HBA treatment does not cause reactive oxygen species accumulation in ACHN cells
To determine whether HBAs have a direct oxidant effect, reactive oxygen species
(ROS) generation was measured. Cells were prepared in 96-well plates and treated
with GA, 17-AAG or 17-DMAG. Following the addition of DCFDA, the resulting
fluorescence was measured for 2 h (Figure 7.7). Cells treated with HBAs did not
demonstrate any ROS production compared with control cells. Glucose oxidase
treated cells were used as a positive control and exhibited significant ROS
production.
HBA treatment does not result in significant apoptosis in ACHN cells
ACHN cells were treated with GA, 17-AAG and 17-DMAG (all 2 pM) for 8 h. Cells
were treated with FITC-conjugated annexin V and propidium iodide (PI) and
underwent flow cytometry (Figure 7.8). Annexin V positivity was not demonstrated
in cells treated with HBAs, suggesting that early cell membrane changes associated















Figure 7.6 Toxicity of geldanamycin, 17-AAG and 17-DMAG on ACHN cells.
Cells were treated with vehicle (DMSO) □, GA H, 17-AAG 10 and 17-DMAG S3 for
16 h. An MTT assay was performed and cell viability expressed as a fraction of
control (C). Results represent mean of 6 independent experiments with S.E.M.
indicated by error bars.
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Figure 7.7 Reactive oxygen species generation following treatment with
geldanamycin, 17-AAG and 17-DMAG.
ACHN cells were treated with DCFDA and geldanamycin (x), 17-AAG (□), 17-
DMAG (o) or glucose oxidase (A). Untreated cells (0) and cells treated with







Figure 7.8 Apoptosis following treatment with HBAs.
ACHN cells were treated with GA, 17-AAG and 17-DMAG (all 2 pM) for 8 h.
Necrotic cells were prepared by treating cells in a microwave for 15 s. After
incubation, detached cells were collected and pooled with trypsinized adherent cells
and combined with FITC-conjugated annexin V and propidium iodide (PI). Samples
underwent FACS analysis with necrotic cells defined as demonstrating positive
staining for both annexin V and PI and apoptotic cells defined as exhibiting positive
staining for annexin V but negative staining for PI. Fluorescence was measured on a
double-parameter histogram, using logarithmic scales.
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HBAs protect ACHN cells from hydrogen peroxide (H202)-mediated oxidative stress
Cells were treated with GA, 17-AAG or 17-DMAG for 8 h, followed by H2O2 (2
pM) for 16 h. An MTT assay was performed and results expressed as a relative
protection from H2O2. Pre-treatment with HBAs protected cells from a hydrogen
peroxide (H2O2) mediated oxidative insult (Figure 7.9). This protection did not reach
statistical significance after 8 h of GA (2 pM), but was significant in groups treated
with 17-AAG (p<0.05) and 17-DMAG (p<0.01). 17-AAG and 17-DMAG treated
cells demonstrated the same viability as control cells not treated with H2O2. Cell
viability in the 17-DMAG group was not significantly greater than that of the GA
group.
HSF1 siRNA abrogates HBA-mediated Hsp induction andprotection
To determine whether HBA-mediated Hsp is HSF1 dependent, cells were transfected
with HSF1 short-interfering RNA (siRNA). 48 h later cells were treated with HBAs
and Hsp induction determined (Figure 7.10). An HSF1 Western blot confirmed
adequate HSF1 silencing was consistently achieved. siRNA transfection resulted in
2.5-times increase in Hsp70 expression. However, when siRNA transfected cells
were treated with HBAs a further 1.5-times increase in Hsp70 protein was found.
This increase was abrogated when cells were transfected with HSF1 siRNA. The
viability of cells transfected with siRNA and exposed to H2O2 was lower than those
exposed to H2O2 alone (Figure 7.11). Comparable levels of protection were seen in
transfected cells pre-treated with HBAs, prior to exposure to H2O2. Importantly, this
protection was reduced in HSF siRNA cells pre-treated with HBAs and exposed to
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Figure 7.9 Protection of ACHN cells from H2O2 induced oxidative stress.
ACHN cells treated with increasing concentrations of geldanamycin (GA), 17-AAG
and 17-DMAG. Hydrogen peroxide (H2O2) (2 pM) was then added for 16 h. An
MTT assay was performed and samples analysed on a plate reader. The results are
the mean of 5 independent experiments expressed as the relative proportion of cells
protected from H2O2; error bars S.E.M. C. control; V, vehicle. ** significantly
different from vehicle (p<0.01; ANOVA with Tukey HSD correction); *
significantly different (p<0.05; ANOVA with Tukey HSD correction); NS, not
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Figure 7.10 Effect of HSF1 siRNA on Hsp70 expression following treatment with
geldanamycin, 17-AAG or 17-DMAG.
ACHN cells were transfected with siRNA target against HSF1, transfected with
control siRNA, or not transfected. 48 h later cells were treated with 2pM GA, 17-
AAG, or 17-DMAG for 8 h. Whole-cell lysates were prepared and analysed by
















Figure 7.11 HBA-mediated cellular protection following HSF1 siRNA treatment.
ACHN cells were transfected with HSF1 siRNA or control siRNA. 48 h later
transfected cells were treated with GA, 17-AAG or 17-DMAG (all 2 pM) for 8 h,
followed by H2O2 for 16 h. An MTT assay was performed with results expressed as




In this chapter, it has been shown that treatment of renal cells with 17-AAG or 17-
DMAG results in a robust up-regulation of Hsps, similar to the effect seen with
geldanamycin treatment. Hsp70 mRNA expression following 17-DMAG showed a
trend to greater expression when compared to GA treatment, although this did not
achieve statistical significance. Similarly, 17-AAG and 17-DMAG both protected
cells from H2O2, with 17-DMAG again tending to protect cells better (although a
statistically significant difference between 17-DMAG and GA was not
demonstrated).
When comparing cells treated with 17-AAG/17-DMAG and GA, the latter was found
to have a small but measurable effect on cell viability (Figure 7.6). Related to this
observation is the induction of heme oxygenase-1, seen following GA but not 17-
AAG nor 17-DMAG (Figure 7.3). What differences exist between the drugs that
could explain these findings? As has been discussed, pre-clinical trials of GA found
significant hepatotoxicity which was not apparent with 17-AAG and 17-DMAG
(352,372). One possible mechanism of toxicity is direct production of reactive
oxygen species (ROS), a capacity common to all compounds containing a quinone
group. Dikalov et al have shown that GA can generate superoxide (373) and Billecke
et al have demonstrated that GA is capable of redox cycling* with nNOS (375). In
the model presented here, 2 h treatment with 2 pM HBAs was not sufficient to show
*
Redox-cycling: typically, a flavoenzyme mediates transfer of electrons from NADPH to the quinone
chemically reducing it to the semiquinone. Subsequent electron transfer to oxygen from the
semiquinone results in the formation of 02". This redox cycle continues until the system becomes
anaerobic at which time the oxygen radical production decreases and the semiquinone begins to
accumulate to detectable levels (374).
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a difference in the generation of ROS between treated and untreated groups. In the
two studies cited, generation of ROS was apparent using high concentrations of GA
(17 - 20 pM). Concentrations of less than 5 pM, as used here, resulted in much lower
generation of ROS and a more recent study has confirmed this (376).
Even if the ROS production had been demonstrated, it would not explain differences
between drugs as all contain a quinone ring and therefore should be equally capable
of generating ROS. A more recent suggestion comes from an American
Biotechnology firm that claims to have linked GA toxicity to an Hsp90-independent
mechanism: inhibition of phosphoribosylaminoimidazole carboxylase, an enzyme
involved in de novo purine biosynthesis (Serenex Inc., Durham, NC 27701;
www.serenex.com). This effect was not observed in a number of unspecified
analogues of GA, and so might explain the differences seen between GA and 17-
AAG/17-DMAG. One might suppose that the mechanism of GA hepatotoxicity may
be similar to that seen with azathioprine and 6-mercaptopurine, which also inhibit
purine biosynthesis. These observations remain speculative as none of this work
appears to have been published in the peer-reviewed literature.
HBA-mediated Hsp27 induction occurred significantly later than that of Hsp70
(Figure 7.3). The 12 - 16 h delay seen in Hsp27 up-regulation may indicate the
presence of additional mechanisms to that of classical HSF1 activation. This
contradicts previous data where, in rat forebrains, Hsp25 induction occurred
concurrently with Hsp70 following GA injection to the lateral cerebral ventricles
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(339), although in a different study no GA-mediated Hsp25 induction occurred in
mouse striatal cells (377).
In an effort to establish whether the HBA-mediated Hsp expression was HSF1
dependent, cells were transfected with HSF1 siRNA. When establishing the Nrf2
siRNA knockdown model used in section 5.4, a low-grade non-specific activation of
the stress protein response was observed. Although HO-1 was not greatly affected by
this, the effect on Hsp70 was greater: Hsp70 was significantly up-regulated by the
control siRNA. This effect was almost certainly due to the combination of the
transfection technique and cell-line used, as others have used siRNA techniques to
knockdown HSF1 with no induction of Hsps (378,379). Treating cells transfected
with control siRNA with HBAs further increased Hsp70. Treatment with HSF1
siRNA resulted in almost complete abolition of HSF1 protein levels, and reduced
Hsp70 levels to that of the control reaction. This would suggest that HBA-mediated
Hsp70 induction occurs in an HSF1-dependent manner.
Similarly, in the oxidative stress model transfection with control siRNA resulted in
greater cell death than cells treated with H2O2 alone (Figure 7.11). Cells were
protected by HBA pre-treatment but transfection with HSF1 siRNA significantly
reduced this protection (p<0.01). Interestingly, in HBA-treated HSF1 siRNA
transfected cells exposed to H2O2, cell viability was not reduced to that of the control
siRNA-transfected H202-treated cells. This may be a reflection of incomplete
knockdown, but does raise the possibility of an HSF1-independent HBA-mediated
protective effect.
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Apoptosis following HBA treatment has received a great deal of attention in the
context of cancer treatment. In neuroblastoma cell-lines, GA has been shown to
induce apoptosis (380,381) although it has shown to cause differentiation in PC 12
(381) and breast cancer cells (382). 17-AAG induces apoptosis in human acute
myeloid leukemia cells (383), however, in a non-cancer cell-line (rat kidney
epithelial cells) apoptosis was not increased by herbimycin A or GA (384). GA-
mediated Hsp70 induction was associated with decreased apoptosis in doxorubicin
treated apoptotic-prone cells and this effect was lost with Hsp70 siRNA treatment
(21). On examining the effects of HBAs on apoptosis in ACHN cells, no significant
apoptosis was seen at 24 h (Figure 7.10). As with many cancer cell-lines, ACHNs
have been shown to have a greater resistance to apoptosis, for example following
treatment with 5-fluorouracil or cisplatin (385), and as will be seen in the next
chapter may not be reflect physiological conditions.
In summary, these data demonstrate that HBAs have the potential of imparting renal
cellular protection through a stress protein-mediated mechanism which is
independent of heme oxygenase-1. There was a trend towards greatest effect with 17-
DMAG, although this did not always reach statistical significance. With this strong
evidence of the benefit of HBAs in vitro, an in vivo model was developed in which
potential protection could be tested following ischemia/reperfusion injury in the
mouse kidney.
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Chapter 8 - Development of a model of renal
ischemia/reperfusion injury in the mouse
8.1 Background
In the previous chapter, it was demonstrated that Hsp induction and cellular
protection occurred following treatment with GA, 17-AAG and 17-DMAG. In order
to determine the potential clinical efficacy of these drugs, a model of renal IRI was
developed. The objective was to impart a moderate renal injury in an animal model
by the temporary interruption of the blood flow to one or both kidneys. The injury




The mouse was determined to be the model of choice for a number of reasons:
• easy handling
• economical
• established model of IR injury
• allows for future work using transgenic animals
Models of renal IR injury in rodents have formed the basis of a number of previous
publications (53,59,386-390). These reports proved useful but varied greatly in
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technique and outcome. A significant amount of work was required to optimise the
experimental conditions for this study.
The aim of the model was to inflict a moderate renal injury with tubular necrosis
while minimising animal morbidity and mortality. Initially, a number of decisions
had to be made:
• choice of strain?
• choice of anaesthetic?
• flank or midline incision?
• interruption of blood supply to one or both kidneys?
• clamp pedicle (i.e. renal vein and artery) or just artery?
• clamp time?
• recovery time prior to measurements?
• outcome measures?
Appropriate UK Home Office training and licensing were obtained prior to the start
of the study and all work involving animals was conducted in accordance with the
provisions of the UK Animals (Scientific Procedures) Act 1986. Development of the
procedure itself began by observing a group performing mouse renal transplantation.
The donor procedure in this model requires dissection of the renal pedicle in a very
similar manner to that required to in the IRI models.
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8.2.2 Strain
Different strains of mice have different susceptibilities to IRI, with NIH Swiss mice
being more resistant than C57BL/6, and BALB/c mice (391). This is particularly
important when comparing the phenotypic effects of specific gene deletions on
different genetic backgrounds.
The BALB/c strain has been successfully used in a number of IRI studies. It is an
inbred strain and therefore exhibits minimal genetic differences between batches. It
is used as a general-purpose strain in many different disciplines and has good
breeding performance and long reproductive life-span (Mouse Genome Informatics:
http://www, i nfo rmat ics. i ax. org).
8.2.3 Anaesthetic
Previous studies have found an intraperitoneal (IP) injectable anaesthetic provides
sufficient time for the procedure to be performed, i.e. no volatile agent is required to
prolong anaesthesia. The initial regime chosen was on the work of Flecknell et al
(392):
• ketamine^ 100 mg/kg IP
• xylazine* 10 mg/kg IP
t Ketamine - dissociative agent. Effects: sedation, some analgesia, increased muscle tone. Side
effects: severe respiratory depression, increased blood pressure, chronic use induces liver enzymes
which decreases efficacy.
* Xylazine - a2 agonist. Effects: sedation, analgesia, muscle relaxation. Side effects: initial
hypertension then hypotension, bradycardia.
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During the pilot phase of the project, two unexplained deaths occurred in sham-
operated animals, which were thought to be related to anaesthesia. The anaesthetic
protocol was modified and no further anaesthetic-related deaths occurred during the
rest of the study:
• ketamine 75 mg/kg IP
• medetomidine5 1 mg/kg IP
• atipamezole** 1 mg/kg IP to reverse medetomidine following procedure
It was predicted that significant fluid losses would occur during the procedure and
these would have to be replaced. Each animal received:
• 0.9% saline 25 ml/kg SC to the scruff prior to and 2 h following the
procedure.
Analgesia was given to all animals in the form of:
• buprenorphine^ 0.05-0.1 mg/kg SC
Buprenorphine has been shown to shorten recovery time following anaesthesia in
mice and does not alter the magnitude of injury following IRI (393).
§ Medetomidine - a2 agonist. Effects/side-effects as for xylazine.
Atipamezole - a2 antagonist. Effects: reverses effects of medetomidine .
Buprenorphine - partial p-opioid receptor agonist and K-opioid receptor antagonist. Effects:
analgesia. Side effects: respiratory depression and other side-effects associated with opiates.
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8.2.4 Procedure
A pilot study was undertaken to test the hypothesis that a consistent renal injury
could be achieved in the mouse model of IRI. Modification of the initial model was
required as described below. A midline incision was chosen for its ease, low blood
loss and good access. In exploratory experiments, it was found that separating the
renal artery and vein was technically difficult and impossible without the use of an
operating microscope. An alternative approach would be to clamp the supra-renal
aorta, but the associated injury delivered to the midgut, hindgut, pelvic organs and
lower limbs was felt to be unacceptable. In the initial experiments, left renal pedicle
occlusion alone was performed for various times (Table 8.1). During these
experiments, two sham treated animals failed to recover from the anaesthetic. The
reason for this was unclear but following advice from the Veterinary Service the
anaesthetic protocol was changed as above. As part of this initial study, dose-
response experiments were performed examining Hsp70 induction following
treatment with Hsp90-binding agents. Renal Hsp expression following HBAs was
variable and it was felt that baseline measurements of Hsp expression would be
required to aid interpretation of the results of IRI experiments. The model was
adapted to include removal of the right kidney during left renal pedicle clamping.
The purpose of model 2 was to identify the optimal left renal pedicle clamp time.
Serum creatinine (SCr) was used as an initial surrogate marker for renal function.
During these experiments it was apparent that significant unexplained variation in
SCr in the IRI group existed (range 48- 108 pmol/1) (Figure 8.1 A). A number of
measures were undertaken to reduce this variation and are detailed in section 8.3.
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The result of this was a reduction in the variation of SCr to an acceptable level
(Figure 8.IB). When a reliable injury could be delivered by the model the
relationship between clamp time and SCr was established (Figure 8.2). As has been
described in similar models, a sigmoid relationship was found. In order to achieve
the greatest effect size the steepest part of the s-shaped curve was targeted: this was
at around 30 min and this time was used for all subsequent experiments. No animals
survived more than 60 min left renal pedicle occlusion with contralateral
nephrectomy.
Model 3 was the protocol which was used for all subsequent experiments. The
procedure performed can be followed in Figure 8.3. Briefly, mice received an IP
injection of ketamine (75 mg/kg) (Vetalar; Pfizer, Sandwich, Kent, UK) and
medetomidine (1 mg/kg) (Domitor; Pfizer) and a SC injection of 0.9% saline (25
ml/kg) and buprenorphine (0.1 mg/kg). A thermostatically controlled heated mat was
used to maintain body temperature. The pedicle of the left kidney was dissected and
occluded using an atraumatic vascular clamp (6 x 1 mm Micro Serrefine; Fine
Science Tools, Linton, UK) for 30 min. Meanwhile, the right kidney was dissected
and a titanium clip placed across the ureter and the renal pedicle (Hemoclip Plus;
Week Closure Systems, Research Triangle Park, NC 27709, USA), after which the
kidney was removed as a control. Following removal of the left pedicle clamp,
reperfusion was confirmed visually prior to closure of the incision with 4/0 silk to the
rectus sheath and clips to the skin (Reflex 7 wound clip applicator; Fine Science
Tools). The anaesthetic was reversed with atipamezole (lmg/kg) (Antisedan; Pfizer)
and a further 25 ml/kg of 0.9% saline was given 2 h after the procedure. Animals
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were recovered in an incubator at 25 °C or a metabolic cage (Techniplast, Exton, PA
19341, USA) depending on the protocol.
Model N (per
group)
Anaesthetic Procedure Clamp time Outcome












Model 3 10 K&M Left RPO +
right
nephrectomy
30 min Final protocol
Table 8.1 Renal ischemia/reperfusion model development.
















Figure 8.1 Serum creatinine 24 h following IRI prior to (A) and after (B)
variation reduction.
Mice were subject to either 30 min left renal pedicle clamping or a sham procedure
(abdomen opened for 30 min then closed). Serum creatinine at 24 h was determined
(A). Following the introduction of a number of measures to reduce variation, the
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Pedicle clamp time (min)
Figure 8.2 Relationship between pedicle clamp time and serum creatinine in
mouse IRI model.
Mice were subject to left renal pedicle clamping for various times and 24 h later
serum creatinine was determined. □ individual animals.
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Figure 8.3 IRI model in mouse.
Left kidney exposed (A). Left renal pedicle dissected (B) and occluded (C, D). Right
renal pedicle dissected (E) and clipped (F). Right ureter dissected (G) and clipped
(H). Right kidney removed (I). Left renal occlusion removed (J).
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8.2.4 Outcome measurements
Severity of injury following renal pedicle occlusion can be estimated by examining
alterations in renal morphology or function.
Morphological outcomes following IRI
Histological changes in the kidney following ischemia are well described and in
carefully controlled experiments correlate closely with measures of renal function
(137). The degree of injury to the renal tubules can be determined following staining
of sections with haematoxylin and eosin. As the magnitude of injury increases, the
pattern of tubular damage progresses from dilatation and loss of the epithelial brush
border to the detachment of epithelial cells and eventually full coagulative necrosis.
With optimisation of the experimental procedure, a consistent renal morphological
injury was produced (Figure 8.4). Other histological features of renal IRI were also
noted including the presence of apoptotic bodies, hyaline casts and the infdtration of
leukocytes (Figure 8.5). The presence or absence of these secondary features were
not found to be good predictors of injury in our model. A semi-quantitative scoring
system was adapted from (387) and developed. A method was sought that would
continue to be predictive across the spectrum of mild to severe renal injury.
Therefore, two scores were determined: the first based on the proportion of tubules
exhibiting dilatation and/or a loss of the epithelial brush border (tubular damage
score, TDS), the second based on the proportion of tubules with necrotic/detached
cells (tubular necrosis score, TNS) (0, none; 1, less than 30%; 2, 30% to 70%; 3,
more than 70%) (Figure 8.6). As can be seen in Figure 8.5, there is good correlation
between the TDS/TNS and SCr (TDS R2 0.76, p<0.01; TNS R2 0.881, pO.Ol).
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Normal tubules 0 mins
Tubular dilatation 15 mins
Loss of brush border 30 mins
Full profile necrosis 45 mins
Figure 8.4 Tubular injury 24 h following left renal pedicle clamping with
indicative occlusion times.





Figure 8.5 Other histological features of renal IRI.
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Figure 8.6 Correlation between tubular damage score (TDS)/tubular necrosis
score (TNS) and serum creatinine.
Pooled data showing histological scores against serum creatinine. TDS R2 0.76,




Tubular damge score - 0
Tubular necrosis score - 0
Mild
Tubular damage score - 2.3
Tubular necrosis score - 0
Moderate
Tubular damage score - 2.8
Tubular necrosis score - 2.2
Severe
Tubular damage score - 3
Tubular necrosis score - 2.7
Figure 8.7 Degrees of tubular injury 24 h following left renal pedicle clamping
with typical tubular injury and tubular necrosis scores.
Scale bar = 200 pm.
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The TDS was better at predicting SCr in animals with a lesser injury, compared with
the TNS which was a better predictor of SCr at greater magnitudes of injury. The
sections were scored in a blinded manner by a consultant pathologist and me.
Example sections of animals subjected to increasing degrees of injury can be seen in
Figure 8.7 together with histological scores.
Function outcomes following IRI
Serum creatinine (SCr) and serum urea (SU) were measured as surrogate markers of
glomerular filtration rate. Previous studies have demonstrated good correlation
between SCr/SU and degree of injury. Measuring GFR by a more direct method such
as FITC-conjugated inulin would have been a more direct alternative approach (394).
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8.3 Controlling sources of variation
In initial experiments a great deal of variation was found in the SCr level following
IRI. Controlling sources of variation proved invaluable in generating comparisons
that were meaningful. Factors that contribute to unwanted variation can be described
as fixed effects (Table 8.1) or random effects variables (Table 8.2). All fixed effects
variables were accounted for in the design of the animal house and the management
of the animals therein. There was no change in sex, strain, age or weight of animals
during the experiments. Care was taken to ensure consistency between individual
procedures performed within an experimental group. Animals were kept in a 12-h
light/dark cycle, with free access to standard mouse chow and tap water.
More difficulty was met in controlling for random effects variables. A randomised
block design was used to account for variation between batches of animals, social
hierarchy within cages and time of year etc. Even after the procedure had been
learned to a high standard, variation still occurred in animals that had an aberrant
renal blood supply and animals where small amounts of bleeding occurred. In
general, mice can tolerate a loss of 10% of their blood volume (around 0.2 ml),
however, this had significant effects on the magnitude of IRI. Blood loss occurred
less often with time but was carefully noted when it did. The most significant
variable to control for was temperature. Small changes in temperature resulted in
large differences in IRI. It was essential, therefore, that scrupulous attention was paid
to reduce variation in the temperature of the animal. This meant controlling for the







Age All 6-8 weeks
Weight All 20-25 g
Procedure
Ischemic injury time Fixed for each set of experiments.
Time of cull Animals culled at exact times after IR injury
Environmental conditions
Bedding, feed etc. All fixed
Table 8.2 Fixed effect variables and controls in renal IRI model.
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Potential random effects Control
Animals
Genotypic and phenotypic variation. Isogenic strain used to minimise this.
Differences in pain threshold/recovery
time/fluid requirements after procedure.
Fixed volumes of subcutaneous fluids and
analgesia administered per body weight animal.
Some animals did recover more slowly which
may have affected body temperature and fluid
intake.
Variations in stock over time, different
cage conditions.
Randomised block design used to account for
these differences.
Procedure
Learning curve Early experiments affected, eliminated latterly.
Variation due to procedures being
performed on different days.
Randomised block design used to account for
these differences.
Aberrant renal blood supply. Looked for during procedure and included in
clamp if identified. Continued to be potential
source of variation.
Blood loss. The animals did not tolerate blood loss. An
extremely accurate midline incision and careful
dissection around the renal pedicle reduced blood
loss to effectively zero in later experiments.
Temperature
Temperature of solutions All solutions warmed to 37 °C.
Temperature of heated mat Thermostatically controlled, but significant
variation existed.
Ambient temperature Room temp fixed at 20 °C. Fairly constant.
Length of time exposed Variation existed initially during learning curve,
eliminated in latter experiments.
Temperature during recovery In early experiments, animals recovered under
heated lamp, but variation existed with different
distances from lamp etc. Eliminated with use of
incubator.




Mice were used at 6 - 8 weeks of age, were all male and were weight matched.
Animals were caged in groups of 4 and a typical experiment would involve using the
4 animals for control, GA, 17-AAG and 17-DMAG. The cage was used as a blocking
variable with two-way analysis of variance (without interaction). This removed
variation that may occur between different cages/batches of animals. Residuals were
found to be normally distributed and equal variances were found within each group.
Power calculation
A power calculation was performed to ensure adequate numbers were used in each
group to maximise the opportunity of demonstrating statistically significant
differences between treatments. A comparative study was used to estimate effect
sizes for the potential reduction in serum urea and creatinine (137). Based on the
reduction in urea and creatinine in treated animals subjected to 30 min bilateral renal
IR injury, an effect size of 1.889 and 1.432 respectively was calculated (Table 8.4).




Test significance level, a 0.05 0.05
Group 1 mean 53 1.13
Group 2 mean 20 0.60
Standard deviation 16.94 0.37
Effect size 1.889 1.432
Power (%) 90 90
n per group 8 12
Table 8.4 Power calculation for group sizes
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Chapter 9 - Heat shock protein 90-binding agents in a
murine model of ischemia/reperfusion injury
9.1 Introduction
In chapter 7, it was demonstrated that HBAs could protect renal cells from an H202-
mediated stress in vitro. This protection was abrogated in cells that had been pre-
treated with HSF1 siRNA, providing strong evidence that protection is HSF1
mediated. However, one weakness in this part of the study was the use of a
transformed cell-line. It is possible that the responses observed in these cells do not
reflect the resultant effect in the physiological environment encountered in the
kidney during organ transplantation. As has been discussed, a major factor that
influences outcome following organ transplantation is IRI. Using the model
developed in the last chapter, the aim of the work described in this chapter was to
determine whether Hsp90 inhibition could reduce the damage caused by renal IRI.
Experimental work began by establishing whether treatment with HBAs induced
Hsps in the mouse, and in which organs. With this information, the work proceeded
to examine whether HBAs could protect kidneys from IRI.
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9.2 Hypotheses
1. HBAs cause up-regulation of Hsps in the mouse kidney.
2. HBAs cause up-regulation in other transplantable organs in the mouse.
3. HBAs cause up-regulation of Hsps in areas of the kidney that are susceptible
toIRI.





Under terminal general anaesthesia, blood was recovered by intra-cardiac puncture.
This was centrifuged at 13 000 rpm/4 °C and the serum stored at -20 °C until
analysis. The left kidney was divided in the transverse plane in two equal parts to
ensure equivalent proportions of cortex and medulla with the superior portion snap-
frozen in liquid nitrogen and the inferior portion being placed in methacarn (70%
methanol, 20% chloroform, 10% glacial acetic acid). The liver, lungs and heart were
then removed and placed in liquid nitrogen. All frozen tissue was maintained at -70
°C until analysis.
9.3.2 Hsp70 enzyme-linked immunosorbent assay (ELISA)
Hsp70 expression in different mouse tissue following treatment with HBAs was
quantified using a commercially available Hsp70 ELISA kit (Stressgen) as per the
manufacturer's instructions.
9.3.3 Serum urea and creatinine determination
Serum was analysed using an automated Olympus AU 2700 Clinical Chemistry
System.
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9.3.4 Caspase 3/7 ELISA
Caspase 111 activity in kidney tissue was measured using a Caspase-Glo 3/7 assay kit
(Promega) with a modified protocol. The assay has previously been shown to detect
caspase 3/7 activity in mouse liver (397). Briefly, whole kidney extracts were
prepared as for the Hsp70 ELISA. Equal volumes of caspase 3/7 reagent and kidney
extract were added to a white-walled 96-well plate and incubated at room
temperature for 1 h. Luminescence was detected using a plate-reading luminometer
(Fluoroskan Ascent Fl, Thermo Electron, Basingstoke, UK).
216
9.4 Results
HBAs induce heat shockproteins in mice
BALB/c mice were given an intraperitoneal injection of HBAs and sacrificed at
various times. Organs were snap-frozen in liquid nitrogen and whole-organ lysates
prepared. Neither Hsp90 nor HO-1 were induced by the HBAs in mice (Figure 9.1).
A 2 - 3-fold increase in Hsp70 was seen following HBA administration. This was
maximal at 6 h in mice treated with 17-DMAG, which was significantly earlier than
in GA or 17-AAG treated groups. A 2 fold increase in Hsp25 was seen which again,
occurred significantly earlier in the 17-DMAG group (6 h) compared with the GA
and 17-AAG group. Hsp70 and Hsp25 induction was maintained in all groups until
at least 24 h. An ELISA for Hsp70 was performed with whole-organ lysates and
showed significant induction of Hsp70 in kidney, liver and lung following HBA
administration (Figure 9.2A, B and C). A 3 fold increase was seen in liver which
became statistically significant at 8 h, 16 h and 6 h for GA, 17-AAG and 17-DMAG
respectively. A 2 - 3 fold increase in Hsp70 was found in lung which was significant
at 6 h in 17-AAG and 17-DMAG groups; an increase occurred in animals treated
with GA, but this did not reach significance. In lung there was a drop-off of Hsp70
levels between 8 and 16 h. In the heart, Hsp70 was found to be expressed in animals
that had been treated with HBAs for 6 or 8 h (Figure 9.2D). Hsp70 levels at all other
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Figure 9.1 Hsp expression in mouse kidney following HBA treatment.
BALB/c mice given an intraperitoneal injection of GA, 17-AAG, 17-DMAG (all 1
mg/kg) or vehicle and were sacrificed at various time points (n = 3/time-point).
Whole-organ lysates were made and Western blots performed.
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Figure 9.2 Hsp expression in mouse kidney, liver, lung and heart following HBA
treatment.
BALB/c mice given an intraperitoneal injection of GA, 17-AAG, 17-DMAG (all 1
mg/kg) or vehicle and were sacrificed at various time points (n = 51). Kidney (A),
liver (B), lung (C) and heart (D) were snap-frozen in liquid N2. Whole-organ lysates
were made and an Hsp70 ELISA performed. * p<0.05 (ANOVA).
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HBAs induce Hsps in the cortex and outer medulla ofthe kidney
Immunohistochemistry was performed to localise the expression of Hsp70 and
Hsp25. BALB/c mice were injected with 17-DMAG (Figure 4E - H and M - P) (1
mg/kg) or vehicle (Figure 4A - D and I - L). In vehicle-treated mice at 16 h, Hsp70
immunopositivity was maximal in the tubular epithelial cells of the inner medulla
(large arrow; Figure 9.3B). Significant immunopositivity was also seen in the outer
medulla (Figure 9.3A and D) with much lower levels in the cortex (Figure 9.3A and
C). Following treatment with HBAs, Hsp70 immunopositivity was increased in the
cortex (Figure 9.3E and G) but most strongly increased in the outer-stripe of the
outer medulla (OSOM) (small arrow; Figure 9.3F and H).
Hsp25 was found to be expressed at lower levels than Hsp70 which is consistent with
the Western blot findings (Figure 9.4). Basal expression was found to increase from
the outer medulla, through the inner medulla, with maximal immunopositivity in the
epithelial cells of the collecting ducts and ducts of Bellini in the renal papillae
(Figure 9.5A). Immunopositivity was also strong in afferent and efferent arterioles
(Figure 9.5B), vascular smooth muscle cells and endothelium (Figure 9.5C) and the
urothelium (Figure 9.5D). Following treatment with HBAs, immunopositivity
increased in the tubular epithelium of the OSOM (small arrow; Figure 9.4E and H),















Figure 9.3 Hsp70 expression in mouse kidneys following HBA treatment.
BALB/c mice were given an intraperitoneal injection of vehicle (A - D) or 17-
DMAG (lmg/kg; E - H) and sacrificed at 16 h. Immunohistochemistry was
performed using antibody to Hsp70 and visualised with DAB. Hsp70 basal
immunopositivity was maximal in the inner medulla (large arrow; B) and maximum
induction following HBA treatment was seen in the outer-stripe of the outer medulla















Figure 9.4 Hsp25 expression in mouse kidneys following HBA treatment.
BALB/c mice were given an intraperitoneal injection of vehicle (A - D) or 17-
DMAG (lmg/kg; E - H) and sacrificed at 16 h. Immunohistochemistry was
performed using antibody to Hsp25 and visualised with DAB. Sections were counter-
stained with haematoxylin. Hsp25 basal immunopositivity was maximal in the inner
medulla (large arrow; B) and maximum induction following HBA treatment was









Figure 9.5 Additional histological features of basal Hsp25 immunopositivity.
Immunohistochemistry was performed using antibody to Hsp25 and visualised with
DAB on untreated mouse kidney. Sections were counter-stained with haematoxylin.
Hsp25 basal immunopositivity increased from the medulla towards the end of the
papilla (A); was apparent in afferent and efferent arterioles (B) and the smooth
muscle (large arrow) and endothelium (small arrow) of the renal artery (C); and was
also strong in urothelium (D).
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HBAs do not cause liver damage within 1 week in the mouse
Given that the GA has been associated with hepatic toxicity in other models, the
livers of mice treated with HBAs were examined. BALB/c mice were given an
intraperitoneal injection of GA, 17-AAG and 17-DMAG (all lmg/kg) and sacrificed
7 days later (Figure 9.6). Sections were examined and no evidence of liver injury was
observed. There was no morphological difference in liver sections from animals
treated with GA, 17-AAG or 17-DMAG.
HBAs reduce morphological renal damage following IRI
BALB/c mice were treated with GA, 17-AAG, 17-DMAG or vehicle. After 16 h, left
renal artery pedicle clamping was performed for 30 min in combination with
contralateral nephrectomy. 24 h later, animals were sacrificed and haematoxylin and
eosin-stained kidney sections examined and scored by two independent observers
(Figure 9.7A - D). Histological injury following left renal pedicle artery clamping
was less severe in animals pre-treated with HBAs, particularly in the OSOM (small
arrow; Figure 9.7A - D). This was scored in a semi-quantitative manner. Tubular
damage score was reduced in mice treated with HBAs and was statistically
significant in the 17-AAG and 17-DMAG groups (Figure 9.8A; p<0.05). Tubular
necrosis score was reduced in mice treated with HBAs and was significant in all
groups (Figure 9.8B; p<0.01).
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Figure 9.6 Mouse liver 7 days after GA treatment.
BALB/c mice were given an intraperitoneal injection of GA (lmg/kg) and sacrificed
7 days later. The liver was fixed and sections stained with haematoxylin and eosin.
On examination of low power (A) and high power (B) fields, no evidence of liver
injury was observed. These sections are also representative of liver sections taken 17-
AAG and 17-DMAG treated mice.
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Figure 9.7 Renal injury following treatment with HBAs and renal pedicle
clamping.
BALB/c mice (n = 50) were pre-treated with an intraperitoneal injection of vehicle
(A), GA (B), 17-AAG (C) or 17-DMAG (D) (all lmg/kg). After 16 h the left renal
pedicle was clamped for 30 min during which the right kidney was removed. 24 h
later the animals were sacrificed and the left kidney was placed immediately in
methacarn. Sections were stained with haematoxylin and eosin and show the outer-
stripe of the outer medulla. Scale bar = 200 pm.
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Figure 9.8 Histological injury scores following treatment with HBAs and renal
pedicle clamping.
BALB/c mice (n = 50) were pre-treated with an intraperitoneal injection of vehicle
(A), GA (B), 17-AAG (C) or 17-DMAG (D) (all lmg/kg). After 16 h the left renal
pedicle was clamped for 30 min during which the right kidney was removed. 24 h
later the animals were sacrificed and the left kidney was placed immediately in
methacarn. The tubular damage (E) and necrosis scores (F) were determined by two
independent observers. * p<0.05, ** p<0.01 compared with vehicle (Mann-Whitney
U test).
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HBAs reduce functional renal damage following IR1
Serum urea and creatinine were significantly increased following 30 min IRI and
contralateral nephrectomy (Figure 9.9A and B). In mice that were pre-treated with
HBAs, both urea and creatinine were found to be lower 24 h after IRI than vehicle
treated groups. This was significant in the 17-AAG (p<0.05) and 17-DMAG
(p<0.01) groups. There was a significant difference in serum urea between those
treated with GA and 17-DMAG treated groups (p<0.05).
HBAs alone increase caspase 3/7 proteolytic activity in mouse kidneys but effect a
reduction in overall caspase 3/7 activityfollowing IRI
As before, BALB/c mice were given an intraperitoneal injection of HBAs, sacrificed
at various times and whole kidney lysates prepared. An increase in renal caspase 3/7
activity was seen after 6 h which became statistically significant for all HBAs at 24 h
(Figure 9.1 OA). In animals treated with HBAs and subjected to IRI 16 h later,
caspase 3/7 activity was reduced at 24 h, although this only reached statistical
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Figure 9.9 Serum urea and creatinine following treatment with HBAs and renal
pedicle clamping.
BALB/c mice (n = 67)were pre-treated with an intraperitoneal injection of vehicle
(A), GA (B), 17-AAG (C) or 17-DMAG (D) (all lmg/kg). For animals undergoing
no procedure, n = 3/treatment; sham, n = 3/treatment; IR, n = 10 / treatment.. After
16 h the left renal pedicle was obstructed for 30 min during which the right kidney
was removed. 24 h later the animals were anaesthetised and blood was recovered by
intracardiac puncture. Serum urea and creatinine were determined by auto-analyser.
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Figure 9.10 Caspase 3/7 expression following treatment with HBAs with (B; n =
67) and without (A; n = 51) renal IRI.
BALB/c mice were given an intraperitoneal injection of GA, 17-AAG, 17-DMAG
(all 1 mg/kg) or vehicle and were sacrificed at various time points (A; n = 3/time
point). In a separate set of experiments, mice treated with HBAs underwent left
kidney pedicle clamping with right nephrectomy, or a sham procedure 16 h later. For
mice undergoing no procedure, n = 3/treatment; sham, n = 3/treatment; IR, n =
10/treatment. After 24 h, the left kidney was snap-frozen in liquid N2. Whole-organ




Hsps are known to reduce the effects of IRI in models of transplantation, yet
practical strategies of up-regulation that may be implemented clinically remain
elusive. In this chapter, it has been demonstrated that treatment with GA, 17-AAG or
17-DMAG results in increased expression of Hsp70 and Hsp25 in mouse kidneys,
liver and lung and that this increased expression is associated with renal protection
following renal IRI in a model which included contralateral nephrectomy.
In the mouse, Hsp70 and Hsp25 induction was significantly earlier following 17-
DMAG than the other HBAs (Figure 9.1 and 9.2). 17-DMAG-treated animals
subjected to IRI had a serum urea at 24 h that was significantly lower than animals
pre-treated with GA (Figure 9.9A). As was discussed in the previous chapter, it is
possible that differences in action at the molecular level exist between GA and 17-
AAG/17-DMAG, but 17-DMAG is the only one of the three drugs that is water-
soluble and improved pharmacokinetics may explain these differences (366).
The baseline distribution of Hsp70 and Hsp25 was found to be similar to previous
descriptions: present in the renal cortex and outer medulla, but particularly abundant
in the inner medulla (398,399) (Figure 9.3 and 9.4). Hsp25 staining has also been
shown to be strong in the vascular endothelium and smooth muscle cells (400)
(Figure 9.5). HBA treatment resulted in significant induction of Hsp70 in the cortex
and but was most striking in the OSOM (Figure 9.3F). This is particularly significant
as the OSOM is most susceptible to ischemic injury. The increase in Hsp25 was less
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pronounced but still apparent, particularly in the outer-stripe of the outer medulla
(Figure 9.4E and H).
As was discussed in the last chapter, apoptosis following HBA treatment appears to
be cell-type dependent. Caspase 3/7 activity was used as a measure of apoptotic
activity in whole - kidney homogenates with and without prior IRI. A 2.5 fold
increase in caspase 3/7 activity was seen 24 h after IP injection of the HBAs. IRI
increased caspase 3/7 activity in vehicle treated cells 5 fold, but pre-treatment with
HBAs reduced this towards the levels of sham-treated animals. It may be that HBAs
have a direct off-target effect on caspase but this is not clinically evident as increased
cell injury in vivo or increased cell death in vitro. In any case, it is likely that the
actual levels of apoptosis following HBA treatment in vivo are quite small, and are
greatly outweighed by the benefits of Hsp induction.
Hsp70 induction was found in kidney, liver, lung and heart following HBA
treatment. This is particularly significant in the context of the multi-organ donor, as
the potential exists for protection to be conferred in all recovered organs. Concerns
have been expressed that Hsp70 may be induced following brainstem death and
therefore therapeutic up-regulation would provide little additional benefit. However,
Hsp70 has been shown to be only basally expressed in the kidney prior to
engraftment and hemodynamic instability in donors and the process of organ
recovery were not found to produce a measurable increase in Hsp70 (401). This
supports a view that therapeutic Hsp70 induction remains potentially beneficial.
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These data demonstrate that HBAs have the potential of imparting protection to
kidneys subjected to IRI through a stress protein-mediated mechanism. The effect
size was greatest with 17-DMAG which is water soluble and has a favourable
toxicity profile compared with GA. Increased expression of Hsps was evident in
kidney, liver, lung and to a lesser extent heart, which is important considering the
practical application in a clinical setting would require administration to potential
multi-organ donors.
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Chapter 10 - General discussion
This thesis has examined potential pharmacological strategies to stimulate the heat
shock/stress protein response and protect organs from IRI. Data presented
demonstrate that alteration of PI3K/Akt activity does not alone alter HSF1 activation
state; that stimulation of the PI3K/Akt axis can induce HO-1 through activation of
the Nrf2 transcription factor; that inhibition of Hsp90 activity alters HSF1 activation
and induces Hsps; that Hsps can be up-regulated by Hsp90 inhibitors in vivo; and
that Hsp90 inhibition protects cells in vitro and reduces IRI in mouse kidneys. Data
from this thesis has been the subject of a number of presentations (Appendix IV,
page 287) and has been published in peer-reviewed journals (Appendix V, page 288).
10.1 Potential weaknesses in hypotheses
10.1.1 Are there long-term benefits from reducing ischemic injury
in renal transplantation?
The over-arching aim of this thesis was to utilise the heat shock/stress protein
response to reduce the effects of IRI in kidney transplantation. Fundamental to this is
the question: does increasing IRI correlate with a negative clinical outcome? The
relationship between the cold ischemic time (CIT; a surrogate for IRI), delayed graft
function and poorer long-term outcome is well established (Table 1.3). However, in
the majority of the studies referenced, CIT is only considered as a binary variable:
typically <12 h or >12 h. When the influence of CIT is compared between organs
subjected to shorter ischemic times, the difference in outcome is less significant. If a
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drug acts only to reduce the direct effects of IRI, it is interesting to consider how
many "hours" of cold ischemic time might be saved by the intervention, i.e. would an
organ pre-treated with a protective drug and subjected to 6 h of ischemia have a
similar outcome to an un-treated organ made ischemic for, say, only 2 h? The most
recent data on CIT comes from a large US registry study of living donors (n =
38,467) and examines CIT in 2 h strata (i.e. 0-2 h, 2-4 h, 4-6 h, 6-8 h) (402).
Although a significant difference was demonstrated in the occurrence of DGF
between the 0-2 h (4.7%) and 4-6 h (8.3%) groups, this did not influence 1 y serum
creatinine levels. There was no difference in death-censored graft survival in any
group with > 2 h CIT compared with the 0-2 h group (median survival 11 y).
Therefore, in this group of patients, the added effect of IRI between 2 and 8 h has
little or no influence on outcome. The caveats to this analysis are: 1) These are living
donor grafts and are typically in excellent condition and subject to very low rates of
DGF anyway, 2) As in the mouse model of IRI, the rate of change of the magnitude
of injury between early time points is likely to be low (Figure 8.2), but will increase
at later time points, e.g. 2 h CIT "saved" after 12 h maybe of greater benefit than 2 h
saved before 12 h. It is interesting to speculate whether the use of a protective drug in
living donors would be beneficial, but the answer is that they would probably not be.
The potential side-effects of drugs in the living donor must also be considered.
Organs from deceased donors are still subjected to long periods of ischemia during
transportation to well-matched recipients (the average CIT in the United Network for
Organ Sharing register is 20 h and has not changed over the years). The influence on
outcome of longer CITs is pronounced, particularly with CIT >30 h. Comparing
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deceased donor organs subjected to <10 h cold ischemia, Salahudeen et al recently
showed that 6-year graft survival was worse (but not significantly) in the 10-20 h
CIT group (RR = 1.03, p = 0.79), 21-30 h CIT (RR =1.12; p=0.27) and significantly
worse for >30 h CIT (RR = 1.32, p<0.011) (403). It follows, therefore, that while the
benefits of transportation to a good match still exist, this group represent an
appropriate target for preconditioning.
The other group that preconditioning is likely to be beneficial in is the expanded-
criteria donors. It is known that the outcome following transplantation from older
donors and donors with cardiovascular co-morbidities is poorer (Figure 1.4C).
Robust data is lacking, but it is hypothesised that expanded-criteria donor grafts are
more sensitive to prolonged ischemia and the particular importance of reducing CIT
has been emphasised (404). It follows, therefore, that these donor grafts are most
likely to benefit from the reductions in IRI that may be possible with
pharmacological intervention.
10.1.2 Are there problems associated with up-regulation of Hsps?
Another fundamental premise of this thesis is that the up-regulation of Hsps does not
result in other negative effects. Concerns have been raised previously that Hsps may
be associated allograft rejection (405). It has been suggested that Hsps are released
from grafts during episodes of acute rejection and that augmented expression of Hsps
in allografts accelerates rejection (406). Hsp70 expression has been shown to be
increased in rat models of heart graft rejection and graft infiltrating lymphocytes
proliferate in response to recombinant Hsp70 (407). Increased Hsp expression is
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found in biopsies from rejecting human lungs grafts (408) and T-cells from rejected
renal grafts respond to Hsp72 (409) (although the presence of Hsp-reactive T-cells
does not necessarily reflect a response to injury: Hsp60 specific T-cells have been
found in humans with remitting juvenile chronic arthritis suggesting that such
reactivity may reflect an autoimmune regulatory mechanism (405,410)). However,
much of the early work demonstrating a relationship between Hsp70 and dendritic
cell maturation has been discredited and the results attributed to lipopolysaccharide
(LPS) contamination of the recombinant Hsps used (411). Yet, a recent report has
suggested that Hsp70 may be critical for the induction of autoimmune diabetes in an
experimental murine model (412).
Further evidence linking Hsps to the innate immune response concerned the
identification of Hsp70 as a ligand for toll-like receptor** 2 and 4 (TLR2, TLR4)
(413). It has lately been appreciated that the innate immune response plays an
important part in the insult associated with IRI (41). In rat kidneys, IRI itself has
been shown to induce TLR2 and TLR4 , mainly on renal tubular cells, associated
with Hsp70 expression (414). In rats receiving liver isografts, increased TLR4
expression was seen in Kupffer cells (415) and TLR4 deficient mice were found to
be less prone to IRI following hepatic ischemia (416). The absence of the TLR
receptor signal adaptor protein MyD88 has been shown to prevent rejection in a
minor antigen-mismatched skin allograft model due to reduced number of mature
DCs leading to impaired generation of anti-graft-reactive T cells (417). In fully MHC
mismatched murine skin and heart allograft models, rejection was shown to occur in
** Toll-like receptors: a family of pattern recognition receptors that are activated by specific
components of microbes and certain other molecules.
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the absence of MyD88 but priming of naive recipient T cells by allogeneic DCs was
diminished, although TH2 immunity remained intact (418).
The importance of the innate immune system in IRI is convincing but the role of
Hsp70 remains unclear. A recent study aiming to clarify this showed that DCs could
not be activated with low-endotoxin Hsp70, but could with LPS; Hsp70 levels were
not found to rise in a highly mismatched murine skin graft model; and in Hsp70"/"
mice acute rejection was not delayed, DC maturation impaired, or Thl immune
responses reduced during acute allograft rejection (419). This study concluded that
Hsp70 did not play an essential role in acute allograft rejection this model.
10.1.3 Are heat shock proteins up-regulated in organ donors
anyway?
It has been suggested that in the deceased donor, the physiological stress associated
with 1) the pre-morbid injury, 2) the process of brainstem death and associated
cardiovascular instability and 3) the procedure of organ retrieval, may up-regulate
Hsps in donor grafts. If this were true, the benefit conferred by a pharmacological
strategy to up-regulate Hsps is likely to be minimal. Mueller et al studied kidney
biopsy specimens taken at the time of engraftment, ensuring that results reflected
organ injury sustained prior to retrieval and that associated with warm and cold
ischemia. Renal tubular expression of Hsp72 was low and not influenced by donor-,
graft-, or procedure-related risk factors. Neither strength nor pattern of pre-transplant
Hsp72 staining discriminated allografts with complicated post-transplant courses
from those without complications. Moreover, low Hsp72 expression in pre-transplant
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donor kidney biopsies did not predict DGF or acute rejection. These findings suggest
that constitutive Hsp72 gene expression at the time of engraftment does not play a
role in graft protection (401).
10.1.4 Are heat shock proteins degraded by cold storage?
Organs from deceased donor are placed in cold storage for varying periods of time
following retrieval. If the up-regulation of heat shock proteins in donor kidneys is
beneficial, one would hypothesise that this benefit would be maximal if Hsp up-
regulation persisted through that period of cold storage up until the point of
implantation. Although Hsps were not measured directly, Torras et al demonstrated
that the effects of ischemic preconditioning persisted in rat renal isografts implanted
after 5 h of cold-storage in Euro-Collins solution (97). Fuller et al also found that the
beneficial effects of ischemic preconditioning persisted in syngeneic rat kidney grafts
transplanted after 42 h cold storage (98). In human renal proximal tubular epithelial
(HK-2) cells, Hsp27 and Hsp70 up-regulation following heat shock was shown to
persist (and confer protection) after 4 and 16 h of cold-storage in University of
Wisconsin solution (420). Finally, our laboratory have demonstrated that curcumin-
mediated HO-1 induction in human hepatoma cells (HUH7s) is maintained after 18 h
cold-storage in University of Wisconsin solution (421). Therefore, strong evidence
exists in cell culture for the resistance of Hsp induction to the effects of cold storage,
although a study has yet to be published which confirms this conclusively in vivo.
239
10.2 Potential weaknesses in study design
10.2.1 In vitro models
Most of the in vitro cell culture work has been performed in a renal adenocarcinoma
cell-line. Observations made in immortalised cancer cell-lines sometimes differ from
more physiological models. This model was chosen for ease of use with the
knowledge that the study was going to be moved into a mouse model of IRI. In
chapter 5, the observation that insulin induces HO-1 was confirmed in a mouse
primary tubular epithelial cell model.
In chapter 4, the PI3K/Akt signalling pathway was manipulated in an effort to alter
the activation state of HSF1. In hindsight, given the complexity and number of
kinase pathways that potentially act to regulate this transcription factor, it was
possibly nai've to hypothesise that alteration in HSF1 activity could be effected
through the manipulation ofjust one. However, on review of the pre-existing
literature the hypothesis was valid and worthy of exploration.
It could be argued that using insulin to alter HO-1 expression has limited clinical
potential as insulin has many side-effects. However, the use of insulin is now
advocated in the treatment of critically ill patients with severe sepsis (422). It
remains unclear whether the reduction in mortality and morbidity from such
treatment is related to the prevention of hyperglycaemia or directly to the infused
insulin. It is possible that benefits are related to the up-regulation of HO-1 as
demonstrated in this thesis. IGF-1 has been used in the treatment of burns patients
(249) and remains a potential strategy for the up-regulation of HO-1.
240
10.2.2 In vivo models
Renal pedicle occlusion in the mouse produces a reliable model of IRI. This study
only examined short-term outcome following IRI and work is on-going looking at
outcome in the longer term.
Renal protection from IRI was demonstrated following administration of HBAs. It is
desirable to confirm that this protective effect is occurring directly as a result of
Hsp90 inhibition, HSF1 activation and Hsp up-regulation. Developing a model that
produces reliable causal data is difficult. Using homologous recombination to
knockout Hsp90 results in embryonic death, although it may be possible to develop a
conditional model. Studying the effects of HBAs on IRI in an HSFl-null mouse
would be useful.
IRI is only one aspect of transplantation and does not take into account the
significant immunological insult present in an allograft model of transplantation.
However, performing this study in an allograft model would be fraught with the
technical difficulty of the model and be subject to greatly increased sources of
variation. Demonstrating significant differences in outcome, therefore, would be very
difficult.
Finally, although the use of HBAs to reduce IRI has been demonstrated in the mouse,
it is necessary to show that these drugs are both safe and efficacious in the human
prior to any clinical study in renal transplantation.
241
10.3 Future directions
This thesis has sought to examine the up-regulation of Hsps and associated benefits
in models relevant to renal transplantation. Although many studies have shown the
benefit of Hsp induction in vitro or in animal models, there has been little translation
into the clinical setting and no accepted clinical strategies involving Hsps currently
exist. This area has great potential to be taken forward into therapeutics, but urgent
exploration in human trials is required before this can take place.
A number of exciting avenues of application are currently being explored. A recent
study has demonstrated HO-1 induction using clinically accepted doses of isoflurane
in rats with an associated protective effect against liver IRI (423). Protection was lost
on treatment with the HO-1 inhibitor, tin protoporphyrin IX. The antioxidant and
cytoprotective effects of bilirubin, CO, and ferritin have also been demonstrated
experimentally, but potential toxicity has limited clinical application. Rinsing grafts
with bilirubin ex vivo has been shown to have a similar effect to inducing HO-1 with
hemin and has clinical potential (424). Inhaled CO and the use of CO-releasing
molecules also hold great clinical promise (124,425).
Similarly, the induction of other Hsps has been shown to be beneficial in
experimental models of transplantation (Table 1.7). Ischemic preconditioning has
been demonstrated to have beneficial effects in some clinical trials (Table 1.5), but
the exact mechanisms conferring benefit remain obscure. Remote ischemic
preconditioning is particularly promising and with its ease of application, clinical
trials should be forth-coming. Up-regulation of Hsp70 has been demonstrated
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following treatment with 17-AAG in cancer patients, but no trial examining potential
protection has been performed. In this work, 17-DMAG has been shown to have
superior efficacy in Hsp induction. A phase 1 trial in healthy volunteers is essential
to provide information on toxicity/side-effects and to measure Hsp expression prior
to instigating a trial in transplantation patients.
It is unclear why there has been a reticence to examine promising pre-clinical
strategies in human models. Apprehensions regarding the potential negative
consequences of strategies applied in such a difficult group of patients, together with
concerns over costs and clinical utility have no-doubt deterred investigators.
However, if outcomes following transplantation are to be further improved, the
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Appendix 1 - Buffers
RIPA
• 1 X PBS
• 1% NONIDET P-40
• 0.5% SODIUM DEOXYCHOLATE
• 0.1% SDS
• Protease inhibitor - 1 tablet/10 ml
D-PBS (calcium and magnesium free)
• KC1 1.0 g
• KH2P04 1.0 g
• NaCl 40.0 g
• Na2HP04 5.75 g (anhydrous)
• H2O to 5000 ml
Tissue homogenising buffer (THB)
50 mM Tris pH 7.4 2M stock
20 mM NaCl 5M stock
lOmMKCl 2M stock
1 mM EDTA 0.2M stock
1% SDS
0.1 mM DTT add fresh 1M stock
• Protease inhibitor 1 tablet/10 ml
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Separating gel (0.375 M Tris, pH 8.8)
15% 12.5% 12% 10% 8% 7.5% 5%
Distilled H20 2.29 3.12 3.29 3.96 4.62 4.79 5.62 ml
1.5M Tris-HCl pH 8.8 2.5 2.5 2.5 2.5 2.5 2.5 2.5 ml
10% SDS 100 100 100 100 100 100 100 pi
Acrylamide/Bis 30% stock 5.0 4.17 4.0 3.33 2.67 2.5 1.67 ml
(Biorad)
-» <
10% ammonium persulphate 100 100 100 100 100 100 100 pi
(fresh daily) (AMPS)
TEMED 10 10 10 10 10 10 10 pi
Total monomer 10ml (enough for 2 gels)
Stacking gel 4% (0.125 M Tris, pH 6.8)
Distilled H20 5.98 ml
0.5M Tris-HCl, pH 6.8 2.5 ml
10% SDS 100 pi
Acrylamide/Bis (30% stock) 1.3 ml
(Biorad)
->














10% SDS 1.6 ml 0.8g
2.0 ml2-b-mercaptoethanol 0.4 ml
0.05% bromophenol blue 1.0 ml 1.0 ml
Low molecular weight Western blot markers
Reconstitute in 200 pi loading buffer for markers (in fume hood)
Heat @ 95°C for 5 mins and aliquot - 5pi
High molecular weight Western blot markers
Reconstitute in 100 pi H2O
Do not heat
Aliquot - 5 pi
Running buffer 5X
• Tris 30 g
• Glycine 144 g
• SDS 10 g
Dissolve in 1800mls dH20
pH to 8.3
Make up to 2 litres with d^O
Transfer buffer
• Glycine 5.86 g
• Tris 11.625 g
• SDS 0.75 g
• Methanol 400 ml
Dissolve and make up to 2 litres with dH20
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10 X TBS
• Tris 121 g
• NaCl 438.5 g
Dissolve in 1800 ml dH^O
pH to 7.4
Make up to 5 litres with dhEO
Divide into 500ml bottles
10XTBE
• Tris 107.8 g
• diNaEDTA.2H20 7.44 g
• Boric acid -55-60 g
Dissolve Tris and EDTA in -800 ml H20
Add boric acid to adjust pH to 8.3
Make up to 1 litre
5XTBE
• Tris 53.9 g
• EDTA 3.72 g
• Boric acid 30 g boric acid
40 X TAE
• Tris 193.6 g
• Na acetate.3H20 108.9 g
• diNaEDTA.2H20 15.2 g
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pH to 7.2 with acetic acid




• 10% glacial acetic acid
282
Appendix II - Abbreviations









CO-RM, carbon monoxide-releasing molecule
Cyp, cyclophilin
DGF, delayed graft function
DTT, Dithiothreitol
EDTA, Ethylene diamine tetra acetic acid
ERK, extracellular signal-related kinase
FITC, fluorescein isothiocyanate
FKBP, FK506 binding protein
GA, geldanamycin
GGA, geranylgeranylacetone
GSK3P, glycogen synthase kinase 3p
E1BA, heat shock protein 90-binding agent
HIF1, hypoxia inducible factor-1
HO-1, heme oxygenase-1
HSF1, heat shock transcription factor 1
Hsp, heat shock protein
ICAM-1, intracellular adhesion molecule-1








MAPK, mitogen-activated protein kinase
MCP-1, monocyte chemoattractant protein-1
MPO, myeloperoxidase
MTT, 3-(4,5-dimethylthiazole-2-yl)-2,5-dipenyltetrazolium bromide
NF-E2, nuclear factor-erythroid 2
Nrf2, NF-E2-related factor 2
OSOM, outer-stripe of outer medulla




PKB, protein kinase B
RAC-PK, Related to A- and C-Protein Kinase
REF, rat embryonic fibroblasts
ROS, reactive oxygen species
RPO, renal pedicle occlusion
SHR, steroid hormone receptor
SI, simulated ischemia
siRNA, small/short-interfering ribonucleic acid
SNP, sodium nitroprusside
SnPP, tin-protoporphyrin IX;
TGFp, transforming growth factor beta
TNFa, tumour necrosis factor alpha




Appendix III - Mouse ischemia/reperfusion protocol
Preparation
1. Sterilise instruments in autoclave (quick unwrapped cycle about 20 mins).
2. Alcohol wipe heated mat, turn on and stick rectangle of lab-top paper to it
with masking tape/micropore.
3. Cut 4 pieces of micropore to stick feet.
4. Set magnifying light to correct distance and turn on.
5. Get instruments from autoclave and place vascular clips on piece of sterile
towel so easy to pick-up.
6. Warm all fluids to 37 °C
Animal set-up
1. Weigh animal
2. Give anaesthetic (ketamine and medetomidine mix, reversed with
atipamezole).
3. Place animal back in cage and replace top.
4. Once asleep (5 min) remove from cage and shave around 0.5 cm on either
side of linea alba (keep shaving to a minimum to reduce heat loss).
5. Give 0.5 ml saline/PBS and 50 pi vetgesic to scruff
6. Place lacrilube on eyes
Procedure
1. Pick-up skin of abdo with toothed forceps just cranial to urethra.
2. Stab through skin with No. 11 blade still holding with forceps.
3. Open skin with tissue scissors.
4. Look for the very thin white line of the linea alba (keep to this to avoid
bleeding).
5. Pick up linea alba with toothed forceps and open with carefully with No. 11
blade or scissors. Open as far as the xyphisternum .Watch out for the liver at
the cranial aspect of the wound.
6. Place wire retractor.
7. Start with left kidney. With wet q-tip (stick with cotton wool at end) displace
bowel to right. Put wet towel over bowel.
8. Jewellers forceps in my right hand and curved forceps in left to gently (very
gently) pull fascia off renal pedicle. Grasp a small piece of fascia with one,
and then pull against it with the other forcep. Do not pull on the vein itself.
9. When the fasica has been dissected, it is easy to place curved forceps around
the back of the pedicle.
10. Pick up the vascular clip with the clip applicator.
11. Open forceps gently and place clip over pedicle
12. Displace bowel to left side and to the same to the right pedicle (when you get
good the dissection only takes a minute or two.
13. Remove retractor and place moist towel over wound. Time accurately the
clamp period.
14. After, remove clip.
15. Close linea alba with around a 4-0 silk/nylon (well anything really).
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16. Clips to skin (titanium).
Post-procedure
1. Reverse anaesthetic.
2. Place in cage on paper towel in incubator (25 °C).
3. Administer further 0.5 ml saline/PBS around 2 hrs after procedure.
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Appendix IV - Presentations of data from this thesis
ORAL PRESENTATIONS
Harrison EM, Ross JA, Wigmore SJ. Pharmacological interventions to reduce
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CLINICAL ETHICS
Ethical considerations in the application of preconditioning
to solid organ transplantation
S J McNally, E M Harrison, S J Wigmore
J Med Ethics 2005;31:631-634. doi: 10.1136/jme.2004.011486
The shortage of organs for transplantation has led research¬
ers to look for new techniques to expand the donor pool.
Preconditioning strategies have the potential to protect
organs from transplant associated injury or may improve
the function of substandard organs so that they become
suitable for transplantation. Translating this type of technol¬
ogy to the clinical setting raises ethical issues, particularly
relating to the deceased donor. It is important that society has
the opportunity to discuss the issues raised by implementation
of preconditioning strategies before they are implemented
rather than as a reaction to them.
Organ transplantation has been one of the great medicalsuccesses of our times. It has revolutionised thetreatme t of organ failure, often allowing the recipient
to resume a normal lifestyle.' Every advance has led to an
increased demand for organs for transplantation and despite
major improvements in immunosuppression, organ preserva¬
tion, and operating techniques, patients continue to die on
waiting lists due to the shortage of donors.2 The number of
potential recipients in the United Kingdom awaiting organ
transplantation has increased annually, reaching more than
7000 by March 2004.2 New sources of organs, such as living
donors, split livers, and non-heartbeating donors, have
increased available organs to a degree; however, these
developments have failed to keep pace with the decline in the
available number of cadaveric organs. Novel therapies such as
stem cell technology and bioartificial livers hold promise for the
future, but have not yet fulfilled their potential. There remains,
therefore, a requirement for solid organ transplantation that is
unlikely to recede in the near future.
Preconditioning is a developing technique, which is currently
making the transition from an experimental concept to a
practical therapeutic option.' The basic premise is that treat¬
ment before a known injury occurs can be used to minimise the
severity of that injury. This principle has widespread application
in many areas of medicine, particularly in surgical disciplines."
Solid organ transplantation, with its attendant ischaemia/
reperfusion injury, represents an area where preconditioning
of the donor or the donated organs could make a great
contribution,5 6 potentially reducing primary non-function and
early graft failure, and thus the requirement for relransplanta-
tion. There is also experimental evidence that preconditioning
may allow organs that would currently be discarded to be used,
thus expanding the organ pool. In this paper we discuss the
practical and ethical issues involved in implementing precondi¬
tioning strategies in solid organ transplantation.
PRECONDITIONING
Practical implementation
The term preconditioning encompasses many different
techniques, which all rely on harnessing aspects of the
innate protective mechanisms that human cells use to
survive stress. Broadly speaking there are two approaches
to induce preconditioning: physical and pharmacological.
Physical techniques include ischaemic preconditioning7
and heat treatment.8' Pharmacological techniques include
the administration of drugs, cytokines, and gene transfer
techniques.I0"'2
Pharmacological preconditioning, with drugs such as
cyclosporin, would require the commencement of an addi¬
tional drug infusion. This would be in addition to a range of
infusions that the donor would already be receiving, and so
would make little difference to the medical management of
the donor. Heat preconditioning requires elevation of the
body temperature by several degrees. This could be achieved
by the use of warming blankets, increasing the temperature
of inhaled gases with which the donor is ventilated, heating
intravenous fluids, and possibly the use of heat lamps.
Ischaemic preconditioning would be applied when the organs
were being removed. This is achieved by commencing the
retrieval operation as normal and then, immediately prior to
perfusing the donor with cold preservation solution, clamp¬
ing the blood vessels supplying the liver for ten minutes, and
subsequently unclamping them for ten minutes to allow
recovery. Perfusion with the cold preservation fluid would
then be commenced and the remainder of the organ retrieval
procedure performed as normal. Thus the practical imple¬
mentation of preconditioning treatments ranges from the
minor addition of a drug or a modification of operative
technique to more interventional options such as whole body
hyperthermia.
Clinical precedents
The optimum management of heartbeating organ donors
currently involves the administration of a variety of drugs
and infusions to maintain the organs in a suitable condition
for transplantation. Preconditioning agents would be used to
improve the target organs, rather than merely limiting the
detrimental effects of brain stem death. Thus preconditioning
crosses the boundary from maintenance to treatment, a fact
which could give rise to ethical concerns. There are, however,
several precedents for this type of active treatment. Hormonal
resuscitation with triiodothyronine, vasopressin, and methyl-
prednisolone is administered to heart transplant donors,"
with the aim of correcting the endocrine imbalances that
occur after brain stem death. These are active treatments,
intended to increase the number of organs suitable for
transplantation. They differ from preconditioning, however,
in that they represent maintenance rather than therapeutic
measures. Thus the boundary between donor mainten¬
ance, optimisation, and preconditioning can be considered
indistinct.
Clinical application of preconditioning
There are several applications for preconditioning. Each
individual setting requires different considerations with
www.jmedethics.com
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regard to both the practical implementation of a precondi¬
tioning strategy, and the ethical issues it raises. Donor organs
for transplantation currently come from three sources: living
donors, brain stem dead heartbeating donors, and non-
heartbeating donors. The application of preconditioning
strategies raises both ethical and practical issues in each of
these three donor groups. Similarly, different methods of
preconditioning may be more or less acceptable to families of
donors and any treatments used for preconditioning may
require lack of objection or assent additional to that obtained
for the actual donation.
ETHICAL CONSIDERATIONS
Lack of objection/assent
Consent for organ donation has been a contentious issue in
the past. In the UK, even when the potential donor carries an
organ donor card, the assent or lack of objection of the next
of kin is sought.14 The introduction of the Human Tissue Bill
may change the emphasis of this process, giving greater
priority to the autonomy of the donor. The provision of in
depth details of the retrieval process required to explain a
preconditioning strategy could potentially lead to a with¬
drawal of lack of objection to organ donation. Thus
describing the preconditioning strategies, or asking for
explicit assent to apply them, could potentially have a
negative effect on donation rates. This issue must be
considered in the light of potential benefits to society as
a whole, of advancing science, and improving medical
outcomes.
There is an alternative argument that preconditioning
represents part of the normal process of organ harvesting and
therefore should not require further assent or lack of
objection beyond that associated with organ donation itself.
Indeed, in his treatise on the ethics of organ donation, Price
suggests that "where an individual has requested that his/her
organs be used for transplantation after death, it seems
correct to infer that permission is granted for procedures
which form part of the routine preliminaries to transplanta¬
tion without seriously compromising the patient in any
way"."
Law and ethics
Even where there is no explicit authorisation of procedures
for maintaining donors and their organs, they are not
necessarily unlawful. Although explicit legislative provision
to cover organ preconditioning techniques may be desirable,
it is far more important that society endorses the concept that
preconditioning strategies in donors to improve organ
function and outcome are ethically acceptable and clinically
warranted. This would avoid the difficulties that occurred
with elective ventilation, which began in the UK in
accordance with Home Office directives and agreement, but
which has since been abandoned due to legal and ethical
concerns.16 17 Such legislation exists in Sweden, and it states:
"Once it has been established that death has occurred,
measures may be taken, if appropriate, in order to preserve
organs or other biological material pending
transplantation...Unless there are special circumstances,
such measures should not continue beyond 24 hours"
(Price," p 170). With regard to organ procurement for
transplantation, the UK Human Tissue Bill currently being
considered by parliament states that "it shall be lawful...to
take steps for the purpose of preserving that part [part of a
body] for use in transplantation, and to retain the body for
that purpose". However, this authorisation "shall only
extend to the taking of the minimum steps necessary...and
to the use of the least invasive procedure".18 It is unclear
whether such authorisation would extend to preconditioning
techniques.
The timing of certain preconditioning treatments may be
crucial, particularly with regard to agents that may require a
significant length of time prior to harvest to provide the
beneficial effect. Thus there may be the requirement to
commence administration of the agent before lack of
objection is obtained. Although this may be against normal
principles, this type of approach has previously been
approved by ethical committees and has been used in clinical
trials on organ donors." This is also analogous to the
management required for uncontrolled non-heartbeating
donors where, if the coroner agrees, cooling is commenced
as soon as practicable, and then withdrawn if an objection to
donation is expressed.20 This is provided for in Dutch law,
which declares that necessary measures to maintain the
organ in a suitable condition for transplantation may be
taken after death, so long as the procedure for obtaining the
necessary consent has not been completed.21
Respect for the donor
The question of preconditioning having ethical issues derives
from the observation that these manipulations will not
benefit the individual directly in any way. There is indirect
benefit, from the donor's volition to donate organs for
transplantation being fulfilled, but is this enough?
Societal beneficence and justice require that the maximum
good be obtained from the gifted organs. This could also be
seen as an extension of autonomy (albeit posthumously),
where respect for the wishes of the deceased to be an organ
donor mandates that the transplant procedure be as effective
and beneficial as possible. Thus it could be argued that there
is a moral and ethical imperative to use preconditioning
strategies if they improve the use of donated organs.
Autonomy is difficult to establish once an individual has
died, but this may become easier as the use of advance
directives increases. As has been described in the debate on
elective ventilation, however, the lack of public knowledge
about specific treatments (such as elective ventilation) means
that any impact of advance directives is likely to be limited
(Price," p 189).
The act of joining an organ donor register or carrying a
donor card may be considered an indication of consent to
organ donation, but it is not clear whether such consent
would extend to preconditioning strategies. There is a need to
establish whether preconditioning can be seen as no different
from other medical interventions, such as the administration
of heparin to donors, and also whether consent to organ
donation implies consent to all techniques required to allow
good use of the organs. As stated above, justice and societal
beneficence require that the best possible use is made of the
organs, and therefore that all beneficial manipulations are
used.
It is conceivable, however, that the relative importance
ascribed to such considerations might alter depending on the
nature of the preconditioning strategy considered. It seems—
for example, unlikely that many relatives would object to the
deceased donor being given a drug to improve organ function
but it is possible that they might raise objection if it were
necessary to keep the donor ventilated for a prolonged period
of time to allow the drug to take effect. Similarly, more
interventional preconditioning techniques, such as whole




In the controlled non-heartbealing donor, death is not
diagnosed until cessation of cardiac function. In this setting
interventions prior to death, either to optimise the donor or to
precondition organs, may alter the process leading to death
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and this is considered unacceptable. The guidelines currently
being drawn up by the Intensive Care Society stale quite
clearly that "It is inappropriate to escalate current treatment,
add new therapies—for example, inotropes, heparin, hor¬
mone replacement, or to undertake invasive interventions—
for example, vascular cannulation before death for cold
perfusion, to improve organ viability".25 Preconditioning in
this setting is only potentially possible after the diagnosis of
death and an acceptable period (frequently 10 minutes)
during which no intervention is made on the potential donor.
In terms of practicality this means that only preconditioning
strategies that involve perfusion of the deceased donor or
involve ex vivo perfusion of organs would be acceptable in
this context.
Living donation
Living donors provide the simplest model, where the donor is
fully aware of the donor procedure and can provide detailed
consent, with prolonged lime for consideration and reflec¬
tion. This situation therefore poses few ethical considerations
not encompassed by fully informed consent. Although all
organs donated for transplantation are considered precious,
the act of living donation places additional responsibilities on
the medical profession. Living donation of organs or tissues is
one of the few circumstances in medicine where the donor
undergoes a procedure with no physical benefit to them¬
selves. In this context it is imperative that the risk to the
donor is minimised. Similarly, because there is a risk to
the donor, however small, it is generally accepted that the
donated organ should have a reasonable chance of successful
transplantation. Considering these issues, any precondition¬
ing strategy applied to a living donor population must not
only demonstrate benefit to the recipient but must also not
place any additional burden or risk on the donor.
Multiorgan donors
The majority of organ donors in the UK donate more than
one organ. This raises the question whether, if a precondi¬
tioning strategy had been demonstrated to confer a beneficial
outcome for a particular organ, it would be acceptable to use
such a treatment in a multiorgan donor if the effects on other
organs were not known. The answer in this case would
probably be negative and so research involved in the
development of such strategies should consider effects on
other organs that might be donated simultaneously in a
clinical setting. If the effects of a treatment on other organs
were not adverse, the question would then arise as to
whether the potential recipients of other organs should be
consulted and requested to give their consent to precondi¬
tioning being used. The issues of consent and collateral
involvement become more prescient in the context of a
clinical trial where the effect of a preconditioning strategy
may be the subject of evaluation.
Recipients of preconditioned organs
In many circumstances where preconditioning would be used
it may be impractical to obtain consent from the recipients in
time to influence the application of the preconditioning
intervention. There is concern therefore that if a recipient
objects to receiving an organ that has undergone precondi¬
tioning this may subvert the normal informed consent
process by placing coercion on the recipient. Thus the desire
to receive a transplant may outweigh the concerns or
objections of the recipient to receiving an organ from a
research protocol. Adopting a utilitarian approach, it could be
argued that preconditioning has the potential to improve the
outcomes of transplantation and that society should support
research which aims to advance science or improve outcomes
in medicine. Following this argument to its practical
application, the occasional refusal to receive a preconditioned
organ would be offset by the perceived benefit to society as a
whole. In practice perhaps the easiest way to deal with this
issue would be to inform patients, at the time of addition to
the waiting list, that they may be offered organs derived from
trials of preconditioning protocols and that they should
consider whether they would accept such an organ. They
should also be informed that such protocols had received
approval from local regional ethics committees and that such
approval would not normally have been granted if there were
issues over either safety or perceived benefit.
Preconditioning in a research setting
In common with other medical research, trials of precondi¬
tioning should abide by the principles enshrined within the
Declaration of Helsinki.24 Specifically there should be an
adequate laboratory and animal research base to support
human studies and these studies should have clear potential
for benefit counterbalanced against the inherent risk of the
intervention. The design of studies should be clearly set out
and be undertaken by competent individuals. Studies should
have been reviewed and approved by an independent
committee—in the UK this would be the local or multicentre
research ethics committee, as appropriate. Articles 10 and II
of the Declaration of Helsinki deal with areas of research
where preconditioning could raise ethical issues. Article 10
relates to the situation where an individual may be in a
dependent relationship with the researcher, a possibility for
the recipient of an organ used in a preconditioning study, and
article 11 describes the case where the individual is legally
incompetent—the situation of the deceased donor. These
issues present specific problems for regional ethics commit¬
tees, which often have to consider them without precedent
for comparison or using guidelines derived from research in
living subjects.
CONCLUSION
Preconditioning strategies have a great potential to improve
outcome in solid organ transplantation and also to increase
the availability of organs by allowing use of marginal donors.
As with many issues in transplantation, there are few
precedents to provide guidance on the practical implementa¬
tion of such programmes. There are likely to be moves to
integrate these treatments into organ procurement protocols
in the near future. There is, therefore, a clear need to
establish an ethical consensus on the acceptability of such
treatments and the responsibilities of those involved in their
administration to donors, their families, and recipients. It is
hoped that transparency in such discussions will both pre¬
empt misunderstandings arising from perceptions of unne¬
cessary intervention or experimentation on the deceased
donor and provide an ethically acceptable framework upon
which preconditioning strategies could be based.
ACKNOWLEDGEMENTS
SJM and EMH are funded by the Scottish Hospital Endowments
Research Trust (SHERT). SJW is funded by the Wellcome Trust.
Authors' affiliations
S J McNally, E M Harrison, S J Wigmore, Tissue Injury and Repair
Group, MRC Centre for Inflammation Research, Medical School,
University of Edinburgh, Edinburgh, UK
Competing interests: The authors all hold grants and work in the field of
experimental preconditioning. SJM and EMH are funded by the Scottish
Hospital Endowments Research Trust (SHERT). SJW is funded by the
Wellcome Trust and is a member of the ethics committee of the British
Transplantation Society, although this article has been written indepen¬
dently of this association and is not intended to represent either the views
of the ethics committee or the society as a whole.
www.jmedethics.com
634
Downloaded fromjme.bmjjoumals.com on 1 December 2005
McNally, Harrison, Wigmore
Correspondence to: Stephen McNally, Tissue Injury and Repair Group,
MRC Centre for Inflammation Research, Medical School (6 floor),
University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, UK;
sj.mcnally@ed.ac.uk
Received 12 December 2004
In revised form 18 January 2005
Accepted for publication 22 February 2005
REFERENCES
1 Lazzaretti CT, Carvalho JG, Mulinari RA, et al. Kidney transplantation
improves the multidimensional quality of life. Transplant Proc
2004;36:872-3.
2 More transplants—new lives. Transplant activity in the UK 2003-4. Bristol:
UK Transplant, 2004.
3 Koti RS, Seifalian AM, Davidson BR. Protection of the liver by ischemic
preconditioning: a review of mechanisms and clinical applications. Dig Surg
2003;20:383-96.
4 Cleveland JC Jr, Raeburn C, Harken AH. Clinical applications of ischemic
preconditioning: from head to toe. Surgery 2001 ;129:664-7.
5 McLaren AJ, Friend PJ. Trends in organ preservation. Transpl Int
2003;16:701-8.
6 Kosieradzki M. Mechanisms of ischemic preconditioning and its application in
transplantation. Ann Transplant 2002;7:12-20.
7 Clavien PA, Selzner M, Rudiger HA, et al. A prospective randomized study in
100 consecutive patients undergoing major liver resection with versus without
ischemic preconditioning. Ann Surg 2003;238:843-50.
8 Redaelli CA, Wagner M, Kulli C, etal. Hyperthermia induced HSP expression
correlates with improved rat renal isograft viability and survival in kidneys
harvested from non-heartbeating donors. Transpl Int 2001,14:351-60.
9 Terajima H, Thiaener A, Hammer C, et al. Attenuation of hepatic
microcirculatory failure during in situ xenogeneic rat liver perfusion by heat
shock preconditioning. Transplant Proc 2000,32:1 111.
10 Yang CW, Ahn HJ, Han HJ, etal. Pharmacological preconditioning with low
dose cydosporine or FK506 reduces subsequent ischemia/reperfusion injury
in rat kidney. Transplantation 2001;72:1753-9.
11 Camargo CA Jr, Madden JF, Gao W, et al. lnterleukin-6 protects liver against
warm ischemia/reperfusion injury and promotes hepatocyte proliferation in
the rodent. Hepatology 1997,26:1513-20.
12 Chauveau C, Bouchet D, Roussel JC, et al. Gene transfer of heme oxygenase-1
and carbon monoxide delivery inhibit chronic rejection. Am J Transplant
2002;2:581-92.
13 Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic
donor management results in more transplanted organs. Transplantation
2003;75:482-7.
14 UK hospital policy for organ and tissue donation. Bristol: UK Transplant
2003.
15 Price D. legal and ethical aspects of organ transplantation. Cambridge
University Press, 2000:211.
16 Shaw AB. Non-therapeutic (elective) ventilation of potential organ donors: the
ethical basis for changing the law. J Med Ethics 1996,22:72-7.
17 Riad H, Nicholls A, Neuberger J, et al. Elective ventilation of potential organ
donors. BMJ 1995;310:714-18.
18 UK Human Tissue Bill 2004: section 44: preservation for transplantation:
subsections 1 and 2.
19 Guesde R, Barrou B, Leblanc I, et al. Administration of desmopressin in brain
dead donors and renal function in kidney recipients. Lancet
1998;352:1178-81.
20 Brook NR, Nicholson ML. Kidney transplantation from non heartbeating
donors. Surgeon 2003,1:311-22.
21 The Organ Donation Act 2003. The Hague: International Publication Series
Health Welfare and Sport no 3, 2003, section 22:subsection 2.
22 Mokuno Y, Berthiaume F, Tompkins RG, et al. Technique for expanding the
donor liver pool: heat shock preconditioning in a rat fatty liver model. Liver
Transpl 2004,10:264-72.
23 Intensive Care Society. Draft guidelines on organ donation. London: Intensive
Care Society, 2004, http://www.ics.ac.uk/downloads/Standards/
Master%20ICS%20Guiaelines%20all%20sections%20(Nov04).pdf (accessed
12 Apr 2005).
24 World Medical Organisation. Declaration of Helsinki. BMJ 1996;313:1448-9.
Notice
Increasing ethics, communication, and social science content for written exams in
undergraduate medicine
Hosted by the Universities Medical Assessment Partnership (UMAP), this is a workshop to
disseminate good practice in question writing whilst also helping to incorporate ethics,
communication, and social science questions into the UMAP bank. This will serve to
encourage these topics to be assessed at UMAP partner medical schools who at present
include Newcastle, Leeds, Liverpool, Manchester, and Sheffield.
Date: Thursday 24th November 2005
Timings: Workshop 11.00 - 1.30pm; Lunch 1.30pm; Workshop 2.30 - 5.00pm
Place: Gartree and Rutland, 4ttl Floor, Charles Wilson Building, Leicester University
Presenter: Andrea Owen, UMAP Project Manager
Places are free of charge and can be booked by contacting the UMAP office by email,





Insulin induces heme oxygenase-1 through the
phosphatidylinositol 3-kinase/Akt pathway and the Nrf2
transcription factor in renal cells
Ewen M. Harrison, Stephen J. McNally, Luke Devey, 0. J. Garden, James A. Ross
and Stephen J. Wigmore
Tissue Injury and Repair Group, University of Edinburgh, UK
Keywords
Akt; heme oxygenase-1; insulin; kidney;
transplantation
Correspondence
E. M. Harrison, Tissue Injury and Repair
Group, University of Edinburgh, Room
FU501, Chancellor's Building, Little France
Crescent, Edinburgh EH16 4SB, UK
Fax; +44 131 242 6520
Tel: +44 797 442 0495
E-mail: mail@ewenharrison.com
(Received 18 August 2005, revised 27
February 2006, accepted 13 March 2006)
doi:10.1111/j. 1742-4658.2006.05224.x
Heme oxygenase-1 catalyzes the breakdown of heme and is protective in
models of kidney transplantation. In this study we describe the induction
of heme oxygenase-1 mRNA and protein by insulin. Following treatment
with insulin, a five-fold increase in heme oxygenase-1 mRNA and a four¬
fold increase in protein expression were observed in renal adenocarcinoma
cells; insulin-induced heme oxygenase-1 expression was also demonstrated
in mouse primary tubular epithelial cells. The induction of heme oxyge¬
nase-1 in renal adenocarcinoma cells was blocked by actinomycin D and
cycloheximide and was abolished by the phosphatidylinositol 3-kinase
inhibitor, LY294002, but not by the inactive analog LY30351I. Over-
expressing a dominant-negative form of Akt abrogated the heme oxyge¬
nase-1-inducing effects of insulin, whereas cells transfected with a
constitutively active Akt construct demonstrated an increase in heme oxyg¬
enase-1 promoter activity and protein expression. The transcription factor
NF-E2-related factor-2 was found to translocate to the nucleus following
insulin treatment in a phosphatidylinositol 3-kinase-dependent manner.
Pretreatment with NF-E2-related factor-2 small-interfering RNA abolished
insulin-induced heme oxygenase-1 induction. Insulin was also found to acti¬
vate the mitogen-activated protein kinase cascades p38 and extracellular
signal-related kinase; however, inhibition of these pathways with SB202190
and PD98059 did not alter insulin-induced heme oxygenase-1 expression.
Thus, insulin induces heme oxygenase-1 mRNA and protein expression in
renal cells in a phosphatidylinositol 3-kinase/Akt and NF-E2-related fac¬
tors-dependent manner.
Cadaveric kidney transplantation is associated with
substantial free radical injury as a consequence of cold
storage and reperfusion of the organ [1,2]. This corre¬
lates with early organ dysfunction, which is associated
with poorer long-term graft survival [3,4], Strategies to
reduce these effects and improve outcome are currently
being sought [5],
Heme oxygenase catalyses the rate-limiting step in
the degradation of heme to carbon monoxide (CO),
free iron and biliverdin, which is immediately conver¬
ted to bilirubin by bilverdin reductase [6], At least two
isoenzymes are known to exist: heme oxygenase-1
(HO-1), which is strongly induced by its substrate
heme and a number of stress stimuli, including UV
Abbreviations
AD, actinomycin D; CHX, cycloheximide; ERK, extracellular signal-related kinase; GSK3P, glycogen synthase kinase 3P; HBSS, HANK'S
balanced salt solution; HIF-1, hypoxia-inducible factor-1; HO-1, heme oxygenase-1; HSF-1, heat shock transcription factor-1; HSP70, heat
shock protein 70; MAPK, mitogen-activated protein kinase; MEK1, mitogen activated protein kinase kinase 1; NF-E2, nuclear factor-erythroid
2; NGF, nerve growth factor; Nrf2, NF-E2-related factor 2; pGSK3p, phosphorylated glycogen synthase kinase 3P; PI3K, phosphatidylinositol
3-kinase; siRNA, small-interfering ribonucleic acid.
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radiation and heavy metals; and constitutive heme
oxygenase-2 [7-9]. The exact role of HO-1 in oxidative
stress is not clear, but it has been shown to be protect¬
ive in a number of animal models of organ transplan¬
tation, including kidney [10], liver [11], heart [12] and
small bowel [13], by virtue of the products of the reac¬
tion it catalyzes [14]. Bilirubin is known to be a power¬
ful antioxidant [15,16], and HO-derived bilirubin has
been shown to provide protection in neuronal cells
[17]. CO was first demonstrated to be protective in a
model of acute lung injury [18], and subsequently in
rodent cardiac [19,20] and renal transplantation models
[21], Two important mechanisms of CO protection
involving p38 mitogen-activated protein kinase
(MAPK) and guanylyl cyclase have been identified,
but these appear to be cell-type specific [14], Although
HO-1 releases the pro-oxidant Fe2 + , this is associated
with the rapid expression of the iron-sequestering pro¬
tein ferritin, which is also known to be protective [22].
It is generally accepted therefore that induction of
heme degradation represents an adaptive response to
oxidative insult.
Insulin is a polypeptide hormone that regulates
glucose, lipid and protein metabolism and promotes
cell growth and differentiation. On ligand binding,
the insulin receptor tyrosine kinase initiates multiple
signaling cascades, including activation of the phos-
phatidylinositol 3-kinase (PI3K) pathway and its
downstream effectors [23]. This pathway is a key sig¬
nal transducer of many growth factors and cytokines
and has been implicated in the regulation of cell
growth, cell migration and cell survival [24], The
protein kinase B/Akt family of serine/threonine kin¬
ases has been identified as an important target of
PI3K in cell survival [25-28], Moreover, recent work
has shown a direct link between the PI3K/Akt path¬
way and HO-1 regulation in PC 12 cells [29,30]. This
may be through nuclear factor E2-related factor-2
(Nrf2), a member of the cap'n'collar family of basic
leucine transcription factors and a well-established
regulator of HO-1 [31].
In view of the beneficial effects of upregulation of
HO-1 in models of organ transplantation, we wished
to identify signaling pathways involved in regulation
of HO-1 gene expression. This study presents data
demonstrating PI3K/Akt-dependent induction of
HO-1 following the administration of insulin to renal
adenocarcinoma cells (ACHN). PI3K activity was
necessary and sufficient for HO-1 induction, and
Nrf2 blockade was found to abolish the response.
Supporting data illustrate similar insulin-induced
HO-1 expression in mouse primary renal tubular epi¬
thelial cells.
Results
Insulin increases HO-1 expression in ACHN cells
Treatment of serum-deprived ACHN cells with
increasing concentrations of human insulin resulted in
a four-fold induction of HO-1 after 6 h (Fig. 1A).
Maximal induction of HO-1 protein was achieved at
concentrations of 200 nM insulin. A time course experi¬
ment using insulin (200 nM) demonstrated accumula¬
tion of HO-1 after 2 h of treatment (Fig. IB). HO-1
mRNA was found to increase over the same concen¬
tration range of insulin (Fig. 1C) and achieved maxi¬
mum induction after 2 h of treatment with insulin
(200 nM) (Fig. ID). HO-1 mRNA returned to resting
levels after 16 h of treatment. To ensure that HO-1
induction was not related to serum deprivation, cells
were cultured in medium containing different concen¬
trations of fetal bovine serum for 16 h (Fig. IF); no
alteration in HO-1 protein expression was detected. To
confirm that HO-1 accumulation was dependent on
gene transcription, ACHN cells were pretreated with
actinomycin D (AD) followed by insulin (Fig. 2A,C).
Basal levels of HO-1 protein were reduced following
AD treatment, and the HO-1 protein and mRNA
response to insulin was abolished. Similarly, cyclohexi-
mide (CHX) was administered to establish the role of
protein synthesis in insulin-induced HO-1 expression
(Fig. 2B,C). CHX abrogated HO-1 protein induction
following insulin treatment but, in agreement with
other studies, also eliminated HO-1 mRNA induction,
suggesting that protein translation is required to acti¬
vate the HO-1 promoter [29,32,33].
Insulin increases HO-1 expression in mouse
primary renal tubular epithelial cells
In order to ensure that insulin-induced HO-1 expres¬
sion was not a characteristic of transformed cells
alone, mouse primary renal tubular epithelial cell cul¬
tures were prepared. These were treated in a similar
manner with insulin (200 nM) for increasing periods of
time (Fig. IE). A robust induction of HO-1 protein
was observed.
Insulin-mediated induction of HO-1 is PI3K
dependent
In our model, phosphorylation of glycogen synthase
kinase 1 (GSK3p) was used as an indicator of PI3K/Akt
axis activity. GSK3(3 phosphorylation was observed
after 30 min of insulin treatment at a concentration of
200 nM (Fig. 3A). Following 30 min of pretreatment
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Fig. 1. Insulin stimulates heme oxygenase-1 (HO-1) protein and mRNA accumulation. Renal adenocarcinoma cells (ACHN) were serum-
deprived for 16 h and treated with increasing concentrations of insulin for 6 h (A) or 4 h (C), or with insulin (200 nM) for various times (B, D).
Mouse primary renal tubular epithelial cells were prepared and treated with increasing concentrations of insulin (E). ACHN cells were cul¬
tured in medium supplemented with different concentrations of fetal bovine serum (FBS) (F). Whole cell lysates were prepared and analysed
by western blotting (A, B, E, F) using antibody to HO-1, with p-actin as loading control. mRNA extracts were prepared (C, D) using TRIzol
and reverse transcribed to cDNA. Fluorescence detection real-time PCR was performed using HO-1 primers and probe with an 18S prim¬
er/probe control; results are expressed as mean relative expression ± SEM of three independent experiments.
with the PI3K inhibitor LY294002 (Fig. 3B), or its inac¬
tive analog LY303511 (Fig. 3C), ACHN cells were trea¬
ted with insulin (200 nM) for 6 h to determine HO-1
protein accumulation and for 30 min to confirm GSK3(3
phosphorylation status. HO-1 was induced as expected
following insulin treatment, but this effect was abolished
with increasing concentrations of LY294002. Following
treatment with LY303511, HO-1 induction was not
altered. LY294002-mediated reduction in GSK3p phos¬
phorylation correlated with inhibition of insulin-induced
HO-1 accumulation.
Akt activity is necessary and sufficient
for HO-1 induction
Forty-eight hours after transfection of ACHN cells
with the pHOGL3/ll.6 reporter construct and a
constitutively active Akt-expressing construct (Akt-
myr), an increase in luciferase activity was observed,
representing a six-fold increase in HO-1 promoter
activity (P < 0.05, anova) (Fig. 4A). Accumulation of
HO-1 protein was also found following transfection
with either the Akt-myr or wild-type (Akt-WT) con¬
struct, in association with an expected increase in
GSK3P phosphorylation (Fig. 4B). Treating cells
transfected with Akt-myr with insulin did not increase
the HO-1 promoter activity (Fig. 4A) over that of cells
transfected alone, demonstrating that the effects of
insulin and Akt overexpression on HO-1 accumulation
are not additive. In cells transfected with a dominant-
negative Akt-expressing construct (Akt-K179M), and
treated 48 h later with insulin, HO-1 promoter activity
was found to increase slightly but this was not statisti¬
cally significant (Fig. 4A).
FEBS Journal 273 (2006) 2345-2356 © 2006 The Authors Journal compilation © 2006 FEBS 2347









AD +1 CHX CHX +1
Fig. 2. Insulin-stimulated heme oxygenase-1 (HO-1) accumulation is
transcription and translation dependent. Cells were serum-deprived
for 16 h and pretreated with actinomycin D (AD) (5 pgmL-1) (A, C)
or cycloheximide (CHX) (10 pg-mL"1) (B, C) for 30 min, and then
treated with insulin (I) (200 nM) for 6 h (A, B) or 2 h (C). Whole cell
lysates were prepared and analysed by western blotting (A, B)
using antibody to HO-1, with p-actin as loading control. mRNA
extracts were prepared (C) using TRIzol and reverse transcribed to
cDNA. Fluorescence detection real-time PCR was performed using
HO-1 primers and probe with an 18S primer/probe control; results
are expressed as mean relative expression ± SEM of three indep¬
endent experiments.
Insulin-mediated HO-1 accumulation is neither
p38-MAPK nor extracellular signal-related kinase
(ERK) dependent
Insulin was found to phosphorylate p38-MAPK
(Fig. 5A) and ERK (Fig. 5B) in a time-dependent man¬
ner. ACHN cells were then pretreated with the p38-
MAPK inhibitor SB202190, or the mitogen-activated
kinase kinase 1 (MEK1) inhibitor PD98059, and treated
with insulin. Adequate inhibition of p38-MAPK was
demonstrated by probing for phosphorylated Hsp27, a
known downstream target of p38-MAPK [34] (Fig. 5C).
MEK1 inhibition was confirmed with blots for phos¬
phorylated ERK 1/2 (Fig. 5D). In cells pretreated with
SB202190 or PD98059 and exposed to insulin, no
decrease in the expected HO-1 accumulation was
observed (Fig. 5C,D), suggesting that neither p38-




























Fig. 3. Insulin stimulates heme oxygenase-1 (HO-1) accumulation
through a phosphatidylinositol 3-kinase (PI3K)-dependent pathway.
Renal adenocarcinoma (ACHN) cells were serum-deprived for 16 h
and treated with increasing concentrations of insulin (200 nM) for
30 min (A). Other groups were pretreated with the PI3K inhibitor
LY294002 (B), or its inactive analog LY303511 (C) for 30 min, and
then treated with insulin (200 nM) for 30 min to determine glycogen
synthase kinase 3P (GSK3p) phosphorylation status, and for 6 h to
determine HO-1 accumulation. Whole cell lysates were prepared
and analysed by western blotting using phospho-specific antibody
to GSK3a/p (ser 21/9) (pGSK3ct/p) and antibody to total GSK3 as a
loading control. As previously, antibody to HO-1 was used, with
p-actin as loading control.
Nrf2 translocates to the nucleus following insulin
treatment
In ACHN cells treated with increasing concentrations
of insulin for 1.5 h, the nuclear fraction of Nrf2 was
found to increase as the cytosolic component decreased
(Fig. 6A). Immunofluorescent labeling of Nrf2 revealed
increased nuclear staining following insulin treatment
(Fig. 6B). Pretreatment with LY294002 abolished
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Fig. 4. Overexpression of active Akt causes heme oxygenase-1
(HO-1) reporter activation. (A) Renal adenocarinoma cells (ACHN)
were triple-transfected with the pHOGL3/11.6 reporter construct,
the pSV-p-galactosidase control construct and vectors expressing
membrane-targeted active Akt (Akt-myr), dominant-negative Akt
(Akt-K179M) or empty vector control (pUSE-amp). Forty-eight hours
later, cells were treated with insulin (200 nM) for 6 h and then lysed
in 100 pL of reporter lysis buffer, 20 pL of which was used for
luciferase assay, the remainder being used for p-galactosidase assay.
Results are expressed as luciferase activity per unit of p-galactos¬
idase activity ± SEM of four independent experiments. *P< 0.05,
anova. (B) ACHN cells were transfected with constructs expressing
wild-type Akt (Akt-WT), membrane-targeted active Akt (Akt-myr),
dominant-negative Akt (Akt-K179M) or empty vector control (pUSE-
amp). Forty-eight hours later, whole cell lysates were produced and
analyzed by western blotting using antibody to HO-1, phospho-spec-
ific antibody to GSK3p (ser 9) (pGSK3p) and antibody to total GSK3 as
loading control. C, control; F, transfection agent alone.
nuclear accumulation of Nrf2 in response to insulin
at doses previously shown to inhibit PI3K activity
(Fig. 7C); the inactive analog, LY3035II, had no
effect on insulin-mediated Nrf2 nuclear accumulation
(Fig. 7D).
Insulin mediated HO-1 induction is abolished
by Nrf2 small-interfering RNA (siRNA)
ACFIN cells were transfected with Nrf2 siRNA
according to the manufacturer's instructions. Forty-
eight hours later they were treated with insulin or the
proteosome inhibitor MG132 (used as a positive con¬
trol for Nrf2 accumulation) for 6 h. Cobalt chloride
(CoCl2), a hypoxia mimetic that activates the HO-l
promoter (data not shown), was also used as a control.
Groups treated with the Nrf2 siRNA demonstrated
greatly reduced Nrf2 and HO-l protein expression
when compared with control siRNA-treated groups
(Fig. 7). In Nrf2 siRNA groups treated with insulin,
no HO-1 induction was observed; however, in Nrf2
siRNA groups treated with CoCl2, HO-1 induction did
occur, demonstrating that Nrf2 activity is not a prere¬
quisite for promoter activation. Although nuclear
localization of Nrf2 following insulin treatment was
apparent, it was not clear whether insulin treatment
resulted in increased total Nrf2. There was a sugges¬
tion on western blotting of whole cell lysates that total
cellular Nrf2 was increased following insulin treatment,
but on quantification of three independent blots, no
difference was demonstrated (Fig. 7).
Discussion
HO-1 is one of the most critical cytoprotective mecha¬
nisms activated during cellular stress, and clinically
applicable pharmacological or gene-based strategies of
induction need to be identified [35], In the setting of
organ transplantation, intervention to upregulate HO-
1 could be directed at the donor, the harvested organ
ex vivo or the recipient and would clearly need to be
efficacious, be specific, lack side-effects and be easily
deliverable to the organ in question. In this study, we
have provided direct evidence of HO-1 induction by
insulin through the PI3K/Akt cascade and the Nrf2
transcription factor in both transformed renal cells and
primary mouse renal tubular epithelial cells. Insulin-
induced HO-1 protein expression was sensitive to
PI3K/Akt inhibition and Nrf2 gene silencing. The
fold-increase in both HO-1 protein and mRNA in
response to insulin was consistent, as well as being
time and concentration dependent.
The role of the PI3K/Akt pathway in the regulation
of HO-l has been the source of much interest lately.
Our data demonstrate that insulin-induced HO-1
accumulation is sensitive to PI3K. inhibition with
LY294002. This is in keeping with results from other
work demonstrating the importance of PI3K/Akt acti¬
vation in HO-1 regulation following cell stimulation
with nerve growth factor (NGF) [29], carnosol [30],
hemin [36] and cadmium [37], Overexpression of active
Akt alone was sufficient to mimic the effects of insulin
on HO-1 expression in our model, adding weight to
the suggestion that the effect of insulin on HO-1 is
mediated predominantly, or possibly exclusively, by
the PI3K/Akt axis. Overexpression of membrane-
targeted active Akt stimulated the HO-1 promoter
but, significantly, adding insulin did not increase this
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Fig. 5. p38 Mitogen-activated protein kinase (p38-MAPK) and extracellular signal-related kinase (ERK) inhibition has no effect on insulin-
induced heme oxygenase-1 (HO-1) accumulation. (A, B) Cells were serum-deprived for 16 h and treated with insulin (200 nM) for various
times. Whole cell lysates were prepared and analyzed by western blotting using antibody to the phosphorylated form of p38-MAPK
(Thr180/Tyr182) (p-p38) (A) and phosphorylated ERK1/2 MAPK (Thr202/Tyr204) (p-ERK1/2) (B). Total p38 (A) and total ERK1/2 (B) were
used as loading controls. (C, D) Cells were serum-deprived for 16 h and pretreated with the p38-MAPK inhibitor SB202190 (C) or the MEK1
inhibitor PD98059 (D) for 30 min, after which insulin (200 nM) was added (6 h). Whole cell lysates were prepared and analyzed by western
blotting using antibody to HO-1 and p-actin to control for protein loading. Adequacy of p38-MAPK inhibition was established with blots for
phosphorylated Hsp27 (C). MEK1 inhibition was confirmed with blots for phosphorylated ERK1/2 (D).
activation. In contrast, Salinas et al. reported that
although the basal level of HO-1 mRNA, measured by
semiquantitative RT-PCR, was higher in cells trans-
fected with a membrane-targeted active Akt expressing
construct, administration of NGF further increased
this expression [29], This may indicate that NGF
exhibits its effect through additional mechanisms in
comparison with insulin, although the differences may
be due to cell type or transfection technique.
The exact role of the MAPK cascades in HO-1 regu¬
lation remains controversial. Inhibition of p38-MAPK
reduces HO-1 expression following carnosol [30], dial-
lyl sulfide [38] and cadmium [37] treatment, although
an earlier study found that p38 inhibition had no effect
on HO-1 mRNA expression following cadmium, arse¬
nate or hemin [39] treatment. Our data, however, show
that despite concentrations of insulin being sufficient
to phosphorylate p38, inhibition of p38 did not alter
insulin-induced HO-1 protein expression. In keeping
with our results, ERK inhibition did not impact on
HO-1 expression following carnosol [30] or arsenite
[40] treatment; however, ERK activity was required for
HO-1 induction in HepG2 cells treated with diallyl sul¬
fide [38] and LMH cells exposed to arsenite [41], It
remains unclear why these disparities exist, but it
appears that p38 and ERK play a significant role in
HO-1 regulation in some models, but not in others.
During our investigation we studied a number of
different transcription factors that may be involved in
mediating the effect of insulin on HO-1 expression,
including heat shock transcription factor-1 (HSF-1),
hypoxia-inducible factor-1 (HIF-1) and NF-E2-related
factor 2 (Nrf2). The PI3K/Akt pathway has been
implicated in HSF-1 regulation by virtue of the repres¬
sive effects of the Akt target GSK3[3 on HSF-1 [42].
Although insulin treatment was sufficient to phos¬
phorylate and deactivate GSK3(3, this did not result in
nuclear localization, trimerization or transactivation of
HSF-1 (data not shown).
The basic helix-loop-helix transcription factor,
hypoxia-inducible factor-1 (HIF-1), mediates essential
homeostatic responses to reduced oxygen [43,44],
HIF-1 has been shown to mediate transcriptional acti¬
vation of HO-1 in a rat model of hypoxia [45] and rat
renal medullary cells [46]. In addition, we have previ¬
ously reported an associative increase in HIF-1 DNA
binding and HO-1 induction in a rat model of liver
ischemia-reperfusion injury [47], The relationship
between HIF-1 and HO-1 induction in humans is less
clear. Hypoxia has been shown to repress HO-1
mRNA expression in primary cultures of human
umbilical vein endothelial cells despite HIF-1 transacti¬
vation, while C0CI2, a known HIF-1 activator, was
shown to induce expression [48]. This reflects our
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Fig. 6. Insulin treatment causes phosphatidylinositol 3-kinase
(PI3K)-sensitive nuclear migration of NF-E2-related factor (Nrf2). (A)
Cells were serum-deprived for 16 h and treated with increasing
concentrations of insulin for 1.5 h. Nuclear and cytosolic lysates
were prepared and analyzed by western blotting using antibody to
Nrf2, with loading control with p-actin for cytosolic extracts and
lamin A/C for nuclear extracts. (B) Cells were treated similarly with
insulin (200 nM) for 1.5 h, prepared for immunofluorescence and
treated with antibody to Nrf2, followed by Hoechst counterstaining.
(C, D) Cells were serum-deprived for 16 h and pretreated with the
PI3K inhibitor LY294002 (C) or its inactive analog LY303511 (D) for
30 min. Cells were treated with insulin (200 nM) for 1.5 h, after
which nuclear lysates were prepared and analyzed by western blot¬
ting, using antibody to Nrf2, with lamin A/C loading control.
observation that ACHN cells subjected to hypoxia
demonstrate a decrease in HO-1 protein expression
(data not shown), while CoCl2 induces HO-1 protein
(Fig. 7). An explanation for this apparent contradic¬
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ovary cells, HO-1 induction by hypoxia and CoCl2 can
occur in an HIF-1-independent manner; while CoCl2
was shown to act in an Nrf2-dependent manner, hyp¬
oxia was not [49]. It is not clear how findings in these
cells translate to other models, but our data would
support this view: Nrf/2 gene silencing resulted in a
reduction in CoCl2-mediated HO-1 expression. Yet
some HO-1 induction was still apparent, possibly rela¬
ting to HIF-1 activity, although this was not examined
specifically. Controversial evidence exists linking PI3K
activity with regulation of HIF-1, in both hypoxic
[50,51] and normoxic [52-56] conditions, although this
appears to be cell-type specific [57,58]. Insulin has been
shown to upregulate HIF-1 directly through the
PI3K/Akt pathway [56]. However, despite all this, in
our model HIF-1 transactivation is not seen following
insulin treatment, as determined by an HIF-1 lucif-
erase reporter construct (data not shown).
Nrf2 has been shown to regulate HO-1 [31] and is
known to be under the influence of PI3K [30,36,59-
62], Consistent with our results, insulin has previ¬
ously been shown to cause nuclear localization of
Nrf2, although PI3K dependency was not investi¬
gated in that study [61]. However, hemin has been
shown to induce Nrf2 nuclear localization in a
PI3K-sensitive manner [36], Using Nrf2 siRNA, we
have clearly shown the dependence of basal HO-1
expression on Nrf2 activity: Nrf2 gene silencing prac¬
tically abolished HO-1 expression. However, the pro¬
moter could still be activated by CoCl2 following
Nrf2 gene silencing, although the mechanism by
which this was occurring was not elucidated. No
HO-1 response was seen following insulin treatment
in Nrf2 siRNA-treated cells, suggesting that insulin-
induced HO-1 expression has an absolute dependence
on Nrf2 activity.
This report demonstrates the ability of insulin to
induce HO-1 in a PI3K/Akt-dependent and Nrf2-
dependent manner. HO-1 induction by PI3K/Akt or
Nrf2 activation requires further delineation in models
of transplantation and may represent an approach that




All reagents were obtained from Sigma-Aldrich Co. Ltd
(Poole, UK) unless otherwise stated. Antibodies to GSK3,
Nrf2 and lamin A/C were obtained from Santa Cruz
(Wembley, UK); antibodies to HO-1, phospho-Hsp27
(Ser78) and total Hsp27 were obtained from Stressgen
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Fig. 7. NF-E2-related factor (Nrf2) silencing
with small-interfering RNA (siRNA) prevents
insulin-induced heme oxygenase-1 (HO-1)
accumulation. Cells were transfected with
Nrf2 siRNA and 48 h later treated with insu¬
lin (200 nM), the proteosome inhibitor
MG132 (20 pM) or cobalt chloride (CoCI2) for
6 h. Whole cell lysates were prepared for
western blotting using antibody to HO-1 and
Nrf2, with p-actin as loading control. Optical
densities of bands were quantified (Quantity
One, Bio-Rad). Bars represent the mean of
three independent experiments, with error
bars representing SEM.
(Victoria, BC, Canada); 0-actin antibody was obtained
from BD Biosciences (San Diego, CA, USA); phospho-
GSK30 (ser9) (pGSK30), phospho-GSK3a/0 (ser21/9)
(pGSK3a/p), phospho-ERK.l/ERK.2 MAPK (Thr202/
Tyr204) (E10) monoclonal (p-ERKl/2), ERK1/ERK2
MAPK (total-ERKl/2), phospho-p38 MAPK (Thrl80/
Tyrl82) (28B10) monoclonal (p-p38) and p38 MAP kinase
(5F11) monoclonal (total p38) antibodies were obtained
from New England Biolabs (Hitchin, Hertfordshire, UK).
Cell culture and transfections
Renal adenocarcinoma cells (ACHN) (European Collec¬
tion of Cell Cultures, Porton Down, UK) were maintained
in Dulbecco's modified Eagle's medium (DMEM) supple¬
mented with 10% fetal bovine serum, penicillin
(50 U-mL-1), streptomycin (50 pg-mL~') and nonessential
amino acids (5%) (all Gibco, Paisley, UK). In experiments
termed serum-deprived, cells were plated out on day 1 in
DMEM with 10% fetal bovine serum. On the evening of
day 2, the medium was changed to DMEM with 0% fetal
bovine serum, and the experiment was performed on day
3. Cultures were maintained at 37 °C in a humidified
atmosphere of 5% C02/95% air. All experiments were
performed with subconfluent cultures. Akt expression con¬
structs (Upstate, Milton Keynes, UK) are based on the
pUSEamp vector. The activated form (Akt-myr) contains
an N-terminal myristoylation sequence targeting Akt to
the plasma membrane. The dominant-negative form
(Akt-K179M) contains a methionine for lysine substitution
at residue 179 abolishing Akt kinase activity. The wild-
type form (Akt-WT) contains the unaltered Akt sequence,
and an empty vector (pUSE-amp) was used as a control.
The HO-1 luciferase reporter construct (pHOGL3/l 1.6)
was a kind gift from A. Agarwal (University of Alabama,
Birmingham, AL, USA). The heat shock protein 70-0-
galactosidase (HSP7O-0-gal) reporter construct was a kind
gift from W. J. Welch (University of California, San Fran¬
cisco, CA, USA). The HIF-1 reporter construct (pHRE-
luc) was a kind gift from H. Esumi (National Cancer
Center Research Institute, Tokyo, Japan). Transfection
efficiency was controlled by cotransfecting with a 0-galac-
tosidase (pSV-0-gal)-expressing or a luciferase (pGL3-luc)-
expressing control vector (Promega, Southampton, UK).
Transient transfections were performed using Fugene
(Roche, Lewes, UK) at a 6 : 1 ratio of reagent to DNA.
In dose-finding experiments using a construct constitu-
tively expressing green fluorescent protein, the transfection
efficiency was found to be 30-40%. Experiments on trans¬
fected cells were performed 24-48 h later.
Mouse primary tubular epithelial cell culture
The kidneys of 6-week-old male BALB/c mice were
removed in sterile conditions and placed in ice-cold
HANK's balanced salt solution (HBSS) containing peni¬
cillin (100 UmL~'), streptomycin (100 pgmL-1) (Gibco)
and lx antibody antimycotic solution. After decapsulation
and bisection, the medulla was removed and the cortices
were reduced with repeated incisions to 1 mm3 pieces.
Kidney pieces were incubated at 37 °C with HBSS
containing freshly prepared collagenase type IV
(0.5 mg-mL~') and DNase (10 pg-mL~'). Following confir¬
mation of the presence of tubules, they were resuspended
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in DMEM-F12 with glutamax, penicillin (100 U-mL"1),
streptomycin 100 gg-mL"1) (all Gibco), lx insulin/transfer-
rin/selenium, dexamethasone (35.7 ng mL~ ) and epidermal
growth factor (25 ng mL"1). Tubules were cultured in six-
well plates for about 5 days until 70% confluent. Culture
conditions were then changed to DMEM-F12 with gluta¬
max, penicillin, streptomycin and dexamethasone for
40 h, after which experiments were performed. Cells were
cytokeratin positive and vimentin negative on immuno-
cytochemistry (data not shown). All experiments involving
animals were conducted in accordance with the provisions
of the UK Animals (Scientific Procedures) Act 1986.
Western blot
Whole cell extracts were produced using radioimmuno
precipitation assay buffer with protease inhibitors and
nuclear lysates using Gobert's method [63]. Proteins were
separated by SDS/PAGE and transferred by electroblotting
to nitrocellulose membranes (Bio-Rad, Hemel Hempstead,
UK). The membranes were soaked in blocking buffer
(NaCl/Tris, 0.05% Tween-20, 5% nonfat milk) followed by
blocking buffer containing primary antibody. After
washing, the membranes were exposed to horseradish
peroxidase-conjugated secondary anti-mouse (Upstate) or
anti-rabbit (Santa Cruz) and were used at a concentration
of 1 : 5000. Enhanced chemiluminescence reagent (Amer-
sham, Chalfont St Giles, UK, and Upstate) was used, with
development using autoradiography. Equality of loading
was confirmed by probing membranes for [J-actin for whole
cell extracts, and lamin A/C for nuclear extracts.
RNA isolation and fluorescence detection
real-time PCR
RNA extraction and purification were performed using a
TRIzol (Invitrogen, Paisley, UK). RNA samples were trea¬
ted with DNase and then run as a template for a standard
PCR reaction using (3-actin primers to exclude the presence
of contaminating DNA. RNA was then reverse transcribed
to cDNA using avian myeloblastosis virus reverse transcrip¬
tase (Promega) and random decamers (Ambion, Hunting¬
don, UK). Fluorescence-detection real-time PCR was then
performed using primers and probes specifically designed
for human HO-1: forward primer 5'-AGGGTGATAG
AAGAGGCCAAGA, reverse primer 5'-CAGCTCCTGCA
ACTCCTCAA and TAMRA-labeled probe 6-FAM-TGC
GTTCCTGCTCAACATCCAGCT-TAMRA. A standard
reaction contained Taqrnan universal master mix 12.5 pL
(Applied Biosystems, Warrington, UK), primer probe mix
7 pL (primers 25 pM, probe 5 pM), 18S primer probe mix
1.25 pL, water 1.75 pL and cDNA template 2.5 pL. Sam¬
ples were run on an AB1 Prism 7700 Sequence Detection
System and analysed using Sequence Detector 7.1 (Applied
Biosystems).
Luciferase/p-galactosidase assay
Cells were cotransfected with the appropriate reporter vec¬
tor and control vector and treated as per the experimental
protocol on the following day. Cells were lysed with repor¬
ter lysis buffer (Promega), after which 20 pL of lysate was
combined with 50 pL of luciferase assay reagent and the
resulting light emission measured on a luminometer (Fluor-
oskan Ascent Fl, Thermo Electron, Basingstoke, UK). The
remaining lysate (80 pL) was combined with [3-galactosidase
assay 2x buffer and, following incubation at 37 °C for 4 h,
was read at 420 nm on a spectrophotometer (Ultraspec
2000, Pharmacia Biotech, Chalfont St Giles, UK).
Immunofluorescence
Cells were cultured in chambered slides, treated as per the
experimental protocol and fixed with methanol. Blocking
with 10% normal goat serum in NaCl/Tris for 20 min was
followed by primary antibody exposure (anti-Nrf2, 1 : 250
in 10% normal goat serum) for 1 h at room temperature.
After being washed in NaCl/Tris, the sections were exposed
to secondary antibody (alexa fluor 568 F(ab')2 fragment of
goat anti-rabbit IgG, 1 : 200 in 10% normal goat serum)
(Invitrogen) for 30 min. Counterstaining with Hoechst
33258 (Sigma) was performed prior to mounting. Fields
were visualized with a Leica DM IRB fluorescence micro¬
scope (Leica Microsystems AG, Wetzlar, Germany) and
images taken with a digital camera. Primary antibody only
and secondary antibody only groups were always included
as controls.
RNA interference
Cells were seeded in six-well plates and transfected on the
following day with Nrf2 siRNA (h) (Santa Cruz) or control
siRNA according to the manufacturer's protocol. Forty-
eight hours later, transfected cells were treated and lysed.
Adequacy of effect was ascertained with western blot anal¬
ysis with anti-Nrf2.
Statistical analysis
Data are presented as means and standard error of the
mean (SEM). Statistical comparisons were made using one¬
way analysis of variance (anova) with the Tukey post hoc
correction for multiple comparisons using SPSS version 10.0
(SPSS, Chicago 1L, USA).
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Abstract
Luciferase reporter constructs are an accurate method of assessing gene promoter activity and vectors constitutively expressing
luciferase are useful in quantifying transfection efficiency. Common methodologies for examining the induction of the heat shock
(stress) response require exposure of cells transfected with luciferase-expressing vectors to a mild heat stress. Here we re-examine
the under-recognised phenomenon that luciferase is exquisitely sensitive to small temperature changes. In cells subjected to mild
heat exposure following transfection with both luciferase and (3-galactosidase reporter vectors, a marked reduction in luciferase
activity was observed compared with (Z-galactosidase activity. On exposing recombinant firefly luciferase to small increases in
temperature in vitro, a time and temperature dependent decrease in luciferase activity was demonstrated. Loss of luciferase activity
following mild heat exposure will result in misinterpretation of reporter activity. This vastly underappreciated effect is worthy of
further emphasis and luciferase reporter vectors should be used with caution in protocols that involve exposure to temperatures
outside the physiological range.
© 2006 Published by Elsevier B.V.
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1. Introduction
The use of reporter vectors is a rapid and highly
sensitive method of investigating factors regulating gene
expression (Schenborn and Groskreutz, 1999). The
promoter region ofthe gene of interest is cloned upstream
ofa sequence encoding the reporter enzyme; the resulting
protein expression is proportional to gene activity and
can be easily and reliably determined. In order to control
for potential variability in transfection efficiency, it is
common practice to co-transfect the reporter vector with
Abbreviations: Hsp, heat shock protein; SV40, simian vims 40.
* Corresponding author. Tel.: +44 797 442 0495.
E-mail address: mail@ewenharrison.com (E.M. Harrison).
a control vector, constitutively expressing a second
distinct reporter enzyme under a viral promoter. For this
second vector to function as an accurate control, enzyme
expression must be independent of the experimental
treatment and depend only on the number of cells that
took up the plasmid DNA (Ibrahim et al., 2000).
Heat shock proteins are highly conserved intracellu¬
lar chaperones and have recently been identified as
important immunoregulatory agents (Pockley, 2003).
While investigating the induction of heat shock protein
70 (Hsp70) following heat exposure in renal adenocar¬
cinoma cells (ACHN), we utilised an Hsp70B f$-
galactosidase reporter vector. It was necessary to control
for transfection efficiency and thus cells were co-
transfected with the pGL3 luciferase control vector,
0022-1759/$ - see front matter © 2006 Published by Elsevier B.V.
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which contains the luc+ gene and expresses firefly
luciferase under the control of the simian virus 40
(SV40) promoter. It was observed that luciferase activity
in groups transfected with the pGL3 vector and
subjected to a mild heat exposure was much lower
than expected.
To investigate whether this observation was an effect
of heat on transcription we co-transfected the pGL3
vector with the pSV p-galactosidase control vector, also
under the control of the SV40 promoter. The following
day, groups were exposed to a mild heat induced stress
(43 °C) for increasing lengths of time up to 45 min, after
which all remaining groups were returned to 37 °C and
recovered for further increasing time intervals. Addi¬
tional examination involved exposing recombinant
firefly luciferase to a series of mild heat exposures for
increasing lengths of time. All experiments were
independently repeated 3 times.
2. Methods
2.1. Cell culture and transfection
Renal adenocarcinoma cells (ACHN) (European
Collection of Cell Cultures, Porton Down, UK) were
maintained in Dulbecco's modified Eagle's medium
(Gibco, Paisley, UK) supplemented with 10% fetal bovine
serum, penicillin (50 U/ml), streptomycin (50 pg/ml) and
non-essential amino acids (5%). Cultures were maintained
at 37 °C in a humidified atmosphere of 5% C02, 95% air.
Cells were passaged regularly and all experiments were
performed with sub-confluent cultures. Luciferase
(pGL3-/wc+) and p-galactosidase (pSV-f-gal) expressing
vectors were obtained from Promega, Southampton, UK.
Transient transfections were performed using Fugene
(Roche, Lewes, East Sussex, UK) at a 6:1 ratio reagent to
DNA. Experiments on transfected cells were performed
24 h later.
2.2. Luciferase and /3-galactosidase assay
Cells were lysed with reporter lysis buffer (Promega)
and the protein concentration determined (Lowrie
method; BioRad) after which 20 pi of lysate were
combined with 50 pi luciferase assay reagent and the
resulting light emission measured on a luminometer
(Fluoroskan Ascent Fl; Thermo Electron, Basingstoke,
UK). The remaining lysate (80 pi) was combined with
P-galactosidase assay 2x buffer and, following incuba¬
tion at 37 °C for 4 h, was read at 420 nm on a
spectrophotometer (Ultraspec 2000; Pharmacia Biotech,
now GE Healthcare, Chalfont St. Giles, UK).
2.3. In-vitro luciferase analysis
Firefly luciferase (Sigma) was dissolved in distilled
water (1 pg/pl) and further diluted 1/20 in PBS. Samples
were placed in a thermocycler (PCR Sprint Thermal
Cycler, Thenno Electron) with the hot-lid facility turned
off, for the specified times.
3. Results and discussion
Cells transfected with both the pGL3 luciferase
vector and the pSV p-galactosidase control and
subjected to mild heat exposure demonstrated a marked
reduction in luciferase activity compared with p-
galactosidase activity, which remained unchanged
(Fig. 1A). This occurred despite both enzymes being
under the control of the same SV40 promoter, suggest¬
ing that the effect was independent of transcription. The
reduction was related to the length of heat exposure and
a statistically significant difference between the pGL3
luciferase group and the pSV p-galactosidase control
was observed following 30 min of heat exposure
(Mann—Whitney U p< 0.05). Luciferase activity in¬
creased during recovery but the difference between the
groups was still statistically significant in the 4 h after
the stimulus, the crucial period examined when
measuring gene promoter activation (Fig. IB).
On exposing recombinant firefly luciferase to various
temperatures (Fig. 1C) a time and temperature dependent
response was observed with luciferase activity decreas¬
ing markedly over time and with increasing temperature.
An increase in temperature to 40 °C for 45 min was
enough to reduce enzyme activity to less than 1% of
control.
Firefly luciferase is the most commonly used
bioluminescent reporter (Wood, 1998). Despite the
sensitivity and convenience of the enzyme assay
Fig. 1. Luciferase and p-galactosidase activity following mild heat exposure. (A) The pGL3 luciferase and pSV p-galactosidase control vectors were
co-transfected into a renal adenocarcinoma cell line (ACHN) using the Fugene transfection reagent. The following day, groups were heated to 43 °C
for various lengths of time. Whole cell extracts were prepared with reporter lysis buffer (RLB), a protein assay was performed and luciferase and p-
galactosidase activity determined. NT, non-transfected control; T, transfected control. (B) Cells were transfected as above and heated to 43 °C for 45
min 24 h later. Cells were lysed and luciferase and p-galactosidase activity were determined. (C) Firefly luciferase was diluted, placed in a
thermocycler and heated for the times specified, after which luciferase activity was determined. * Mann-Whitney U /><0.05.
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inherent problems exist, particularly relating to thermo¬
stability, both in vivo and in vitro (Nguyen et al., 1989).
Improved heat tolerance of luciferase has been demon¬
strated using mutagenesis to achieve a single amino acid
substitution in both the Japanese Firefly (Luciola
cruciata and Luciola lateralis) (Kajiyama and Nakano,
1993) and the North American Firefly (Photinus
pyralis) (White et al., 1996). Modifications of the
luciferase gene have improved performance in other
areas, including the elimination of peroxisomal translo¬
cation (Wood, 1998). However, thermostability is not a
feature of current commercial versions since Nguyen et
al. (1989) have previously demonstrated the sensitivity
of luciferase to heat. Inconsistent with our findings, their
data demonstrates a significant decrease in p-galacto-
sidase activity in mouse-derived cells exposed to heat,
although no loss of activity was seen in in vitro studies.
However, our model used a human cell line, protein
translation was not abolished with cyclohexamide and
cells were heated to 43 °C, not 45 °C. These factors may
explain the difference in findings.
In conclusion, when a luciferase reporter vector is
used to determine gene expression in cells exposed to
mild heat, the activity of the gene in question may be
underestimated. When, however, a luciferase control
vector is used in cells exposed to heat, transfection
efficiency may be underestimated, and so gene expres¬
sion overestimated between groups.
These data demonstrate the propensity of firefly
luciferase to become inactive following mild heat
exposure. The pGL3 control vector should be used
with caution in protocols that involve exposure to a mild
heat insult.
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